STATUTORY INSTRUMENTS

1997 No. 1830

MEDICINES

The Prescription Only Medicines (Human Use) Order 1997

Made	25th July 1997
Laid before Parliament	28th July 1997
Coming into force	18th August 1997

The Secretary of State concerned with health in England, the Secretaries of State concerned with health and with agriculture in Wales and in Scotland respectively, the Minister of Agriculture, Fisheries and Food, the Department of Health and Social Services for Northern Ireland and the Department of Agriculture for Northern Ireland, acting jointly, in exercise of powers conferred on them by sections 58(1), (4) and (5), 59(1) and 129(4) of the Medicines Act 1968(1) or, as the case may be, those conferred by the said provisions and now vested in them(2), and of all other powers enabling them in that behalf, after consulting such organisations as appear to them to be representative of interests likely to be substantially affected by this Order, pursuant to section 129(6) of that Act, and after consulting and taking into account the advice of the Medicines Commission pursuant to sections 58(6) and 129(7) of that Act, hereby make the following Order:

Citation, commencement and interpretation

1.—(1) This Order may be cited as the Prescription Only Medicines (Human Use) Order 1997 and shall come into force on 18th August 1997.

(2) In this Order, unless the context otherwise requires-

"the Act" means the Medicines Act 1968;

[^{F1}"additional supply optometrist" means a person who is registered as an optometrist, and against whose name particulars of the additional supply speciality have been entered in the relevant register;]

"aerosol" means a product which is dispersed from its container by a propellent gas or liquid;

^{(1) 1968} c. 67. Section 58 has been amended by the Prescription by Nurses Etc. Act 1992 (c. 28), section 1. The expression "the appropriate Ministers" is defined in section 1(2) of the Medicines Act 1968.

⁽²⁾ In the case of the Secretaries of State concerned with health in England and in Wales by virtue of article 2(2) of, and Schedule 1 to, the Transfer of Functions (Wales) Order 1969 (S.I. 1969/388); in the case of the Secretary of State concerned with Agriculture in Wales by virtue of article 2(3) of, and Schedule 1 to, the Transfer of Functions (Wales) (No. 1) Order 1978 (S.I. 1978/272) and in the case of the Northern Ireland Departments by virtue of section 40 of, and Schedule 5 to, the Northern Ireland Constitution Act 1973 (c. 36) and section 1(3) of, and paragraph 2(1)(b) of Schedule 1 to, the Northern Ireland Act 1974 (c. 28).

[^{F2}"clinical management plan" means a written plan (which may be amended from time to time) relating to the treatment of an individual patient agreed by—

(a) the patient to whom the plan relates,

- (b) the doctor or dentist who is a party to the plan, and
- (c) any supplementary prescriber who is to prescribe, give directions for administration or administer under the plan;]

[^{F3}"clinical trial" has the meaning given by regulation 2(1) of the Medicines for Human Use (Clinical Trials) Regulations 2003;]

F4

[^{F5}"Common Services Agency" means the Common Services Agency for the Scottish Health Service established under section 10 of the National Health Service (Scotland) Act 1978;]

[^{F5}"Community marketing authorization" means a marketing authorization granted by the European Community under Council Regulation (EEC) No. 2309/93;]

"controlled drug" has the meaning assigned to it by section 2 of the Misuse of Drugs Act 1971(3);

"cyanogenetic substances" means preparations which-

- (a) are presented for sale or supply under the name of, or as containing, amygdalin, laetrile or vitamin B17, or
- (b) contain more than 0.1 per cent by weight of any substance having the formula either α -Cyanobenzyl-6-O- β -d-glucopyranosyl- β -d-glucopyranoside or α -Cyanobenzyl- β -d-glucopy ranosiduronic acid;

[^{F6} district nurse/health visitor prescriber" means a first level nurse, or a registered midwife, against whose name in the professional register there is an annotation that he is qualified to order drugs, medicines and appliances from the Nurse Prescriber's Formulary for District Nurses and Health Visitors Appendix in the current edition of the British National Formulary];

"dosage unit" means-

- (a) where a medicinal product is in the form of a tablet or capsule or is an article in some other similar pharmaceutical form, that tablet, capsule or other article, or
- (b) where a medicinal product is not in any such form, the unit of measurement which is used as the unit by reference to which the dose of the medicinal product is measured;

[^{F7}"Extended Formulary" means the Nurse Prescribers' Extended Formulary Appendix in the current edition of the British National Formulary;]

[^{F7}"extended formulary nurse prescriber" means a person—

- (a) [^{F8}who is a first level nurse [^{F9}or registered midwife], and]
- (b) against whose name is recorded in [^{F10}the professional register] an annotation signifying that he is qualified to order drugs, medicines and appliances from the Extended Formulary;]

"external use" means application to the skin, hair, teeth, mucosa of the mouth, throat, nose, ear, eye, vagina or anal canal when a local action only is intended and extensive systemic absorption is unlikely to occur; and references to medicinal products for external use shall be read accordingly except that such references shall not include throat sprays, throat pastilles, throat lozenges, throat tablets, nasal drops, nasal sprays, nasal inhalations or teething preparations; [^{F11}"first level nurse" means a person registered in Sub-Part 1 of the Nurses' Part of the professional register;]

[^{F5}"Health Authority"—

- (a) in relation to England and Wales, has the same meaning as in the National Health Service Act 1977;
- (b) in relation to Scotland, means a Health Board constituted under section 2 of the National Health Service (Scotland) Act 1978; and
- (c) in relation to Northern Ireland, means a Health and Social Services Board established under Article 16 of the Health and Personal Social Services (Northern Ireland) Order 1972;]

 $[{}^{F12}\mbox{``health care'' means services for or in connection with the prevention, diagnosis or treatment of disease;]$

"health prescription" means a prescription issued by a doctor, dentist $[^{F13}$, supplementary prescriber] $[^{F14}$, a district nurse/health visitor prescriber or an extended formulary nurse prescriber] under or by virtue of–

- (a) in England and Wales, the National Health Service Act 1977(4),
- (b) in Scotland, the National Health Service (Scotland) Act 1978(5), and
- (c) in Northern Ireland, the Health and Personal Social Services (Northern Ireland) Order 1972(6);

[^{F15}"health record" has the meaning given by section 68(2) of the Data Protection Act 1998(6);]

[^{F5} chomoeopathic certificate of registration" means a certificate of registration for the purposes of the Medicines (Homoeopathic Medicinal Products For Human Use) Regulations 1994;]

[^{F16}"independent clinic"—

- (a) in relation to England and Wales, has the meaning given by section 2(4) of the Care Standards Act 2000(8), and
- (b) in relation to Scotland, has the meaning given by section 77(1) of the Regulation of Care (Scotland) Act 2001;]

[^{F16}"independent hospital"—

- (a) in relation to England and Wales, shall be construed in accordance with section 2(2), (3) and (6) of the Care Standards Act 2000, and
- (b) in relation to Scotland, means-
 - (i) an independent hospital, or
 - (ii) a private psychiatric hospital,

as defined by section 77(1) of the Regulation of Care (Scotland) Act 2001;]

[^{F16}"independent medical agency"—

- (a) in relation to England and Wales, has the meaning given by section 2(5) of the Care Standards Act 2000, and
- (b) in relation to Scotland, has the meaning given by section 77(1) of the Regulation of Care (Scotland) Act 2001;]

⁽**4**) 1977 c. 49.

^{(5) 1978} c. 29.

⁽⁶⁾ S.I. 1972/1265 (N.I. 14).

⁽⁶⁾ S.I. 1972/1265 (N.I. 14).

⁽⁸⁾ S.I. 1985/2066.

"inhaler" does not include an aerosol;

[^{F17}"Local Health Board" has the same meaning as in the National Health Service Act 1977;]

[^{F5}"marketing authorization" includes a reference both to a United Kingdom marketing authorization and to a Community marketing authorization;]

"master" has the same meaning as in section 313(1) of the Merchant Shipping Act 1995(7);

"maximum daily dose" or "MDD" means the maximum quantity of a substance contained in the amount of a medicinal product which it is recommended should be taken or administered in a period of 24 hours;

"maximum dose" or "MD" means the maximum quantity of a substance contained in the amount of a medicinal product which it is recommended should be taken or administered at any one time;

"maximum strength" means-

- (a) the maximum quantity of a substance by weight or volume contained in a dosage unit of a medicinal product;
- (b) the maximum percentage of a substance contained in a medicinal product calculated in any of the following ways-
 - (i) weight in weight,
 - (ii) weight in volume,
 - (iii) volume in weight, or
 - (iv) volume in volume,

and if the maximum percentage calculated in those ways differs, the higher or highest such percentage;

"medicinal product" includes any article or substance in respect of which section 58 of the Act has effect by virtue of an order made under section 104 of the Act, but does not include–

- (a) a medicinal product which is a veterinary drug as defined in section 132(1) of the Act or
- (b) an article or substance in respect of which section 58 has such effect where that article or substance is only to be administered to animals;

"the Misuse of Drugs Regulations" means, in relation to England, Wales and Scotland, the Misuse of Drugs Regulations 1985(8) and in relation to Northern Ireland, the Misuse of Drugs (Northern Ireland) Regulations 1986(9);

[^{F5}"NHS trust"—

- (a) in relation to England and Wales, has the same meaning as in the National Health Service and Community Care Act 1990;
- (b) in relation to Scotland, has the same meaning as in the National Health Service (Scotland) Act 1978; and
- (c) in relation to Northern Ireland, means a Health and Social Services trust established under article 10 of the Health and Social Services (Northern Ireland) Order 1991;]

[^{F18}"NHS foundation trust" has the same meaning as in section 1(1) of the Health and Social Care (Community Health and Standards) Act 2003;]

[^{F19}"nursing home" has the meaning given by article 16 of the Registered Homes (Northern Ireland) Order 1992;]

^{(7) 1995} c. 21.

⁽⁸⁾ S.I. 1985/2066.

⁽⁹⁾ SR 1986 No. 52.

"occupational health scheme" means a scheme in which a person, in the course of a business carried on by him, provides facilities for his employees for the treatment or prevention of disease;

"offshore installation" means an offshore installation within the meaning of the Mineral Workings (Offshore Installations) Act 1971(10) which is within–

- (a) tidal waters and parts of the sea in or adjacent to the United Kingdom up to the seaward limits of territorial waters;
- (b) waters in any area designated under section 1(7) of the Continental Shelf Act 1964(11);

"operator", in relation to an aircraft, means the person for the time being having the management of the aircraft;

"parenteral administration" means administration by breach of the skin or mucous membrane;

[^{F5}"Patient Group Direction" means—

- (a) in connection with the supply of a prescription only medicine as referred to in article 12A(2), [^{F20}12B, 12C, 12D or 12E], a written direction relating to the supply and administration of a description or class of prescription only medicine; or
- (b) in connection with the administration of a prescription only medicine as referred to in article 12A(2), 12B or 12C, a written direction relating to the administration of a description or class of prescription only medicine,

and which, in the case of either (a) or (b)—

- (i) is signed by a doctor or dentist, and by a pharmacist; and
- (ii) relates to supply and administration, or to administration, to persons generally (subject to any exclusions which may be set out in the Direction);]

"prescription only medicine" means a medicinal product of a description or falling within a class specified in article 3 of this Order;

[^{F5}"Primary Care Trust" has the same meaning as in the National Health Service Act 1977;]

[^{F21}"prison service" means—

- (a) in relation to England and Wales, a Minister of the Crown exercising functions in relation to prisons (within the meaning of the Prison Act 1952),
- (b) in relation to Scotland, the Scottish Ministers exercising functions in relation to prisons (within the meaning of the Prisons (Scotland) Act 1989), and
- (c) in relation to Northern Ireland, the Northern Ireland Department exercising functions in relation to prisons (within the meaning of the Prison Act (Northern Ireland) 1953);]

[^{F22}"professional register" means the register maintained by the Nursing and Midwifery Council [^{F23}under article 5 of] the Nursing and Midwifery Order 2001;]

"prolonged release" in relation to a medicinal product means a formulation of that product which-

- (a) is used to reduce the rate at which the active ingredient in that product is released after administration, and
- (b) is sold or supplied as a prolonged, controlled or sustained release medicinal product;

[^{F24}"registered chiropodist" means a person who is registered in Part 2 of the register maintained by the Health Professions Council under article 5 of the Health Professions Order 2001;];

^{(10) 1971} c. 61; section 1 was substituted by section 24 of the Oil and Gas (Enterprise) Act 1982 (c. 23).

^{(11) 1964} c. 29.

[^{F25}"registered dietitian" means a person who is registered in Part 4 of the register maintained by the Health Professions Council under article 5 of the Health Professions Order 2001;]

[^{F26}"registered midwife" means a person registered in the Midwives' Part of the professional register;]

[^{F27}"registered nurse" means a person registered in the Nurses' Part of the professional register;]

[^{F25}"registered occupational therapist" means a person who is registered in Part 6 of the register maintained by the Health Professions Council under article 5 of the Health Professions Order 2001;]

[^{F28}"registered optometrist" means a person whose name is registered in the register of optometrists maintained under section 7(a) of the Opticians Act 1989;]

[^{F24}"registered orthoptist" means a person who is registered in Part 7 of the register maintained by the Health Professions Council under article 5 of the Health Professions Order 2001;];

[^{F25}"registered orthotist and prosthetist" means a person who is registered in Part 10 of the register maintained by the Health Professions Council under article 5 of the Health Professions Order 2001;]

[^{F24}"registered paramedic" means a person who is registered in Part 8 of the register maintained by the Health Professions Council under article 5 of the Health Professions Order 2001;]

[^{F24}"registered physiotherapist" means a person who is registered in Part 9 of the register maintained by the Health Professions Council under article 5 of the Health Professions Order 2001;]

[^{F29}"registered provider" means—

- (a) in relation to an independent hospital, an independent clinic or an independent medical agency—
 - (i) in relation to England and Wales, the person who is registered under Part II of the Care Standards Act 2000 as the person carrying on the establishment or agency,
 - (ii) in relation to Scotland, the person who is registered under Part 1 of the Regulation of Care (Scotland) Act 2001 as the person providing the establishment or agency, and
- (b) in relation to a nursing home, the person registered under Part III of the Registered Homes (Northern Ireland) Order 1992 as the person carrying on the nursing home, other than a manager who is to be treated as carrying on the home by virtue of article 17(2) of that order;]

[^{F24}"registered radiographer" means a person who is registered in Part 11 of the register maintained by the Health Professions Council under article 5 of the Health Professions Order 2001;]

[^{F25}"registered speech and language therapist" means a person who is registered in Part 12 of the register maintained by the Health Professions Council under article 5 of the Health Professions Order 2001;]

[^{F29}"relevant manager" means—

- (a) in relation to an independent hospital, an independent clinic or an independent medical agency—
 - (i) in relation to England and Wales—
 - (aa) a person who is registered under Part II of the Care Standards Act 2000 as the manager of the establishment or agency, but who is not the registered provider for that establishment or agency, or

- (bb) if there is no such person, but the registered provider has appointed a person to manage the establishment or agency, that appointed person,
- (ii) in relation to Scotland, a person, other than the registered provider, who was identified as an individual who is to manage the establishment or agency on the application for registration of that establishment or agency under Part 1 of Regulation of Care (Scotland) Act 2001, and
- (b) in relation to a nursing home, the manager of the nursing home, unless they are the registered provider for that home;]

[^{F29}"relevant register" means—

- (a) in relation to a first level nurse [^{F30} or registered midwife], the professional register, ^{F31}...
- (b) in relation to a pharmacist, the register maintained in pursuance of section 2(1) of the Pharmacy Act 1954 or the register maintained in pursuance of Articles 6 and 9 of the Pharmacy (Northern Ireland) Order 1976; ^{F32}...
- (c) [^{F33}in relation to a person whose name is registered in the part of the register maintained by the Health Professions Council in pursuance of article 5 of the Health Professions Order 2001 relating to—
 - (i) chiropodists and podiatrists;
 - (ii) physiotherapists; or
 - (iii) radiographers diagnostic or therapeutic

that register [^{F34}; and]

(d) [^{F35}in relation to a registered optometrist, the register of optometrists maintained under section 7(a) of the Opticians Act 1989;]]

"repeatable prescription" means a prescription which contains a direction that it may be dispensed more than once;

"sell" means sell by retail as defined in section 131 of the Act and "sale" has a corresponding meaning;

"soap" means any compound of a fatty acid with an alkali or amine;

[^{F5}"Special Health Authority"—

- (a) in relation to England and Wales, has the same meaning as in the National Health Service Act 1977;
- (b) in relation to Scotland, means a Special Health Board constituted under section 2 of the National Health Service (Scotland) Act 1978; and
- (c) in relation to Northern Ireland, means a Special Health and Social Services Agency established under the Health and Personal Social Services (Special Agencies) (Northern Ireland) Order 1990;]

F36

F36

[^{F37}"Strategic Health Authority" means a Strategic Health Authority established under section 8 of the National Health Service Act 1977;]

[^{F38}"supplementary prescriber" means—

- (a) a first level nurse, ^{F39}...
- (b) a pharmacist, ^{F40}[^{F41}...

- (c) a registered midwife, J^{F42} ...
- (d) [^{F43}a person whose name is registered in the part of the register maintained by the Health Professions Council in pursuance of article 5 of the Health Professions Order 2001 relating to—
 - (i) chiropodists and podiatrists;
 - (ii) physiotherapists; or
 - (iii) radiographers diagnostic or therapeutic [^{F44}or]]
- (e) [^{F45}a registered optometrist,]

against whose name is recorded in the relevant register an annotation [F46 or entry] signifying that he is qualified to order drugs, medicines and appliances as a supplementary prescriber;]

"supply" means supply in circumstances corresponding to retail sale as defined in section 131 of the Act;

"unit preparation" means a preparation, including a mother tincture, prepared by a process of solution, extraction or trituration with a view to being diluted tenfold or one hundredfold, either once or repeatedly, in an inert diluent, and then used either in this diluted form or, where applicable, by impregnating tablets, granules, powders or other inert substances.

[^{F5}^{cc}United Kingdom marketing authorization" means a marketing authorization granted by the licensing authority under the Medicines For Human Use (Marketing Authorisations Etc.) Regulations 1994 (including a product licence having effect as such an authorization by virtue of Schedule 6 to those Regulations).]

(3) For the purposes of this Order, the equivalence of a substance to a reference material shall be determined by calculating the amount of that reference material which is contained in that substance either by weight or, where the amount of the reference material is specified in terms of international units of activity, those units.

(4) In this Order, unless the context otherwise requires, a reference-

- (a) to a numbered section is to the section of the Act which bears that number,
- (b) to a numbered article or Schedule is to the article of, or Schedule to, this Order which bears that number,
- (c) in an article or in a Part of a Schedule to a numbered paragraph is to the paragraph of that article or Part of that Schedule which bears that number, and
- (d) in a paragraph to a lettered sub-paragraph is to the sub-paragraph of that paragraph which bears that letter.
- (5) In [^{F47}Schedules 1, 2, 3A and 5]-
 - (a) entries specified in columns 2 to 5 relate to the substances listed in column 1 against which they appear and where, in relation to a particular substance listed in column 1, an entry in columns 2 to 5 bears a number or letter it relates only to such entries in the other of those columns as bear the same number or letter;
 - (b) the following abbreviations are used:

"g" for gram,

"iu" for international unit of activity,

"mcg" for microgram,

"mg" for milligram,

"ml" for millilitre.

(6) In Schedule 3, the abbreviation "NPF" means the Nurse Prescribers' Formulary Appendix in the British National Formulary.

^{F48}(7) In articles 12 to [$^{F49}12E$], a reference to a prescription only medicine being sold or supplied for the purpose of being administered in accordance with the written directions of a doctor or dentist relating to a particular person, or in accordance with a Patient Group Direction, includes a reference to it being sold or supplied in accordance with such directions or such a Direction.

(8) In articles 12A and 12C, a reference to an arrangement for the supply or administration of prescription only medicines includes a reference to an arrangement which covers such supply or administration and other matters.

(9) In Schedule 7, Part I, a reference to treatment of a clinical situation includes a reference to any form of management of that situation.]]

Textual Amendments

- F1 Words in art. 1(2) inserted (30.6.2005) by The Medicines for Human Use (Prescribing) (Miscellaneous Amendments) Order 2005 (S.I. 2005/1507), arts. 1(1), **3(a)**
- F2 Words in art. 1(2) inserted (4.4.2003) by The Prescription Only Medicines (Human Use) Amendment Order 2003 (S.I. 2003/696), arts. 1(1), 2(2)(a)
- F3 Words in art. 1(2) substituted (1.5.2004) by The Medicines for Human Use (Clinical Trials) Regulations 2004 (S.I. 2004/1031), reg. 1, Sch. 10 Pt. 2 para. 13(a)
- F4 Words in art. 1 omitted (1.4.2002) by virtue of The Prescription Only Medicines (Human Use) Amendment Order 2002 (S.I. 2002/549), arts. 1(1), **2(2)(a)**
- **F5** Words in art. 1(2) inserted (9.8.2000) by The Prescription Only Medicines (Human Use) Amendment Order 2000 (S.I. 2000/1917), arts. 1(1), **2(a)**
- **F6** Words in art. 1(2) substituted (1.8.2004) by The Health Act 1999 (Consequential Amendments) (Nursing and Midwifery) Order 2004 (S.I. 2004/1771), art. 1(1), Sch. para. 39(a)(i)
- **F7** Words in art. 1 inserted (1.4.2002) by The Prescription Only Medicines (Human Use) Amendment Order 2002 (S.I. 2002/549), arts. 1(1), **2(2)(c)**
- **F8** Words in art. 1(2) substituted (4.4.2003) by The Prescription Only Medicines (Human Use) Amendment Order 2003 (S.I. 2003/696), arts. 1(1), **2(2)(b)(i)**
- **F9** Words in art. 1(2) inserted (1.8.2004) by The Health Act 1999 (Consequential Amendments) (Nursing and Midwifery) Order 2004 (S.I. 2004/1771), art. 1(1), Sch. para. 39(a)(ii)
- **F10** Words in art. 1(2) substituted (4.4.2003) by The Prescription Only Medicines (Human Use) Amendment Order 2003 (S.I. 2003/696), arts. 1(1), **2(2)(b)(ii)**
- F11 Words in art. 1(2) substituted (1.8.2004) by The Health Act 1999 (Consequential Amendments) (Nursing and Midwifery) Order 2004 (S.I. 2004/1771), art. 1(1), Sch. para. 39(a)(iii)
- **F12** Words in art. 1(2) inserted (4.4.2003) by The Prescription Only Medicines (Human Use) Amendment Order 2003 (S.I. 2003/696), arts. 1(1), **2(2)(d)**
- **F13** Words in art. 1(2) inserted (4.4.2003) by The Prescription Only Medicines (Human Use) Amendment Order 2003 (S.I. 2003/696), arts. 1(1), **2(2)(e)**
- **F14** Words in art. 1 inserted (1.4.2002) by The Prescription Only Medicines (Human Use) Amendment Order 2002 (S.I. 2002/549), arts. 1(1), **2(2)(d)**
- **F15** Words in art. 1(2) inserted (4.4.2003) by The Prescription Only Medicines (Human Use) Amendment Order 2003 (S.I. 2003/696), arts. 1(1), **2(2)(f)**
- **F16** Words in art. 1(2) inserted (4.4.2003) by The Prescription Only Medicines (Human Use) Amendment Order 2003 (S.I. 2003/696), arts. 1(1), **2(2)**(g)
- F17 Words in art. 1(2) inserted (19.11.2004) by The Prescription Only Medicines (Human Use) Amendment (No. 3) Order 2004 (S.I. 2004/2693), arts. 1(1), 2

- F18 Words in art. 1(2) inserted (1.4.2004) by The Health and Social Care (Community Health and Standards) Act 2003 (Supplementary and Consequential Provision) (NHS Foundation Trusts) Order 2004 (S.I. 2004/696), arts. 1(1)(b), 3(8), Sch. 8
- F19 Words in art. 1(2) inserted (4.4.2003) by The Prescription Only Medicines (Human Use) Amendment Order 2003 (S.I. 2003/696), arts. 1(1), 2(2)(h)
- **F20** Words in art. 1 substituted (10.12.2003) by The Prescription Only Medicines (Human Use) Amendment (No. 2) Order 2003 (S.I. 2003/2915), arts. 1(1), **2**
- F21 Words in art. 1(2) inserted (4.4.2003) by The Prescription Only Medicines (Human Use) Amendment Order 2003 (S.I. 2003/696), arts. 1(1), 2(2)(i)
- F22 Words in art. 1 inserted (1.4.2002) by The Prescription Only Medicines (Human Use) Amendment Order 2002 (S.I. 2002/549), arts. 1(1), 2(2)(e)
- F23 Words in art. 1(2) substituted (1.8.2004) by The Health Act 1999 (Consequential Amendments) (Nursing and Midwifery) Order 2004 (S.I. 2004/1771), art. 1(1), Sch. para. 39(a)(iv)
- F24 Words in art. 1 inserted (9.7.2003) by The Health Professions Order 2001 (Consequential Amendments) Order 2003 (S.I. 2003/1590), art. 1, Sch. para. 21(2)(a)
- F25 Words in art. 1(2) inserted (18.5.2004) by The Prescription Only Medicines (Human Use) Amendment (No. 2) Order 2004 (S.I. 2004/1189), arts. 1(1), 2
- F26 Words in art. 1(2) substituted (1.8.2004) by The Health Act 1999 (Consequential Amendments) (Nursing and Midwifery) Order 2004 (S.I. 2004/1771), art. 1(1), Sch. para. 39(a)(v)
- F27 Words in art. 1(2) substituted (1.8.2004) by The Health Act 1999 (Consequential Amendments) (Nursing and Midwifery) Order 2004 (S.I. 2004/1771), art. 1(1), Sch. para. 39(a)(vi)
- F28 Words in reg. 1(2) substituted (30.6.2005 as notified in the London Gazette dated 3.6.2005) by The Opticians Act 1989 (Amendment) Order 2005 (S.I. 2005/848), Sch. 1 para. 27(a)
- F29 Words in art. 1(2) inserted (4.4.2003) by The Prescription Only Medicines (Human Use) Amendment Order 2003 (S.I. 2003/696), arts. 1(1), 2(2)(j)
- **F30** Words in art. 1(2) inserted (1.8.2004) by The Health Act 1999 (Consequential Amendments) (Nursing and Midwifery) Order 2004 (S.I. 2004/1771), art. 1(1), Sch. para. 39(a)(vii)
- **F31** Word in art. 1(2) omitted (7.4.2005) by virtue of The Medicines for Human Use (Prescribing) Order 2005 (S.I. 2005/765), arts. 1(1), **3(a)(i)**
- **F32** Word in art. 1(b) omitted (30.6.2005) by virtue of The Medicines for Human Use (Prescribing) (Miscellaneous Amendments) Order 2005 (S.I. 2005/1507), arts. 1(1), **3(b)(i)**
- **F33** Words in art. 1(2) inserted (7.4.2005) by The Medicines for Human Use (Prescribing) Order 2005 (S.I. 2005/765), arts. 1(1), **3(a)(iii)**
- **F34** Word in art. 1(c) inserted (30.6.2005) by The Medicines for Human Use (Prescribing) (Miscellaneous Amendments) Order 2005 (S.I. 2005/1507), arts. 1(1), **3(b)(ii)**
- F35 Words inserted (30.6.2005) by The Medicines for Human Use (Prescribing) (Miscellaneous Amendments) Order 2005 (S.I. 2005/1507), arts. 1(1), 3(b)(iii)
- **F36** Words in art. 1 omitted (9.7.2003) by virtue of The Health Professions Order 2001 (Consequential Amendments) Order 2003 (S.I. 2003/1590), art. 1, Sch. para. 21(2)(b)
- F37 Words in art. 1(2) inserted (1.10.2002) by The National Health Service Reform and Health Care Professions Act 2002 (Supplementary, Consequential etc. Provisions) Regulations 2002 (S.I. 2002/2469), regs. 1, 7, Sch. 4
- **F38** Words in art. 1(2) inserted (4.4.2003) by The Prescription Only Medicines (Human Use) Amendment Order 2003 (S.I. 2003/696), arts. 1(1), **2(2)(k)**
- **F39** Word in art. 1(2) omitted (1.8.2004) by virtue of The Health Act 1999 (Consequential Amendments) (Nursing and Midwifery) Order 2004 (S.I. 2004/1771), art. 1(1), Sch. para. 39(a)(viii)
- **F40** Word in art. 1(2) omitted (7.4.2005) by virtue of The Medicines for Human Use (Prescribing) Order 2005 (S.I. 2005/765), arts. 1(1), **3(b)(i)**
- F41 Words in art. 1(2) inserted (1.8.2004) by The Health Act 1999 (Consequential Amendments) (Nursing and Midwifery) Order 2004 (S.I. 2004/1771), art. 1(1), Sch. para. 39(a)(viii)
- **F42** Word in art. 1(2)(c) omitted (30.6.2005) by virtue of The Medicines for Human Use (Prescribing) (Miscellaneous Amendments) Order 2005 (S.I. 2005/1507), arts. 1(1), **3(c)(i)**

- **F43** Words in art. 1(2) inserted (7.4.2005) by The Medicines for Human Use (Prescribing) Order 2005 (S.I. 2005/765), arts. 1(1), **3(b)(iii)**
- F44 Word in art. 1(2)(d) inserted (30.6.2005) by The Medicines for Human Use (Prescribing) (Miscellaneous Amendments) Order 2005 (S.I. 2005/1507), arts. 1(1), 3(c)(ii)
- **F45** Art. 1(2)(e) inserted (30.6.2005) by The Medicines for Human Use (Prescribing) (Miscellaneous Amendments) Order 2005 (S.I. 2005/1507), arts. 1(1), **3(c)(iii)**
- F46 Words in art. 1(2) inserted (7.4.2005) by The Medicines for Human Use (Prescribing) Order 2005 (S.I. 2005/765), arts. 1(1), 3(c)
- F47 Words in art. 1(5) substituted (1.4.2002) by The Prescription Only Medicines (Human Use) Amendment Order 2002 (S.I. 2002/549), arts. 1(1), **2(3)**
- **F48** Words in art. 1(7)-(9) inserted (9.8.2000) by The Prescription Only Medicines (Human Use) Amendment Order 2000 (S.I. 2000/1917), arts. 1(1), **2(b)**
- **F49** Word in art. 1(7) substituted (4.4.2003) by The Prescription Only Medicines (Human Use) Amendment Order 2003 (S.I. 2003/696), arts. 1(1), **2(3)**

Appropriate practitioners

2. For the purposes of section 58 (medicinal products on prescription only), the following shall be appropriate practitioners–

- (a) in relation to the descriptions and classes of medicinal products specified in article
 3, doctors, dentists [^{F50}, supplementary prescribers], veterinary surgeons and veterinary practitioners;
- [^{F51}(b) in relation to the descriptions and classes of medicinal products specified in Schedule 3, district nurse/health visitor prescribers;
 - (c) in relation to the descriptions and classes of medicinal products specified in article 3A(1), extended formulary nurse prescribers.]

Textual Amendments

- **F50** Words in art. 2(a) inserted (4.4.2003) by The Prescription Only Medicines (Human Use) Amendment Order 2003 (S.I. 2003/696), arts. 1(1), **3**
- **F51** Art. 2(b)(c) substituted for art. 2(b) (1.4.2002) by The Prescription Only Medicines (Human Use) Amendment Order 2002 (S.I. 2002/549), arts. 1(1), **3**

[^{F52}Medicinal products on prescription only

3. The following descriptions and classes of medicinal products are specified for the purposes of section 58, namely—

- (a) medicinal products in respect of which a marketing authorization has been granted, which in the marketing authorization are classified as being prescription only medicines;
- (b) medicinal products in respect of which no marketing authorization has been granted consisting of or containing a substance listed in column 1 of Schedule 1;
- (c) medicinal products that are for parenteral administration;
- (d) medicinal products that are controlled drugs unless a marketing authorization has been granted in respect of that medicinal product in which the product is classified as being a pharmacy only or on general sale list medicine;
- (e) cyanogenetic substances, other than preparations for external use;

- (f) medicinal products that on administration emit radiation, or contain or generate any substance which emits radiation, in order that radiation may be used.
- [^{F53}(g) medicinal products in respect of which a marketing authorization has been granted consisting of or containing aloxiprin, aspirin or paracetamol in the form of non-effervescent tablets or capsules which in the marketing authorization are classified as being pharmacy only or general sale list medicines.]]

Textual Amendments

- **F52** Art. 3 substituted (1.4.2002) by The Prescription Only Medicines (Human Use) Amendment Order 2002 (S.I. 2002/549), arts. 1(1), 4
- **F53** Art. 3(g) added (4.4.2003) by The Prescription Only Medicines (Human Use) Amendment Order 2003 (S.I. 2003/696), arts. 1(1), 4

[^{F54}Prescribing by extended formulary nurse prescribers

3A.—(1) Subject to paragraph (2), the description and classes of medicinal products in relation to which extended formulary nurse prescribers are appropriate practitioners are those prescription only medicines which consist of, or contain, one or more of the substances specified in column 1 of Schedule 3A, but which do not contain any other substance or combination of substances which is a prescription only medicine not included in Schedule 3A.

- (2) [^{F55}Subject to paragraph (4),] an extended formulary nurse prescriber may—
 - (a) give a prescription for a medicinal product referred to in paragraph (1); or
 - (b) if that medicinal product is for parenteral administration—

(i) administer that medicinal product, or

(ii) give directions for the administration of that medicinal product,

only where he complies with any condition as to the cases or circumstances in which he may do so that is specified by virtue of paragraph (3).

(3) If the entry in column 2 of Schedule 3A relating to a substance specifies one or more requirements as to use, route of administration or pharmaceutical form, it is a condition for the purposes of paragraph (2) that a medicinal product which consists of, or contains, that substance is administered, or is prescribed or directed for administration, in accordance with the specified requirements.

^{F56}(4) An extended formulary nurse prescriber may prescribe or administer a medicinal product referred to in paragraph (1), or give directions for administration of such a product, without complying with any condition specified by virtue of paragraph (3) if—

- (a) he is a supplementary prescriber; and
- (b) he complies with the applicable conditions set out in article 3B(3).]]

Textual Amendments

- F54 Art. 3A inserted (1.4.2002) by The Prescription Only Medicines (Human Use) Amendment Order 2002 (S.I. 2002/549), arts. 1(1), 5
- **F55** Words in art. 3A(2) inserted (4.4.2003) by The Prescription Only Medicines (Human Use) Amendment Order 2003 (S.I. 2003/696), arts. 1(1), **5(a)**

F56 Art. 3A(4) added (4.4.2003) by The Prescription Only Medicines (Human Use) Amendment Order 2003 (S.I. 2003/696), arts. 1(1), **5(b)**

[^{F57}Prescribing and administration by supplementary prescribers

- **3B.**—(1) Subject to paragraph (2), a supplementary prescriber may—
 - (a) give a prescription for a medicinal product referred to in article 3; or
 - (b) if that medicinal product is for parenteral administration—
 - (i) administer that medicinal product, or
 - (ii) give directions for the administration of that medicinal product,

only where he complies with the conditions as to the cases or circumstances in which he may do so specified in paragraph (3).

- (2) Paragraph (1) does not apply if-
 - (a) the supplementary prescriber is a district nurse/health visitor prescriber and the medicinal product prescribed or administered, or in respect of which he gives directions for administration, falls within a description or class of medicinal products specified in Schedule 3; or
 - (b) the supplementary prescriber is an extended formulary nurse prescriber and—
 - (i) the medicinal product prescribed or administered, or in respect of which he gives directions for administration, falls within a description or class of medicinal products specified in article 3A(1), and
 - (ii) he satisfies any applicable condition specified by virtue of article 3A(3).
- (3) The conditions referred to in paragraph (1) are that—
 - (a) the supplementary prescriber is acting in accordance with the terms of a clinical management plan which—
 - (i) relates to the patient for whom the product is prescribed or to whom it is, or is to be, administered,
 - (ii) is in effect at the time the prescription or direction is given or, as the case may be, the product is administered, and
 - (iii) includes the particulars specified in Schedule 3B;
- $^{F58}(b)$
 - (c) the supplementary prescriber has access to the health records of the patient to whom the plan relates which are used by any doctor or dentist who is a party to the plan.

Textual Amendments

- F57 Arts. 3B, 3C inserted (4.4.2003) by The Prescription Only Medicines (Human Use) Amendment Order 2003 (S.I. 2003/696), arts. 1(1), 6
- F58 Art. 3B(3)(b) omitted (7.4.2005) by virtue of The Medicines for Human Use (Prescribing) Order 2005 (S.I. 2005/765), arts. 1(1), 4

Exemptions from conditions in respect of the cases or circumstances in which an extended formulary nurse prescriber or supplementary prescriber may administer a medicinal product

3C. The conditions specified by virtue of article 3A(3) and in article 3B(3) shall not apply in relation to the administration of a medicinal product by an extended formulary nurse prescriber or a supplementary prescriber where-

- (a) that person is acting in accordance with the directions of another person who is an appropriate practitioner, or
- (b) that administration is exempt from the restriction in section 58(2)(b) (restriction on administration) by virtue of any of the subsequent provisions of this Order.]

Textual Amendments

F57 Arts. 3B, 3C inserted (4.4.2003) by The Prescription Only Medicines (Human Use) Amendment Order 2003 (S.I. 2003/696), arts. 1(1), 6

Duration of special provisions in relation to new medicinal products

Textual Amendments

F59 Art. 4 revoked (1.4.2002) by The Prescription Only Medicines (Human Use) Amendment Order 2002 (S.I. 2002/549), arts. 1(1), 11

Exempt medicinal products

5.—(1) A medicinal product shall be exempt from the restrictions imposed by section 58(2)(a)(restrictions on sale or supply) if it, or a substance in it, is listed in column 1 of Schedule 1 and there-

- (a) is an entry in column 2, 3, 4 or 5 of that Schedule which contains a condition and that condition is satisfied in accordance with the following provisions of this article; or
- (b) there is more than one such condition which applies where that substance is used in that product and each of those conditions is so satisfied.

(2) Where a maximum strength is specified in column 2 in relation to a substance, a medicinal product which consists of or contains that substance satisfies the condition where the maximum strength of that substance in that medicinal product, or where specified in that column the maximum strength of a medicinal product which contains that substance, does not exceed that specified maximum or, where the medicinal product consists of more than one of the substances sodium fluoride, sodium monofluorophosphate or stannous fluoride combined in a dentifrice, where the maximum strength of that combination of substances in a product does not exceed the equivalent of 0.15 per cent of fluorine.

(3) Where a route of administration is specified in column 3 in relation to a substance, a medicinal product which consists of or contains that substance satisfies the condition where it is sold or supplied for administration only by that route.

(4) Where a use is specified in column 3 in relation to a substance, a medicinal product which consists of or contains that substance satisfies the condition in respect of use where it is sold or supplied only for use-

(a) where a purpose for which it may be used is so specified, for that purpose;

(b) where the class of persons in whom it may be used is so specified, in persons of that class I^{F60} .

provided that, where the entry in column 3 contains a condition to the effect that the product is to be wholly or mainly for use in a specified class of persons, the product satisfies that condition where it is sold or supplied wholly or mainly for use in persons of that class].

(5) Where a pharmaceutical form is specified in column 3 in relation to a substance, a medicinal product which consists of or contains that substance satisfies the condition where it is sold or supplied in that pharmaceutical form.

(6) Where a maximum dose is specified in column 4 in relation to a substance, a medicinal product which consists of or contains that substance satisfies the condition where it is sold or supplied for use at a maximum dose which does not exceed that specified maximum dose.

(7) Subject to paragraph (8), where a maximum daily dose is specified in column 4 in relation to a substance, a medicinal product which consists of or contains that substance satisfies the condition where it is sold or supplied for use at a maximum daily dose which does not exceed that specified maximum daily dose.

(8) A medicinal product which contains more than one of the substances-

Atropine

Atropine Methobromide

Atropine Methonitrate

Atropine Oxide Hydrochloride

Atropine Sulphate

Hyoscine

- Hyoscine Butylbromide
- Hyoscine Hydrobromide
- Hyoscine Methobromide
- Hyoscine Methonitrate

Hyoscyamine

- Hyoscyamine Hydrobromide
- Hyoscyamine Sulphate,

satisfies the condition only where it is sold or supplied for use at a maximum daily dose which does not exceed 1 milligram in total of the alkaloids derived from belladonna, hyoscyamus, stramonium or other solanaceous plant which are contained in that medicinal product.

(9) Where a maximum period of use or a maximum frequency of use is specified in column 4 in relation to a substance, a medicinal product which consists of or contains that substance satisfies the condition where it is sold or supplied for use for a maximum period or frequency, as the case may be, which does not exceed the maximum period of use or the maximum frequency of use which is so specified.

(10) Where a maximum quantity is specified in column 5 in relation to a substance, a medicinal product which consists of or contains that substance satisfies the condition where it, or where so specified in that column, the medicinal product which contains that substance is sold or supplied in a quantity which does not exceed that specified maximum quantity.

(11) In paragraphs (2) to (7) and (9) and (10) a reference to a numbered column is a reference to the column bearing that number in Schedule 1.

Textual Amendments F60 Words in art. 5(4) added (16.11.2000) by The Prescription Only Medicines (Human Use) Amendment (No. 2) Order 2000 (S.I. 2000/2899), arts. 1(1), 2

[^{F61}Exemption for products consisting of or containing aloxiprin, aspirin or paracetamol

5A. A medicinal product falling within article 3(g) shall be exempt from the restrictions imposed by section 58(2) (restrictions on sale, supply and administration) if the quantity of that product sold or supplied to a person at any one time does not exceed 100 tablets or capsules.]

```
Textual Amendments
```

Circumstances in which controlled drugs and medicinal products authorized by the European Community are not prescription only medicines

```
Textual Amendments
```

F62 Art. 6 revoked (1.4.2002) by The Prescription Only Medicines (Human Use) Amendment Order 2002 (S.I. 2002/549), arts. 1(1), 11

Exemption for parenteral administration in an emergency to human beings of certain prescription only medicines

7. The restriction imposed by section 58(2)(b) (restriction on administration) shall not apply to the administration to human beings of any of the following medicinal products for parenteral administration–

Adrenaline Injection 1 in 1000 (1 mg in 1 ml)

Atropine Sulphate Injection

[^{F63}Atropine sulphate and obidoxime chloride injection]

[^{F63}Atropine sulphate and pralidoxime chloride injection]

[^{F63}Atropine sulphate, pralidoxime mesilate and avizafone injection]

[^{F64}Chlorphenamine Injection]

[^{F65}Dicobalt Edetate Injection]

F66

F66

Glucagon Injection

[^{F67}Glucose Injection 50%]

Hydrocortisone Injection

[^{F68}Naloxone Hydrochloride]

F61 Art. 5A inserted (4.4.2003) by The Prescription Only Medicines (Human Use) Amendment Order 2003 (S.I. 2003/696), arts. 1(1), 7

[^{F63}Pralidoxime chloride injection] [^{F63}Pralidoxime mesilate injection] Promethazine Hydrochloride Injection Snake Venom Antiserum Sodium Nitrite Injection Sodium Thiosulphate Injection Sterile Pralidoxime

where the administration is for the purpose of saving life in an emergency.

Textual Amendments

- **F63** Words in art. 7 inserted (19.11.2004) by The Prescription Only Medicines (Human Use) Amendment (No. 3) Order 2004 (S.I. 2004/2693), arts. 1(1), **3**
- **F64** Words in art. 7 substituted (30.6.2005) by The Medicines for Human Use (Prescribing) (Miscellaneous Amendments) Order 2005 (S.I. 2005/1507), arts. 1(1), **4(a)**
- **F65** Words in art. 7 substituted (30.6.2005) by The Medicines for Human Use (Prescribing) (Miscellaneous Amendments) Order 2005 (S.I. 2005/1507), arts. 1(1), **4(b)**
- **F66** Words in art. 7 omitted (30.6.2005) by virtue of The Medicines for Human Use (Prescribing) (Miscellaneous Amendments) Order 2005 (S.I. 2005/1507), arts. 1(1), **4(c)**
- **F67** Words in art. 7 inserted (30.6.2005) by The Medicines for Human Use (Prescribing) (Miscellaneous Amendments) Order 2005 (S.I. 2005/1507), arts. 1(1), 4(d)
- **F68** Words in art. 7 substituted (30.6.2005) by The Medicines for Human Use (Prescribing) (Miscellaneous Amendments) Order 2005 (S.I. 2005/1507), arts. 1(1), 4(e)

[^{F69}Exemptions for administration of smallpox vaccine

7A.—(1) The restriction imposed by section 58(2)(b) (restriction on administration) shall not apply to the administration to human beings of smallpox vaccine where the conditions specified in paragraph (2) or (3) are satisfied.

(2) The conditions referred to in this paragraph are—

- (a) the vaccine has been supplied by, or on behalf of, or under arrangements made by—
 - (i) the Secretary of State,
 - (ii) the Scottish Ministers,
 - (iii) the National Assembly for Wales,
 - (iv) the Department of Health, Social Services and Public Safety,
 - (v) an NHS body; and
- (b) the vaccine is administered for the purpose of providing protection against smallpox virus in the event of a suspected or confirmed case of smallpox in the United Kingdom.
- (3) The conditions referred to in this paragraph are—
 - (a) the vaccine has been supplied by, or on behalf of, or under arrangements made by Her Majesty's Forces;
 - (b) the vaccine is administered for the purpose of providing protection against smallpox virus to—
 - (i) members of Her Majesty's Forces; or
 - (ii) other persons employed or engaged by those Forces.

- (4) For the purposes of this regulation, "NHS body" means-
 - (a) the Common Services Agency,
 - (b) a Strategic Health Authority, Health Authority or Special Health Authority,
 - (c) a Primary Care Trust,
 - (d) a Local Health Board, or
 - (e) an NHS trust or NHS foundation trust]

Textual Amendments

F69 Art. 7A inserted (19.11.2004) by The Prescription Only Medicines (Human Use) Amendment (No. 3) Order 2004 (S.I. 2004/2693), arts. 1(1), 4

Exemptions for emergency sale or supply

8.—(1) The restrictions imposed by section 58(2)(a) (restriction on sale and supply) shall not apply to the sale or supply of a prescription only medicine by a person lawfully conducting a retail pharmacy business where the conditions specified in paragraph (2) are satisfied.

- (2) The conditions referred to in paragraph (1) are-
 - (a) that the pharmacist by or under whose supervision the prescription only medicine is to be sold or supplied is satisfied that the sale or supply has been requested by a doctor [^{F70}, a supplementary prescriber][^{F71}, a district nurse/health visitor prescriber or an extended formulary nurse prescriber] who by reason of an emergency is unable to furnish a prescription immediately;
 - (b) that the doctor [^{F72}, supplementary prescriber][^{F73}, district nurse/health visitor prescriber or extended formulary nurse prescriber] has undertaken to furnish the person lawfully conducting a retail pharmacy business with a prescription within 72 hours of the sale or supply;
 - (c) that the prescription only medicine is sold or supplied in accordance with the directions of the doctor [^{F74}, supplementary prescriber][^{F75}, district nurse/health visitor prescriber or extended formulary nurse prescriber] requesting it;
 - (d) subject to paragraph (5), that the prescription only medicine is not a controlled drug specified in Schedule 1, 2 or 3 to the Misuse of Drugs Regulations;
 - (e) that an entry is made in the record kept under regulation 6 of the Medicines (Sale or Supply) (Miscellaneous Provisions) Regulations 1980(12) within the time specified in that regulation stating the particulars required under paragraph 1 of Schedule 2 to those Regulations.

(3) The restrictions imposed by section 58(2)(a) shall not apply to the sale or supply of a prescription only medicine by a person lawfully conducting a retail pharmacy business where the conditions specified in paragraph (4) are satisfied.

(4) The conditions referred to in paragraph (3) are-

(a) that the pharmacist by or under whose supervision the prescription only medicine is to be sold or supplied has interviewed the person requesting a prescription only medicine and has satisfied himself-

(12) S.I. 1980/1923, amended by S.I. 1997/1831.

- (i) that there is an immediate need for the prescription only medicine requested to be sold or supplied and that it is impracticable in the circumstances to obtain a prescription without undue delay,
- (ii) that treatment with the prescription only medicine requested has on a previous occasion been prescribed by a doctor [^{F76}, supplementary prescriber][^{F77}, district nurse/health visitor prescriber or extended formulary nurse prescriber] for the person requesting it, and
- (iii) as to the dose which in the circumstances it would be appropriate for that person to take;
- (b) that no greater quantity of the prescription only medicine than will provide 5 days' treatment is sold or supplied except that where the prescription only medicine–
 - (i) is [^{F78}a preparation of insulin,] an aerosol for the relief of asthma, an ointment or cream, and has been made up for sale in a container elsewhere than at the place of sale or supply, the smallest pack that the pharmacist has available for sale or supply may be sold or supplied,
 - (ii) is an oral contraceptive, a quantity sufficient for a full treatment cycle may be sold or supplied,
 - (iii) is an antibiotic for oral administration in liquid form, the smallest quantity that will provide a full course of treatment may be sold or supplied;
- (c) subject to paragraph (5), that the prescription only medicine does not consist of or contain a substance specified in Schedule 4 to this Order and is not a controlled drug specified in Schedule 1, 2 or 3 to the Misuse of Drugs Regulations;
- (d) that an entry is made in the record kept under regulation 6 of the Medicines (Sale or Supply) (Miscellaneous Provisions) Regulations 1980 within the time specified in that regulation stating the particulars required under paragraph 3 of Schedule 2 to those Regulations;
- (e) that the container or package of the prescription only medicine is labelled so as to show-
 - (i) the date on which the prescription only medicine is sold or supplied,
 - (ii) the name, quantity and, except where it is apparent from the name, the pharmaceutical form and strength of the prescription only medicine,
 - (iii) the name of the person requesting the prescription only medicine,
 - (iv) the name and address of the registered pharmacy from which the prescription only medicine is sold or supplied, and
 - (v) the words "Emergency Supply".

(5) The conditions specified in paragraphs (2)(d) and (4)(c) shall not apply where the prescription only medicine consists of or contains phenobarbitone or phenobarbitone sodium (but no other substance specified in Schedule 4 to this Order or Schedule 1, 2 or 3 to the Misuse of Drugs Regulations) and is sold or supplied for use in the treatment of epilepsy.

Textual Amendments

- **F70** Words in art. 8(2)(a) inserted (4.4.2003) by The Prescription Only Medicines (Human Use) Amendment Order 2003 (S.I. 2003/696), arts. 1(1), 8(a)(i)
- **F71** Words in art. 8(2)(a) inserted (1.4.2002) by The Prescription Only Medicines (Human Use) Amendment Order 2002 (S.I. 2002/549), arts. 1(1), **6(a)(i)**
- **F72** Words in art. 8(2)(b) inserted (4.4.2003) by The Prescription Only Medicines (Human Use) Amendment Order 2003 (S.I. 2003/696), arts. 1(1), 8(a)(ii)

F73	Words in art. 8(2)(b) inserted (1.4.2002) by The Prescription Only Medicines (Human Use)
	Amendment Order 2002 (S.I. 2002/549), arts. 1(1), 6(a)(ii)
F74	Words in art. 8(2)(c) inserted (4.4.2003) by The Prescription Only Medicines (Human Use)
	Amendment Order 2003 (S.I. 2003/696), arts. 1(1), 8(a)(iii)
F75	Words in art. 8(2)(c) inserted (1.4.2002) by The Prescription Only Medicines (Human Use)
	Amendment Order 2002 (S.I. 2002/549), arts. 1(1), 6(a)(iii)
F76	Words in art. 8(4)(a)(ii) inserted (4.4.2003) by The Prescription Only Medicines (Human Use)
	Amendment Order 2003 (S.I. 2003/696), arts. 1(1), 8(b)
F77	Words in art. 8(4)(a)(ii) inserted (1.4.2002) by The Prescription Only Medicines (Human Use)

- Amendment Order 2002 (S.I. 2002/549), arts. 1(1), **6(b) F78** Words in art. 8(4)(b)(i) inserted (16.9.1998) by The Prescription Only Medicines (Human Use)
- Amendment (No. 3) Order 1998 (S.I. 1998/2081), arts. 1(1), **2**

Exemption for non-parenteral administration to human beings

9. The restriction imposed by section 58(2)(b) (restriction on administration) shall not apply to the administration to human beings of a prescription only medicine which is not for parenteral administration.

Exemption for medicinal products at high dilutions

10.— $[^{F79}(1)]$ The restrictions imposed by section 58(2) (restrictions on sale, supply and administration) shall not apply to the sale, supply or administration of a medicinal product which is not for parenteral administration and which consists of or contains, any of the substances listed in column 1 of Schedule 1 or 2, only one or more unit preparation of such substances, if—

- (a) each such unit preparation has been diluted to at least one part in a million (6x), and the person selling, supplying or administering the medicinal product has been requested by or on behalf of a particular person and in that person's presence to use his own judgment as to the treatment required; or
- (b) each such unit preparation has been diluted to at least one part in a million million (6c).

[^{F80}(2) The restrictions imposed by section 58(2) (restrictions on sale, supply and administration) shall not apply to the sale, supply or administration of a medicinal product which is not for parenteral administration and which consists of or contains solely one or more unit preparations of the following substances—

Aconite Arsenic Trioxide Belladonna Herb Ignatia Bean Nux Vomica Seed,

if each such unit preparation has been diluted to at least one part in a million (6x)]

Textual Amendments F79 Art. 10 renumbered as art. 10(1) (4.4.2003) by The Prescription Only Medicines (Human Use) Amendment Order 2003 (S.I. 2003/696), arts. 1(1), 9 F80 Art. 10(2) inserted (4.4.2003) by The Prescription Only Medicines (Human Use) Amendment Order 2003 (S.I. 2003/696), arts. 1(1), 9

Exemptions for certain persons

11.—(1) The restrictions imposed by section 58(2)(a) (restrictions on sale and supply) shall not apply–

- (a) to the sale or supply by a person listed in column 1 of Part I of Schedule 5 of the prescription only medicines listed in relation to that person in column 2 of that Part where the conditions specified in the corresponding paragraphs in column 3 of that Part are satisfied;
- (b) to the supply by a person listed in column 1 of Part II of Schedule 5 of the prescription only medicines listed in relation to that person in column 2 of that Part where the conditions specified in the corresponding paragraphs in column 3 of that Part are satisfied.

(2) The restriction imposed by section 58(2)(b) (restriction on administration) shall not apply to the administration by a person listed in column 1 of Part III of Schedule 5 of the prescription only medicines for parenteral administration listed in relation to that person in column 2 of that Part where the conditions specified in the corresponding paragraphs in column 3 of that Part are satisfied.

[^{F81}Exemption for sale or supply in hospitals

12.—(1) Subject to paragraph (3), the restrictions imposed by section 58(2)(a) (restrictions on sale and supply) shall not apply to the sale or supply of a prescription only medicine in the course of the business of a hospital where the medicine is sold or supplied for the purpose of being administered (whether in the hospital or elsewhere) to a particular person in accordance with directions satisfying the conditions specified in paragraph (2).

(2) The conditions specified in paragraph (1) are that the directions—

- (a) are in writing;
- (b) relate to the particular person to whom the medicine is to be administered; and
- (c) are given by a person (other than a veterinary surgeon or veterinary practitioner) who is an appropriate practitioner in relation to that medicine.

(3) Such directions may be given by an extended formulary nurse prescriber or a supplementary prescriber only where he complies with any condition as to the cases or circumstances in which he may give a prescription for that medicine specified by virtue of article 3A or 3B, as if the directions are a prescription.

(4) The exemption in paragraph (1) applies notwithstanding that the directions do not satisfy the conditions specified in article 15(2).]

Textual Amendments

F81 Art. 12 substituted (31.1.2004) by The Prescription Only Medicines (Human Use) Amendment Order 2004 (S.I. 2004/2), arts. 1(1), **2**

[^{F82}Exemptions for the supply and administration of prescription only medicines by national health service bodies

12A.—(1) The restrictions imposed by section 58(2)(a) (restrictions on sale and supply) shall not apply to the supply of a prescription only medicine by—

- (a) the Common Services Agency;
- (b) a [^{F83}Strategic Health Authority,] Health Authority or Special Health Authority;
- (c) an NHS trust [^{F84}or NHS foundation trust];
- (d) a Primary Care Trust; or

(e) where sub-paragraphs (a) to (d) do not apply, a person other than an excepted person, pursuant to an arrangement made with one of the persons specified in those sub-paragraphs for the supply of prescription only medicines,

where the medicine is supplied for the purpose of being administered to a particular person in accordance with the written directions of a doctor or dentist relating to that person notwithstanding that those directions do not satisfy the conditions specified in article 15(2).

(2) The restrictions imposed by section 58(2) (restrictions on sale, supply and administration) shall not apply to the supply or, as the case may be, the administration of a prescription only medicine by—

- (a) the Common Services Agency;
- (b) a [^{F85}Strategic Health Authority,] Health Authority or Special Health Authority;
- (c) an NHS trust [^{F86} or NHS foundation trust];
- (d) a Primary Care Trust; or
- (e) where sub-paragraphs (a) to (d) do not apply, a person other than an excepted person, pursuant to an arrangement made with one of the persons specified in those sub-paragraphs for the supply or, as the case may be, the administration of prescription only medicines,

where the medicine is supplied for the purpose of being administered, or, as the case may be, is administered, to a particular person in accordance with a Patient Group Direction and where the conditions specified in paragraph (3) are satisfied.

- (3) The conditions referred to are that—
 - (a) the Patient Group Direction relates to the supply or, as the case may be, the administration, by the person who supplies or administers the medicine, of a description or class of prescription only medicine, and the Direction has effect at the time at which the medicine is supplied or, as the case may be, is administered;
 - (b) the Patient Group Direction contains the particulars specified in Part I of Schedule 7 to this Order (but with the omission of paragraph (c) of that Part in the case of a Direction which relates to administration only);
 - (c) the Patient Group Direction is signed on behalf of the person specified in column 2 of the Table in Part II of Schedule 7 to this Order ("the authorising person") against the entry in column 1 of that Table for the class of person by whom the medicine is supplied or administered;
 - (d) the individual who supplies or, as the case may be, administers the medicine belongs to one of the classes of individual specified in Part III of Schedule 7 to this Order, and is designated in writing, on behalf of the authorising person, for the purpose of the supply or, as the case may be, the administration of prescription only medicines under the Patient Group Direction; and
 - (e) at the time at which the medicine is supplied or, as the case may be, is administered, a product licence, a marketing authorization or a homoeopathic certificate of registration has effect in respect of it.
- (4) In this article, "excepted person" means-
 - (a) a doctor or dentist; or
 - (b) a person lawfully conducting a retail pharmacy business within the meaning of section 69.

Textual Amendments

F82 Arts. 12A-12C inserted (9.8.2000) by The Prescription Only Medicines (Human Use) Amendment Order 2000 (S.I. 2000/1917), arts. 1(1), **2(d)**

- **F83** Words in art. 12A(1)(b) inserted (1.10.2002) by The National Health Service Reform and Health Care Professions Act 2002 (Supplementary, Consequential etc. Provisions) Regulations 2002 (S.I. 2002/2469), reg. 1, Sch. 1 para. 73(2)(a)
- F84 Words in art. 12A(1)(c) inserted (1.4.2004) by The Health and Social Care (Community Health and Standards) Act 2003 (Supplementary and Consequential Provision) (NHS Foundation Trusts) Order 2004 (S.I. 2004/696), arts. 1(1)(b), 3(2), Sch. 2
- F85 Words in art. 12A(2)(b) inserted (1.10.2002) by The National Health Service Reform and Health Care Professions Act 2002 (Supplementary, Consequential etc. Provisions) Regulations 2002 (S.I. 2002/2469), reg. 1, Sch. 1 para. 73(2)(b)
- F86 Words in art. 12A(2)(c) inserted (1.4.2004) by The Health and Social Care (Community Health and Standards) Act 2003 (Supplementary and Consequential Provision) (NHS Foundation Trusts) Order 2004 (S.I. 2004/696), arts. 1(1)(b), 3(2), Sch. 2

Exemption for health professionals who supply or administer prescription only medicines under a Patient Group Direction in order to assist doctors or dentists in providing national health services

12B.—(1) The restrictions imposed by section 58(2) (sale, supply and administration) shall not apply to the supply or, as the case may be, the administration of a prescription only medicine by an individual belonging to one of the classes specified in Part III of Schedule 7 to this Order where—

- (a) the individual supplies or, as the case may be, administers the medicine in order to assist a doctor or dentist in the provision of, respectively, NHS primary medical services or NHS primary dental services;
- (b) the medicine is supplied for the purpose of being administered, or, as the case may be, is administered, in accordance with a Patient Group Direction; and
- (c) the conditions specified in paragraph (2) are satisfied.

(2) The conditions referred to are that—

- (a) the Patient Group Direction relates to the supply or, as the case may be, the administration of a description or class of prescription only medicine in order to assist the doctor or dentist in question in providing the services referred to in paragraph (1)(a) (whether or not it also relates to such supply or administration in order to assist any other doctor or dentist);
- (b) the Patient Group Direction has effect at the time at which the medicine is supplied or, as the case may be, is administered;
- (c) the Patient Group Direction contains the particulars specified in Part I of Schedule 7 to this Order (but with the omission of paragraph (c) of that Part in the case of a Direction which relates to administration only);
- (d) the Patient Group Direction is signed—
 - (i) by the doctor or dentist in question or, alternatively, where the Direction also relates to supply or administration in order to assist one or more other doctors or dentists, as referred to in sub-paragraph (a), by one of those other doctors or dentists; and
 - (ii) on behalf of the health authority [^{F87} or Primary Care Trust]—
 - (a) in the case of the provision of general medical services or general dental services, with which an arrangement has been made for the provision of those services; or
 - (b) in the case of the performance of personal medical services or personal dental services, which is a party to the pilot scheme under which those services are provided;

- (e) the individual referred to in paragraph (1) is designated in writing for the purpose of the supply or, as the case may be, the administration of prescription only medicines under the Patient Group Direction, by the doctor or dentist in question, or, alternatively, where the Direction also relates to supply or administration in order to assist one or more other doctors or dentists, as referred to in sub-paragraph (a), by one of those other doctors or dentists; and
- (f) at the time at which the medicine is supplied or, as the case may be, is administered, a product licence, a marketing authorization or a homoeopathic certificate of registration has effect in respect of it.
- (3) In this article—
 - (a) a reference to the provision of NHS primary dental services shall be construed as a reference to—
 - (i) in relation to England and Wales, the provision of general dental services under Part II of the National Health Service Act 1977, or the performance of personal dental services in connection with a pilot scheme under the National Health Service (Primary Care) Act 1997;
 - (ii) in relation to Scotland, the provision of general dental services under Part II of the National Health Service (Scotland) Act 1978, or the performance of personal dental services in connection with a pilot scheme under the National Health Service (Primary Care) Act 1997; and
 - (iii) in relation to Northern Ireland, the provision of general dental services under the Health and Personal Social Services (Northern Ireland) Order 1972, or the performance of personal dental services in connection with a pilot scheme under the Health Services (Primary Care) (Northern Ireland) Order 1997;
 - (b) a reference to the provision of NHS primary medical services shall be construed as a reference to—
 - [^{F88}(i) in relation to England and Wales, the provision of primary medical services under Part I of the National Health Service Act 1977;]
 - [^{F89}(ii) in relation to Scotland, the provision of primary medical services under Part I of the National Health Service (Scotland) Act 1978; and]
 - [^{F90}(iii) in relation to Northern Ireland, the provision of primary medical services under Article 15B or Part VI of the Health and Personal Social Services (Northern Ireland) Order 1972.]

Textual Amendments

- **F82** Arts. 12A-12C inserted (9.8.2000) by The Prescription Only Medicines (Human Use) Amendment Order 2000 (S.I. 2000/1917), arts. 1(1), **2(d)**
- F87 Words in art. 12B(2)(d)(ii) inserted (1.10.2002) by The National Health Service Reform and Health Care Professions Act 2002 (Supplementary, Consequential etc. Provisions) Regulations 2002 (S.I. 2002/2469), regs. 1, 8, Sch. 5
- F88 Art. 12B(3)(b)(i) substituted (E.) (1.4.2004) by The General Medical Services and Personal Medical Services Transitional and Consequential Provisions Order 2004 (S.I. 2004/865), art. 1(1), Sch. 1 para. 18(2); and substituted (W.) by The General Medical Services Transitional and Consequential Provisions (Wales) (No. 2) Order 2004 (S.I. 2004/1016), art. 1(1), Sch. 1 para. 18(2)
- F89 Art. 12B(3)(b)(ii) substituted (1.10.2004) by The Primary Medical Services (Scotland) Act 2004 (Consequential Amendments) Order 2004 (S.I. 2004/2261), art. 1(1), Sch. para. 2
- **F90** Art. 12B(3)(b)(iii) substituted (18.11.2004) by The Primary Medical Services (Northern Ireland) Order 2004 (Consequential Amendments) Order 2004 (S.I. 2004/3038), art. 1(1), **Sch. para. 3**

Exemption for persons conducting a retail pharmacy business who supply or administer prescription only medicines under a Patient Group Direction

12C.-(1) The restrictions imposed by section 58(2) (restrictions on sale, supply and administration) shall not apply to the supply or, as the case may be, the administration of a prescription only medicine by a person lawfully conducting a retail pharmacy business within the meaning of section 69 where-

- $[^{F91}(a)$ the medicine is supplied, or as the case may be, is administered by such a person pursuant to an arrangement made with—
 - (i) a body referred to in article 12A(a) to (d),
 - (ii) an authority or person carrying on the business of an establishment or agency referred to in article 12D(1),
 - (iii) a force or service referred to in article 12E(1)(a)(i) to (iii), or
 - (iv) Her Majesty's Forces,

for the supply or, as the case may be, the administration of prescription only medicines;]

- (b) the medicine is supplied for the purpose of being administered, or, as the case may be, is administered, to a particular person in accordance with a Patient Group Direction; and
- (c) the conditions specified in paragraph (2) are satisfied.
- (2) The conditions referred to are that—
 - (a) the Patient Group Direction relates to the supply or, as the case may be, the administration of a description or class of prescription only medicine by the person lawfully conducting a retail pharmacy business who supplies or, as the case may be, administers the prescription only medicine, and the Direction has effect at the time at which the medicine is supplied or, as the case may be, is administered;
 - (b) the Patient Group Direction contains the particulars specified in Part I of Schedule 7 to this Order (but with the omission of paragraph (c) of that Part in the case of a Direction which relates to administration only);
- [^{F92}(c) the Patient Group Direction is signed—
 - (i) in the case of an arrangement with a body referred to in article 12A(a) to (d), on behalf of that body,
 - (ii) in the case of an arrangement with an authority or person carrying on the business of an establishment or agency referred to in article 12D(1), by or on behalf of the relevant provider and, if there is a relevant manager for the establishment or agency, that manager,
 - (iii) in the case of an arrangement with a prison service, by or on behalf of the person specified in column 2 of the Table in Part IIA of Schedule 7 to this Order against the entry in column 1 of that Table for that service,
 - (iv) in the case of an arrangement with a police force or the Police Service of Northern Ireland—
 - (a) by or on behalf of the person specified in column 2 of the Table in Part IIA of Schedule 7 to this Order against the entry in column 1 of that Table for that force or service, and
 - (b) a doctor who is not employed or engaged by, and who does not provide services under arrangements made with, any police force or the Police Service of Northern Ireland, and

- (v) in the case of an arrangement with Her Majesty's Forces, by or on behalf of a person specified in column 2 of the Table in Part IIA of Schedule 7 to this Order against the entry in column 1 of that Table for Her Majesty's Forces;]
- [where the prescription only medicine is administered by the person lawfully conducting a ^{F93}(cc) retail pharmacy business within the meaning of section 69, the individual who administers the medicine belongs to one of the classes of individual specified in Part III of Schedule 7 to this Order, and is [^{F94}designated in writing—
 - (i) in the case of an arrangement with a body referred to in article 12A(a) to (d), on behalf of that body,
 - (ii) in the case of an arrangement with an authority or person carrying on the business of an establishment or agency referred to in article 12D(1), by or on behalf of the relevant provider or, if there is a relevant manager for the establishment or agency, that relevant manager,
 - (iii) in the case of an arrangement with a force or service referred to in article 12E(1)(a)
 (i) to (iii), by or on behalf of the person specified in column 2 of the Table in Part IIA of Schedule 7 to this Order against the entry in column 1 of that Table for that force or service, or
 - (iv) in the case of an arrangement with Her Majesty's Forces, by or on behalf of a person specified in column 2 of the Table in Part IIA of Schedule 7 to this Order against the entry in column 1 of that Table for Her Majesty's Forces,

for the purpose of the administration of prescription only medicines under the Patient Group Direction; and]]

(d) at the time at which the medicine is supplied or, as the case may be, is administered, a product licence, a marketing authorization or a homoeopathic certificate of registration has effect in respect of it.]

Textual Amendments

- **F82** Arts. 12A-12C inserted (9.8.2000) by The Prescription Only Medicines (Human Use) Amendment Order 2000 (S.I. 2000/1917), arts. 1(1), **2(d)**
- **F91** Art. 12C(1)(a) substituted (4.4.2003) by The Prescription Only Medicines (Human Use) Amendment Order 2003 (S.I. 2003/696), arts. 1(1), **10(a)**
- **F92** Art. 12C(2)(c) substituted (4.4.2003) by The Prescription Only Medicines (Human Use) Amendment Order 2003 (S.I. 2003/696), arts. 1(1), **10(b)(i)**
- **F93** Art. 12C(2)(cc) inserted (16.11.2000) by The Prescription Only Medicines (Human Use) Amendment (No. 2) Order 2000 (S.I. 2000/2899), arts. 1(1), **3(1)**
- **F94** Words in art. 12C(2)(cc) substituted (4.4.2003) by The Prescription Only Medicines (Human Use) Amendment Order 2003 (S.I. 2003/696), arts. 1(1), **10(b)(ii)**

[^{F95}Exemption for the supply and administration of prescription only medicines by independent hospitals, clinics and agencies

12D.—(1) The restrictions imposed by section 58(2) (restrictions on sale, supply and administration) shall not apply to the supply or, as the case may be, the administration of a prescription only medicine in the course of the business of—

- (a) in England, Wales or Scotland—
 - (i) an independent hospital,
 - (ii) an independent clinic, or

- (iii) an independent medical agency; or
- (b) in Northern Ireland, a nursing home,

where the medicine is supplied for the purpose of being administered, or, as the case may be, is administered, to a particular person in accordance with a Patient Group Direction and where the conditions specified in paragraph (2) are satisfied.

- (2) The conditions referred to are that—
 - (a) the Patient Group Direction relates to the supply or, as the case may be, the administration, by the person who supplies or administers the medicine, of a description or class of prescription only medicine, and the Direction has effect at the time at which the medicine is supplied or, as the case may be, is administered;
 - (b) the Patient Group Direction contains the particulars specified in Part I of Schedule 7 to this Order (but with the omission of paragraph (c) of that Part in the case of a Direction which relates to administration only);
 - (c) the Patient Group Direction is signed—
 - (i) by or on behalf of the registered provider, and
 - (ii) if there is a relevant manager for the independent hospital, clinic or agency, or nursing home, by that manager;
 - (d) the individual who supplies or, as the case may be, administers the medicine belongs to one of the classes of individual specified in Part III of Schedule 7 to this Order, and is designated in writing—
 - (i) by or on behalf of the registered provider, or
 - (ii) if there is a relevant manager for the independent hospital, clinic or agency, or nursing home, by that manager,

for the purpose of the supply or, as the case may be, the administration of prescription only medicines under the Patient Group Direction; and

(e) at the time at which the medicine is supplied or, as the case may be, is administered, a product licence, a marketing authorization or a homoeopathic certificate of registration has effect in respect of it.

Textual Amendments

```
F95 Arts. 12D, 12E inserted (4.4.2003) by The Prescription Only Medicines (Human Use) Amendment Order 2003 (S.I. 2003/696), arts. 1(1), 11
```

Exemption for health professionals who supply or administer prescription only medicines under a Patient Group Direction in order to assist the provision of health care by or on behalf of the police, the prison services or the armed forces

12E.—(1) The restrictions imposed by section 58(2) (sale, supply and administration) shall not apply to the supply or, as the case may be, the administration of a prescription only medicine by an individual belonging to one of the classes specified in Part III of Schedule 7 to this Order where—

- (a) the individual supplies or, as the case may be, administers the medicine in order to assist the provision of health care by, on behalf of, or under arrangements made by—
 - (i) a police force in England, Wales or Scotland,
 - (ii) the Police Service of Northern Ireland,
 - (iii) a prison service, or

(iv) Her Majesty's Forces;

- (b) the medicine is supplied for the purpose of being administered, or, as the case may be, is administered, in accordance with a Patient Group Direction; and
- (c) the conditions specified in paragraph (2) are satisfied.
- (2) The conditions referred to are that—
 - (a) the Patient Group Direction relates to the supply or, as the case may be, the administration of a description or class of prescription only medicine in order to assist the provision of health care by, or on behalf of, or under arrangements made by the police force or service, the prison service or, as the case may be, Her Majesty's Forces;
 - (b) the Patient Group Direction has effect at the time at which the medicine is supplied or, as the case may be, is administered;
 - (c) the Patient Group Direction contains the particulars specified in Part I of Schedule 7 to this Order (but with the omission of paragraph (c) of that Part in the case of a Direction which relates to administration only);
 - (d) the Patient Group Direction is signed—
 - (i) by or on behalf of a person specified in column 2 of the Table in Part IIA of Schedule 7 to this Order ("the authorising person") against the entry in column 1 of that Table for the police force or service, the prison service or Her Majesty's Forces by whom, or on whose behalf, the health care is provided, or with whom arrangements are made for the provision of such care; and
 - (ii) in the case of a police force or the Police Service of Northern Ireland, by a doctor who is not employed or engaged by, and who does not provide services under arrangements made with, any police force or the Police Service of Northern Ireland;
 - (e) the individual referred to in paragraph (1) is designated in writing, by or on behalf of the authorising person, for the purpose of the supply or, as the case may be, the administration of prescription only medicines under the Patient Group Direction; and
 - (f) at the time at which the medicine is supplied or, as the case may be, is administered, a product licence, a marketing authorization or a homoeopathic certificate of registration has effect in respect of it.]

Textual Amendments

F95 Arts. 12D, 12E inserted (4.4.2003) by The Prescription Only Medicines (Human Use) Amendment Order 2003 (S.I. 2003/696), arts. 1(1), **11**

Exemption in cases involving another's default

13. The restrictions imposed by section 58(2)(a) (restrictions on sale and supply) shall not apply to the sale or supply of a prescription only medicine by a person who, having exercised all due diligence, believes on reasonable grounds that the product sold or supplied is not a prescription only medicine.

[^{F96}Exemptions relating to prescriptions given by nurses

13A.— $[^{F97}(1)$ The restrictions imposed by section 58(2)(a) (restrictions in sale and supply) shall not apply to the sale or supply of a prescription only medicine by a pharmacist in accordance with a prescription given by—

(a) another pharmacist,

- (b) a registered nurse, ^{F98}...
- (c) a registered midwife, ^{F99}...
- [^{F100}(d) a person whose name is registered in the part of the register maintained by the Health Professions Council in pursuance of article 5 of the Health Professions Order 2001 relating to—
 - (i) chiropodists and podiatrists;
 - (ii) physiotherapists; or
 - (iii) radiographers: diagnostic or therapeutic, [^{F101}or]]
- [^{F102}(e) a registered optometrist,]

who is not an appropriate practitioner in relation to that medicine where the pharmacist selling or supplying the medicine, having exercised all due diligence, believes on reasonable grounds that the person is such a practitioner.]

(2) The restrictions imposed by section 58(2)(a) (restrictions on sale and supply) shall not apply to the sale or supply of a prescription only medicine by a pharmacist in accordance with a prescription given by an extended formulary nurse prescriber [^{F103}or supplementary prescriber] where the pharmacist, having exercised all due diligence, believes on reasonable grounds that the extended formulary nurse prescriber [^{F103}or supplementary prescriber] has complied with any condition with which he is required to comply by virtue of [^{F104}articles 3A(2) and (3) or 3B].]

Textual Amendments

- **F96** Art. 13A inserted (1.4.2002) by The Prescription Only Medicines (Human Use) Amendment Order 2002 (S.I. 2002/549), arts. 1(1), 7
- **F97** Art. 13A(1) substituted (4.4.2003) by The Prescription Only Medicines (Human Use) Amendment Order 2003 (S.I. 2003/696), arts. 1(1), **12(a)**
- **F98** Word in art. 13A(1)(b) omitted (7.4.2005) by virtue of The Medicines for Human Use (Prescribing) Order 2005 (S.I. 2005/765), arts. 1(1), **5(a)**
- **F99** Word in art. 13A(1)(c) omitted (30.6.2005) by virtue of The Medicines for Human Use (Prescribing) (Miscellaneous Amendments) Order 2005 (S.I. 2005/1507), arts. 1(1), **5(a)**
- **F100** Art. 13A(1)(d) inserted (7.4.2005) by The Medicines for Human Use (Prescribing) Order 2005 (S.I. 2005/765), arts. 1(1), **5(c)**
- **F101** Word in art. 13A(d) inserted (30.6.2005) by The Medicines for Human Use (Prescribing) (Miscellaneous Amendments) Order 2005 (S.I. 2005/1507), arts. 1(1), **5(b)**
- **F102** Art. 13A(e) inserted (30.6.2005) by The Medicines for Human Use (Prescribing) (Miscellaneous Amendments) Order 2005 (S.I. 2005/1507), arts. 1(1), **5(c)**
- **F103** Words in art. 13A(2) inserted (4.4.2003) by The Prescription Only Medicines (Human Use) Amendment Order 2003 (S.I. 2003/696), arts. 1(1), **12(b)(i)**
- **F104** Words in art. 13A(2) substituted (4.4.2003) by The Prescription Only Medicines (Human Use) Amendment Order 2003 (S.I. 2003/696), arts. 1(1), **12(b)(ii)**

Exemption in the case of a forged prescription

14. The restrictions imposed by section 58(2)(a) (restrictions on sale and supply) shall not apply to the sale or supply of a prescription only medicine by a pharmacist in accordance with a forged prescription where the pharmacist, having exercised all due diligence, believes on reasonable grounds that the prescription is genuine.

Prescriptions

[F105 15.—(1) For the purposes of section 58(2)(a), and subject to paragraph (3), a prescription only medicine shall not be taken to be sold or supplied in accordance with a prescription given by an appropriate practitioner unless the conditions specified in paragraph (2) are fulfilled.

(2) The conditions referred to in paragraph (1) are that the prescription—

- (a) shall be signed in ink with his own name by the appropriate practitioner giving it;
- (b) shall, without prejudice to sub-paragraph (a), be written in ink or otherwise so as to be indelible, unless it is a health prescription which is not for a controlled drug specified in Schedule 1, 2 or 3 to the Misuse of Drugs Regulations, in which case it may be written by means of carbon paper or similar material;
- (c) shall contain the following particulars—
 - (i) the address of the appropriate practitioner giving it,
 - (ii) the appropriate date,
 - (iii) such particulars as indicate whether the appropriate practitioner giving it is a doctor, a dentist, a supplementary prescriber, a district nurse/health visitor prescriber, an extended formulary nurse prescriber, a veterinary surgeon or a veterinary practitioner,
 - (iv) where the appropriate practitioner giving it is a doctor, dentist, a supplementary prescriber, a district nurse/health visitor prescriber, or an extended formulary nurse prescriber, the name, address and the age, if under 12, of the person for whose treatment it is given, and
 - (v) where the appropriate practitioner giving it is a veterinary surgeon or a veterinary practitioner, the name and the address of the person to whom the prescription only medicine is to be delivered and a declaration by the veterinary surgeon or veterinary practitioner giving it that the prescription only medicine is prescribed for an animal or herd under his care;
- (d) shall not be dispensed after the end of the period of 6 months from the appropriate date, unless it is a repeatable prescription in which case it shall not be dispensed for the first time after the end of that period nor otherwise than in accordance with the directions contained in the repeatable prescription;
- (e) in the case of a repeatable prescription which does not specify the number of times it may be dispensed, shall not be dispensed on more than two occasions unless it is a prescription for an oral contraceptive in which case it may be dispensed 6 times before the end of the period of 6 months from the appropriate date.

(3) For the purposes of paragraph (1) the prescription may, as an alternative to fulfilling the conditions specified in paragraph (2)(a) and (b), fulfil instead the conditions specified in paragraph (4), unless the prescription is a health prescription for a controlled drug specified in Schedule 1, 2 or 3 to the Misuse of Drugs Regulations or is given by a veterinary surgeon or a veterinary practitioner.

(4) The conditions referred to in paragraph (3) are that the prescription shall be created in electronic form and signed with an advanced electronic signature and transferred to the person by whom it is dispensed as an electronic communication (including where it is so transferred through one or more intermediaries).

(5) The prohibition on sale or supply imposed by section 58(2)(a) shall not apply where a prescription only medicine is sold or supplied other than in accordance with a prescription given by an appropriate practitioner and –

- (a) the reason the sale or supply is not in accordance with such a prescription is that a condition specified in paragraph (2) or (4) is not fulfilled; and
- (b) the person selling or supplying the prescription only medicine has exercised all due diligence and believes on reasonable grounds that the condition is fulfilled.
- (6) In paragraph (2) "appropriate date" means-
 - (a) in the case of a health prescription, the date on which it was signed by the appropriate practitioner giving it or a date indicated by him as being the date before which it shall not be dispensed; and
 - (b) in every other case, the date on which the prescription was signed by the appropriate practitioner giving it,

and, for the purposes of sub-paragraphs (d) and (e) of that paragraph, where the health prescription bears both the date on which it was signed and a date indicated as being that before which it shall not be dispensed, the appropriate date is the later of those dates.

(7) In this Article—

"advanced electronic signature" means an electronic signature which is-

- (a) uniquely linked to the signatory,
- (b) capable of identifying the signatory,
- (c) created using means that the signatory can maintain under his sole control, and
- (d) which is linked to the data to which it relates in such a manner that any subsequent change of data is detectable;

"electronic communication" means a communication transmitted (whether from one person to another, from one device to another or from a person to a device or vice versa)—

- (a) by means of a telecommunication system (within the meaning of the Telecommunications Act 1984, or
- (b) by other means but while in an electronic form; and

"signatory" means the appropriate practitioner giving the prescription.]

Textual Amendments

F105 Art. 15 substituted (7.4.2005) by The Medicines for Human Use (Prescribing) Order 2005 (S.I. 2005/765), arts. 1(1), 6

Revocations

16.—(1) The Orders specified in Schedule 6 are revoked.

(2) In the Medicines (Prescription Only, Pharmacy and General Sale) Amendment Order 1989(13) articles 2 to 6 and Schedules 1 and 2 are revoked.

Signed by authority of the Secretary of State for Health

Baroness Jay Minister of State, Department of Health

Win Griffiths Parliamentary Under Secretary of State, Welsh Office

Sam Galbraith Parliamentary Under Secretary of State, The Scottish Office

Jeff Rooker Minister of State, Ministry of Agriculture, Fisheries and Food

Sealed with the Official Seal of the Department of Health and Social Services for Northern Ireland on 22nd July 1997.



D. C. Gowdy Permanent Secretary Status: Point in time view as at 30/06/2005. Changes to legislation: There are currently no known outstanding effects for the The Prescription Only Medicines (Human Use) Order 1997. (See end of Document for details)

Sealed with the Official Seal of the Department of Agriculture for Northern Ireland on 18th July 1997.



P. Small Permanent Secretary

SCHEDULE 1

Articles 3(a), 5(1) and 10

SUBSTANCES WHICH IF INCLUDED IN MEDICINAL PRODUCTS MAKE THOSE PRODUCTS PRESCRIPTION ONLY MEDICINES AND EXEMPTIONS FROM RESTRICTIONS ON THE SALE AND SUPPLY OF PRESCRIPTION ONLY MEDICINES

Exemptions from the restrictions on the sale and supply of prescription only medicines					
Column 1 Column 2 Substance Maximum strength		Column 3 Column 4 Route of Treatment limitations administration, use or pharmaceutical form		Column 5 Maximum quantity	
[^{F106} Acampr	osate]				
Acarbose					
Acebutolol Hydrochlori	de				
[^{F106} Aceclofe	enac]				
Acemetacin					
Acetarsol					
Acetazolami	ide				
Acetazolami Sodium	ide				
Acetohexam	nide				
Acetylcholine0.2 per cent Chloride		External			
Acetylcystei	ine				
Acipimox					
Acitretin	5.0 per cent	External For treatment of herpes simplex virus infections of the lips and face (Herpes labialis)		Container or package containing not more than 2g of medicinal product	
Aclarubicin Hydrochlori	de				
Aconite	1.3 per cent	External			

Status: Point in time view as at 30/06/2005. Changes to legislation: There are currently no known outstanding effects for the The Prescription Only Medicines (Human Use) Order 1997. (See end of Document for details)

	Exemptions from the restrictions on the sale and supply of prescription only medicines				
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administrati use or pharmaceuti form		Column 5 Maximum quantity	
Acrivastine		-	24 mg (MDD)	Container or package containing not more than 240mg of Acrivastine	
Acrosoxacin					
Actinomycin C					
Actinomycin D					
[^{F107} Adapalen	e]				
Adenosine					
Adrenaline		(1) By inhaler			
		(2) External [^{F108} (except ophthalmic)]			
Adrenaline Acid Tartrate		(1) By inhaler			
		(2) External			
Adrenaline Hydrochlorid	e	(1) By inhaler			
		(2) External			
Adrenocortic Extract	al				
Albendazole					
Alclofenac					
Alclometasor Dipropionate					
Alcuronium Chloride					
Aldesleukin					
Aldosterone					

Status: Point in time view as at 30/06/2005. Changes to legislation: There are currently no known outstanding effects for the The Prescription Only Medicines (Human Use) Order 1997. (See end of Document for details)

		Exemptions from the restrictions on the sale and supply of prescription only medicines				
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administrati use or pharmaceut form	Column 4 Treatment limitations ion,	Column 5 Maximum quantity		
[^{F106} Alendron Sodium]	nate					
Alfacalcidol						
Alfuzosin Hydrochlorid	de					
Allergen Extracts						
Allopurinol						
Allyloestren	ol					
[^{F109} Aloxipri	n (1) 620 mg	(1) Non- effervescent tablets and capsules		(1) The quantity sold or supplied in one container or package shall not exceed 32		
				The quantity of non- effervescent tablets, capsules or a combination of both sold or supplied to a person at any one time shall not exceed 100		
		(2) All preparations other than non- effervescent tablets or capsules]				

		from the restriction only medicine.	ctions on the sale and sup	ply of
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administratio use or pharmaceuti form	Column 4 Treatment limitations on,	Column 5 Maximum quantity
Alphadolone Acetate				
Alphaxalone				
Alprenolol				
Alprenolol Hydrochlorid	e			
Alprostadil				
Alseroxylon				
[^{F107} Altretami	ne]			
Amantadine Hydrochlorid	e			
Ambenonium Chloride	l			
Ambutonium Bromide				
Amcinonide				
Ametazole Hydrochlorid	e			
Amethocaine		Non- ophthalmic use		
Amethocaine Gentisate		Non- ophthalmic use		
Amethocaine Hydrochlorid		Non- ophthalmic use		
Amikacin Sulphate				
Amiloride Hydrochlorid	e			
Aminocaproi Acid	с			
Aminogluteth	nimide			

	Exemptions from the restrictions on the sale and supply of prescription only medicines					
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administrati use or pharmaceut form		Column 5 Maximum quantity		
Aminopterin Sodium						
Amiodarone Hydrochlorid	e					
Amiphenazol Hydrochlorid						
[^{F110} Amisulpr	ide]					
Amitriptyline	;					
Amitriptyline Embonate	;					
Amitriptyline Hydrochlorid						
Amlodipine Besylate						
Ammonium Bromide						
Amodiaquine Hydrochlorid						
Amorolfine Hydrochlorid	e					
Amoxapine						
Amoxycillin						
Amoxycillin Sodium						
Amoxycillin Trihydrate						
Amphomycin Calcium	1					
Amphotericir	ı					
Ampicillin						
Ampicillin Sodium						
Ampicillin Trihydrate						

		<i>Exemptions from the restrictions on the sale and supply of prescription only medicines</i>				
Column 1 Substance	Column 2 Maximum strength	Column 3 Column 4 Route of Treatment administration, use or pharmaceutical form	limitations	Column 5 Maximum quantity		
Amsacrine						
Amygdalin						
Amyl Nitrite						
Amylocaine Hydrochlorid	e	Non- ophthalmic use				
[^{F106} Anastrozo	ole]					
Ancrod						
Androsterone						
Angiotensin Amide						
Anistreplase						
Anterior Pituitary Extract						
Antimony Barium Tartrate						
Antimony Dimercaptosu	iccinate					
Antimony Lithium Thiomalate						
Antimony Pentasulphide						
Antimony Potassium Tartrate						
Antimony Sodium Tartrate						
Antimony Sodium Thioglycollat	e					

	<i>Exemptions from the restrictions on the sale and supply of prescription only medicines</i>					
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administrati use or pharmaceut form		Column 5 Maximum quantity		
Antimony Sulphate						
Antimony Trichloride						
Antimony Trioxide						
Antimony Trisulphide						
Apiol						
Apomorphine	e					
Apomorphine Hydrochlorid						
[^{F107} Apraclon Hydrochlorid						
Aprotinin						
Arecoline Hydrobromid	le					
Argipressin						
Aristolochia						
Aristolochia Clematitis						
Aristolochia Contorta						
Aristolochia Debelis						
Aristolochia Fang-chi						
Aristolochia Manshuriensi	is					
Aristolochia Serpentaria						
Arsenic						
Arsenic Triiodide						

	Exemptions from the restrictions on the sale and supply of prescription only medicines					
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administratio use or pharmaceuti form		Column 5 Maximum quantity		
Arsenic Trioxide						
Arsphenami	ne					
[^{F111} Aspirin	[^{F112} (1) 75mg	[] ^{F112} (1) Non- effervescent tablets and capsules]		[F112(1) The quantity sold or supplied in one container or package shall not exceed 100 The quantity of non- effervescent tablets, capsules or a combination of both sold or supplied to a person at any one time shall not exceed 100]		
	[^{F113} [^{F1} 50(0 mg])] [^{F114} (12))n- effervescent tablets and capsules		[^{F114} (2)]he quantity sold or supplied in one container or package		

	Exemptions from the restrictions on the sale and supply of prescription only medicines					
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administrati use or pharmaceuti form	Column 4 Treatment limitations on,	Column 5 Maximum quantity		
				shall not exceed 32		
		[^{F114} (3)]All preparations other than non- effervescent tablets or capsules		The quantity of non- effervescent tablets, capsules or a combination of both sold or supplied to a person at any one time shall not exceed 100]		
Astemizole		F115	F115	F115		
		F115 F115				
Atenolol		• • •				
Atracurium Besylate						
Atropine		(1) Internal(a) byinhaler				
		(b) otherwise	(b) 300mcg (MD)			

		from the restruction only medicine	ictions on the sale and suppers	ply of	
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administrati use or pharmaceut form than by		Column 5 Maximum quantity	
		inhaler			
		(2) External (except ophthalmic)	1mg (MDD)		
Atropine		(1) Internal			
Methobromi	de	(a) by inhaler			
		(b) otherwise than by inhaler	(b) 400mcg (MD)		
			1.3mg (MDD)		
		(2) External (except ophthalmic)			
Atropine		Internal			
Methonitrate		(a) by inhaler			
		(b) otherwise than by inhaler	(b) 400mcg (MD)		
			1.3mg (MDD)		
Atropine Oxide		(1) Internal			
Hydrochlorid	le	(a) by inhaler			
		(b) otherwise than by inhaler	(b) 360mcg (MD)		
			1.2mg (MDD) 3		
		(2) External (except ophthalmic)			

	prescription	from the restring only medicine	ictions on the sale and supples	ly of
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administrati use or pharmaceut form		Column 5 Maximum quantity
Atropine Sulphate		(1) Internal(a) byinhaler		
		(b) otherwise than by inhaler	(b) 360mcg (MD)	
			1.2mg (MDD)	
		(2) External (except ophthalmic)		
Auranofin				
Azapropazon	e			
Azathioprine				
Azathioprine Sodium				
Azelaic Acid				
Azelastine Hydrochlorid	e	For nasal administratio	140mcg per nostril (MD)	Container or package
		For the treatment of seasonal allergic rhinitis [^{F116} or perennial allergic rhinitis] For use in adults and children not less than [^{F117} 5 years] As a non- aerosol,	280mcg per nostril (MDD)	containing not more than 5,040mcg of Azelastine Hydrochloride

		from the restri only medicine	ctions on the sale and support	ly of
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administrati use or pharmaceuti form		Column 5 Maximum quantity
		aqueous form		
Azidocillin Potassium				
Azithromycin	l			
Azlocillin Sodium				
Aztreonam				
Bacampicillir Hydrochlorid				
Bacitracin				
Bacitracin Methylene Disalicylate				
Bacitracin Zinc				
Baclofen				
[^{F110} Balsalazio Sodium]	de			
Bambuterol Hydrochlorid	e			
Barium Carbonate				
Barium Chloride				
Barium Sulphide				
Beclamide				
Beclomethase	one			
Beclomethase Dipropionate	one	For nasal administratio (non- aerosol)	100mcg per nostril (MD) n	Container or package containing not more than [^{F118} 20,000 mcg] of

		from the restr 1 only medicine	ictions on the sale and supp	ly of
Column 1	Column 2	Column 3	Column 4	Column 5
Substance	Maximum	Route of	Treatment limitations	Maximum
	strength	administrat	ion,	quantity
		use or pharmaceut	ical	
		form		
		For the prevention	200 mcg per nostril (MDD)	Beclomethasone Dipropionate
		and treatment of allergic rhinitis	[^{F119} For a maximum period of 3 months]	
		[^{F120} For use in persons aged 18 years and over]		
Belladonna Herb		(1) Internal	(1) 1mg of the alkaloids (MDD)	
		(2) External		
Belladonna Root		(1) Internal	(1) 1mg of the alkaloids (MDD)	
		(2) External		
Bemegride				
Bemegride Sodium				
Benapryzine Hydrochlorid	le			
Bendrofluazi	de			
Benethamine Penicillin				
Benoxaprofe	n			
Benperidol				
[^{F110} Benseraz	ide]			
Benserazide Hydrochlorid	-			
Bentiromide				
Benzathine Penicillin				
Benzbromarc	one			

	Exemptions from the restrictions on the sale and supply of prescription only medicines				
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administratiuse or pharmaceut	Column 4 Treatment limitations ion,	Column 5 Maximum quantity	
Benzhexol Hydrochlorid	le				
Benzilonium Bromide					
Benzocaine		Any use except ophthalmic use			
Benzoctamin Hydrochlorid					
Benzoyl Peroxide	10.0 per cent	External			
N-Benzoyl Sulphanilami	de				
Benzquinami	de				
Benzquinami Hydrochlorid					
Benzthiazide					
Benztropine Mesylate					
Benzylpenici Calcium	llin				
Benzylpenici Potassium	llin				
Benzylpenici Sodium	llin				
Beractant					
Betahistine Hydrochlorid	le				
Betamethaso	ne				
Betamethaso Adamantoate					
Betamethaso Benzoate	ne				

	Exemptions from the restrictions on the sale and supply of prescription only medicines				
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administrati use or pharmaceut form		Column 5 Maximum quantity	
Betamethaso Dipropionate					
Betamethaso Sodium Phosphate	ne				
Betamethaso Valerate	ne				
Betaxolol Hydrochlorid	le				
Bethanechol Chloride					
Bethanidine Sulphate					
Bezafibrate					
[^{F107} Bicaluta	mide]				
Biperiden Hydrochlorid	le				
Biperiden Lactate					
Bismuth Glycollylarsa	anilate				
Bisoprolol Fumarate					
Bleomycin					
Bleomycin Sulphate					
Bretylium Tosylate					
[^{F110} Brimonic Tartrate]	line				
Bromhexine Hydrochlorid	le				
Bromocriptin Mesylate	ne				
Bromperidol					

		from the restri only medicine	ctions on the sale and suppl	ly of
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administrati use or pharmaceuti form	Column 4 Treatment limitations on,	Column 5 Maximum quantity
Bromvaleton	e			
Brotizolam				
Budesonide		For nasal administratio	200mcg per nostril (MD) n	Container or package
		For the prevention or treatment of seasonal allergic rhinitis	[^{F119} For a maximum period of 3 months]	containing not more than 10mg of Budesonide
		200 mcg per nostril (MDD)		
		[^{F120} For use in persons aged 18 years and over]		
		As a non- aerosol, aqueous form		
Bufexamac				
Bumetanide				
Buphenine			6mg (MD)	
Hydrochloric	le		18mg (MDD)	
Bupivacaine		Any use except ophthalmic use		
Bupivacaine Hydrochloric	le	Any use except ophthalmic use		
Buserelin Acetate				

	<i>Exemptions from the restrictions on the sale and supply of prescription only medicines</i>					
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administratuuse or pharmaceut form		Column 5 Maximum quantity		
Buspirone Hydrochlorie	de					
Busulphan						
Butacaine Sulphate		Any use except ophthalmic use				
Butorphanol Tartrate						
Butriptyline Hydrochlori	de					
[^{F121} Cabergo	line]					
Calcipotriol						
[^{F107} Calcipot Hydrate]	riol					
Calcitonin						
Calcitriol						
Calcium Amphomyci	n					
Calcium Benzamidos	alicylate					
Calcium Bromide						
Calcium Bromidolact	obionate					
Calcium Carbimide						
Calcium Folinate						
Calcium Metrizoate						
Calcium Sulphaloxate	9					
[^{F122} Candesa Cilexetil]	rtan					
			50			

	-	from the restring from the restrict from the res	ctions on the sale and sup	ply of
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administrati use or pharmaceut form		Column 5 Maximum quantity
Candicidin				
Canrenoic Acid				
Cantharidin	0.01 per cent	External		
Capreomycir Sulphate	1			
Captopril				
Carbachol				
Carbamazepi	ine			
Carbaryl				
[^{F110} Carbasal Calcium]	ate			
Carbenicillin Sodium	l			
Carbenoxolo	one	(1) Pellet	(1) 5mg (MD)	
Sodium			25mg (MDD)	
	(2) 2.0 per cent	(2) Gel		
	(3) 1.0 per cent	(3) Granules for mouthwash in adults and children not less than 12 years	(3) 20mg (MD) 80mg (MDD)	(3) Container or package containing not more than [^{F123} 560mg] of Carbenoxolone Sodium
Carbidopa				
Carbimazole				
Carbocistein	e			
Carbon Tetrachloride	2			
Carboplatin				

	Exemptions from the restrictions on the sale and supply of prescription only medicines				
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administrati use or pharmaceut form		Column 5 Maximum quantity	
Carboprost Trometamol					
Carbuterol Hydrochloride	;				
Carfecillin Sodium					
Carindacillin Sodium					
Carisoprodol					
Carmustine					
Carperidine					
Carteolol Hydrochloride	;				
Cefaclor					
Cefadroxil					
Cefazedone Sodium					
[^{F110} Cefdinir]					
Cefixime					
Cefodizime Sodium					
Cefotaxime Sodium					
Cefoxitin Sodium					
Cefpodoxime Proxetil					
[^{F121} Cefprozil]					
Cefsulodin Sodium					
Ceftazidime					
Ceftizoxime Sodium					

	<i>Exemptions from the restrictions on the sale and supply of prescription only medicines</i>					
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administratic use or pharmaceutic form		Column 5 Maximum quantity		
Ceftriaxone Sodium						
Cefuroxime Axetil						
Cefuroxime Sodium						
Celiprolol Hydrochloride	2					
Cephalexin						
Cephalexin Sodium						
Cephaloridine						
Cephalothin Sodium						
Cephamandol Nafate	e					
Cephazolin Sodium						
Cephradine						
Cerium Oxalate						
Cerivastatin						
[^{F110} Cerivastat Sodium]	in					
Ceruletide Diethylamine						
Cetirizine Hydrochloride	2		10mg (MDD)	F124		
Chenodeoxycl Acid	holic					
Chloral Hydrate		External				
Chlorambucil	1					
Chlorampheni	col					

		from the restr n only medicine	ictions on the sale and sup es	ply of
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administratiuse or pharmaceut form	Column 4 Treatment limitations ion,	Column 5 Maximum quantity
Chloramphe Cinnamate	nicol			
Chloramphe Palmitate	nicol			
Chloramphe Sodium Succinate	nicol			
Chlorhexado	ol			
Chlormadino Acetate	one			
Chlormerodi	rin			
Chlormethia	zole			
Chlormethia Edisylate	zole			
Chlormezan	one			
Chloroform(14)) 5.0 per cent	(1) Internal		
		(2) External		
Chloroquine Phosphate		Prophylaxis of malaria		
Chloroquine Sulphate		Prophylaxis of malaria		
Chlorothiazi	de			
Chlorotrianis	sene			
Chlorphenox Hydrochlori				
Chlorpromaz	zine			
Chlorpromaz Embonate	zine			
Chlorpromaz Hydrochlorie				
Chlorpropan	nide			

⁽¹⁴⁾ SeeS.I. 1979/382 amended by S.I. 1980/263 and S.I. 1989/1124.

Column 1 Substance		only medicine Column 3 Route of administratio use or pharmaceuti	Column 4 Treatment limitations on,	Column 5 Maximum quantity
Chlorprothix	ene	form		
Chlorprothix Hydrochlorid				
Chlortetracyc	cline			
Chlortetracyc Calcium	eline			
Chlortetracyc Hydrochlorid				
Chlorthalidor	ne			
Chlorzoxazor	ne			
Cholestyrami	ine			
Ciclacillin				
Ciclobendazo	ole			
Cilastatin Sodium				
Cilazapril				
Cimetidine		(a) For the	(a) 200mg (MD)	
		short-term symptomatic	800mg (MDD)	
		relief of heartburn, dyspepsia, indigestion, acid indigestion and hyperacidity and for the prophylaxis of meal- induced heartburn	For a maximum period of 14 days	
		(b) For the prophylactic management of nocturnal heartburn by a single	-	

		from the restri only medicine	ctions on the sale and sup	pply of
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administration use or pharmaceution form	Column 4 Treatment limitations on,	Column 5 Maximum quantity
		dose taken at night		
Cimetidine Hydrochlorid	le			
Cinchocaine	3.0 per cent	Non- ophthalmic use		
Cinchocaine Hydrochlorid		Non- ophthalmic use		
Cinchophen				
Cinoxacin				
Ciprofibrate				
Ciprofloxacia	1			
Ciprofloxacii Hydrochlorid				
Cisapride				
Cisplatin				
[^{F107} Citalopra Hydrobromic				
Clarithromyc	in			
Clavulanic Acid				
Clidinium Bromide				
Clindamycin				
Clindamycin Hydrochlorid				
Clindamycin Palmitate Hydrochlorid				
Clindamycin Phosphate				

			ctions on the sale and sup	ply of
Column 1 Substance	prescription Column 2 Maximum strength	only medicine Column 3 Route of administrati use or pharmaceuth form	Column 4 Treatment limitations on,	Column 5 Maximum quantity
Clioquinol		(1) External (other than treatment of mouth ulcers)		
	(2) 35mg	(2) Treatment of mouth ulcers	(2) 350mg (MDD)	
Clobetasol Propionate				
Clobetasone Butyrate	[^{F125} 0.05 per cent]	[^{F125} Cream for use in adults and in children aged 12 years and over, for external use for the short term symptomatic treatment and control of patches of eczema and dermatitis (excluding seborrhoeic dermatitis)]		[^{F125} Container or package containing not more than 15g of medicinal product]
Clofazimine				
Clofibrate				
Clomiphene Citrate				
Clomipramin				
Clomipramin Hydrochlorid				
Clomocycline	e			

		from the restruction only medicine	ictions on the sale and sup	ply of
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administrati use or pharmaceut form	Column 4 Treatment limitations ion,	Column 5 Maximum quantity
Clomocycline Sodium	e			
Clonidine				
Clonidine Hydrochlorid	e			
Clopamide				
Clopenthixol Decanoate				
Clopenthixol Hydrochlorid	e			
Clorexolone				
Clotrimazole		External but in the case of vaginal use only external use for the treatment of vaginal candidiasis		
Cloxacillin Benzathine				
Cloxacillin Sodium				
Clozapine				
Cocculus Indicus				
Co- dergocrine Mesylate				
Colaspase				
Colchicine				
Colestipol Hydrochlorid	e			
Colfosceril Palmitate				

	<i>Exemptions from the restrictions on the sale and supply of prescription only medicines</i>					
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administratio use or pharmaceutic form	,	Column 5 Maximum quantity		
Colistin Sulphate						
Colistin Sulphometha	te					
Colistin Sulphometha Sodium	te					
Coniine						
Conium Leaf	7.0 per cent	External				
Corticotrophi	n					
Cortisone						
Cortisone Acetate						
Co- tetroxazine						
Co- trimoxazole						
Cropropamid	e					
Crotethamide	;					
Croton Oil						
Croton Seed						
Curare						
Cyclofenil						
Cyclopenthia	zide					
Cyclopentola Hydrochlorid						
Cyclophosph	amide					
Cycloserine						
Cyclosporin						
Cyclothiazide	e					
Cyproterone Acetate						

	Exemptions from the restrictions on the sale and supply of prescription only medicines				
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administrati use or pharmaceut form	Column 4 Treatment limitations ion,	Column 5 Maximum quantity	
Cytarabine					
Cytarabine Hydrochlorid	e				
Dacarbazine					
Dalteparin Sodium					
Danazol					
Danthron					
Dantrolene Sodium					
Dapsone					
Dapsone Ethane Ortho Sulphonate					
Daunorubicir Hydrochlorid					
Deanol Bitartrate			26mg (MDD)		
Debrisoquine Sulphate					
Demecarium Bromide					
Demeclocycl	ine				
Demeclocycl Calcium	ine				
Demeclocycl Hydrochlorid					
Deoxycorton Acetate	e				
Deoxycorton Pivalate	3				
Deptropine Citrate					

		from the restrient from the restrient from the restrict from the r	ctions on the sale and sup	ply of	
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administratio use or pharmaceuti form	Column 4 Treatment limitations on,	Column 5 Maximum quantity	
Dequalinium Chloride	n (1) 0.25mg	(1) Internal: throat lozenges or throat pastilles			
	(2) 1.0 per cent	(2) External: paint			
Deserpidine					
Desferrioxan Mesylate	nine				
Desflurane					
Desipramine Hydrochlorid					
Deslanoside					
Desmopressi	n				
Desmopressi Acetate					
Desogestrel					
Desonide					
Desoxymeth	asone				
Dexamethas	one				
Dexamethase Acetate	one				
Dexamethase Isonicotinate					
Dexamethase Phenylpropie					
Dexamethase Pivalate	one				
Dexamethase Sodium Metasulphob					
Dexamethase Sodium Phosphate					

		from the restrient only medicine.	ctions on the sale and suppl	y of
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administratio use or pharmaceuti form	Column 4 Treatment limitations on,	Column 5 Maximum quantity
Dexamethaso Troxundate	one			
Dexfenflurar Hydrochloric				
Dextrometho Hydrobromio		Internal	(a) In the caseof a prolongedrelease preparation:equivalent of 30mg ofDextromethorphan (MD)	
			equivalent of 75mg of Dextromethorphan (MDD)	
			(b) in any other case: equivalent of 15mg of Dextromethorphan (MD)	
			equivalent of 75mg of Dextromethorphan (MDD)	
Dextrothyrox Sodium	kine			
Diazoxide				
Dibenzepin Hydrochloric	le			
Dichloralphe	enazone			
Dichlorphena	amide			
Diclofenac Diethylamm	1.16 per owienti	External For local symptomatic relief of pain and inflammation in trauma of the tendons, ligaments, muscles and joints and in localised forms of	For maximum period of 7 days	Container or package containing not more than 30g of medicinal product

		from the restrict only medicine	ctions on the sale and sup s	ply of
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administratio use or pharmaceuti form soft tissue		Column 5 Maximum quantity
		rheumatism		
		For use in adults and children not less than 12 years		
Diclofenac Potassium				
Diclofenac Sodium				
Dicyclomine			10mg (MD)	
Hydrochlorid	e		60mg (MDD)	
[^{F106} Didanosir	ne]			
Dienoestrol				
Diethanolami Fusidate	ne			
Diflucortolon Valerate	e			
Diflunisal				
Digitalin				
Digitalis Leaf				
Digitalis Prepared				
Digitoxin				
Digoxin				
Dihydralazine Sulphate	2			
Dihydroergot Mesylate	amine			
Dihydrostrept	tomycin			
Dihydrostrept Sulphate	tomycin			

		from the restri only medicine	ctions on the sale and supp s	ly of
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administrativ use or pharmaceuti form		Column 5 Maximum quantity
Diloxanide Furoate				
Diltiazem Hydrochloric	le			
Dimercaprol				
Dimethisoqu Hydrochloric		Non- ophthalmic use		
Dimethistero	ne			
Dimethothiaz Mesylate	zine			
Dimethyl Sulphoxide				
Dimethyltube Bromide	ocurarine			
Dimethyltubo Chloride	ocurarine			
Dimethyltubo Iodide	ocurarine			
Dinoprost				
Dinoprost Trometamol				
Dinoprostone	2			
[^{F109} Diphenh <u>y</u> Hydrochloric	verlamine epreparations except liquid-filled capsules]			
[^{F126} Diphenoz Hydrochloric	k∳Îât2.5 mg] le]	[^{F126} In combination with Atropine Sulphate for short term use as an adjunctive therapy to	[^{F126} 25 mg (MDD)]	[^{F126} Container or package containing not more than 20 tablets]

		from the restri only medicine	ctions on the sale and supply	v of
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administrati use or pharmaceuti	,	Column 5 Maximum quantity
		<i>form</i> appropriate rehydration in acute diarrhoea		
		For use in persons aged 16 years and over		
		Tablets]		
Dipivefrin Hydrochlorid	e			
Dipyridamole				
Disodium Etidronate				
Disodium Pamidronate				
Disopyramide	e			
Disopyramide Phosphate	2			
Distigmine Bromide				
Disulfiram				
Dithranol	1.0 per cent			
Dobutamine Hydrochlorid	e			
[^{F126} Dolasetro Mesilate]	'n			
Domperidone		[^{F127} For the relief of post- prandial symptoms of excessive fullness, nausea, epigastric	[^{F127} 10mg of Domperidone (MD)] [^{F127} 40mg of Domperidone (MDD)]	[^{F127} Container or package containing not more than 200mg of Domperidone]

	Exemptions	from the restri	ctions on the sale and sup	ply of
Column 1 Substance	prescriptior Column 2 Maximum strength	n only medicine Column 3 Route of administrati use or pharmaceuti form	Column 4 Treatment limitations on,	Column 5 Maximum quantity
		bloating and belching, occasionally accompanied by epigastric discomfort and heartburn]		
Domperidone Maleate	2	[^{F128} For the relief of post- prandial symptoms of excessive fullness, nausea, epigastric bloating and belching, occasionally accompanied by epigastric discomfort and heartburn,]	[^{F129} 10 mg of Domperidone as Domperidone Maleate (MD)] [^{F129} 40 mg of Domperidone as Domperidone Maleate (MDD)]	[^{F128} Container or package containing not more than [^{F130} 200mg] of Domperidone as Domperidone Maleate;]
[^{F110} Donepezi Hydrochlorid	1 e]			
Dopamine Hydrochlorid	e			
Dopexamine Hydrochlorid	e			
[^{F107} Dorzolan Hydrochlorid				
Dothiepin				
Dothiepin Hydrochlorid	e			
Doxapram Hydrochlorid	e			
			66	

	prescription	only medicine	ictions on the sale and suppers	ply of
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administrati use or pharmaceut form		Column 5 Maximum quantity
Doxazosin Mesylate				
Doxepin Hydrochloride	e			
Doxorubicin				
Doxorubicin Hydrochloride	e			
Doxycycline				
Doxycycline Calcium Chelate				
Doxycycline Hydrochloride	e			
Droperidol				
Dydrogestero	ne			
Dyflos				
Econazole		External but in the case of vaginal use only external use for the treatment of vaginal candidiasis		
Econazole Nitrate		External but in the case of vaginal use only external use for the treatment of vaginal candidiasis		
Ecothiopate Iodide				
Edrophonium Chloride				

Column 1 Column 2 Column 3 Column 4 Column 5 Substance Maximum administration, maximum quantity use or pharmaceutical form form Effornithine Hydrochloride firm form [fifterFormoterol Fumarate] Emetrine 1.0 per cent Emetrine 1.0 per cent Emetrine Emetrine Bismuth Iodide form form Idide Iop recent Encephalitis form Enalapril Maleate Encephalitis form Enoxacin Enoxacin Enoxaparin Sodium Enoximone (1) Internal (1) 30mg (MD) (other than nasal sprays or nasal drops) 60mg (MDD) (2) 2.0 per (2) Nasal sprays or nasal drops) form		prescription	from the restrue only medicine	ictions on the sale and supp es	ply of
Hydrochloride I pitonaterol Fumaratej Embutramide Empronium Bromide Emerine 1.0 per cent Emerine Bismuth lodide Emerine Equivalent Hydrochloridor 1.0 per cent of Equivalent Hydrochloridor 1.0 per cent of Emetine Emetine Emetine Emetine Bismuth lodide Emetine Enchalapril Kirus, Tick-borne, Cent Equivalent Enoxacin Enoxacin Enoxaparin Sodium Enoximone Enoximone Enotime (1) Internal (1) 30mg (MD) (other than an and arguitation of argu		Maximum	Route of administrati use or pharmaceut	Treatment limitations ion,	Maximum
Fumarate Embutramide Emeroni Bromide Emetine Bismuth lodide Emetine Bismuth lodide		le			
Emepronium Bromide Encetine 1.0 per cent Emetine Bismuth lodide Emetine Equivalent Hydrochlor 2010 per cent of Emetine Encaphalitis Virus, Tick- borne, Cent Enc Encephalitis Virus, Tick- borne, Cent Enc Encaphalitis Virus, Tick- borne, Cent Enc Encephalitis Virus, Tick- borne, Cent Enc Encephalitis Virus, Tick- borne, Cent Enc Encephalitis Virus, Tick- borne, Cent Enc Encephalitis Virus, Tick- borne, Cent Enc Enc Encephalitis Virus, Tick- borne, Cent Enc Enc Enc Enc Enc Enc Enc Enc	•	erol			
Bromide Emetine 1.0 per cent Emetine Bismuth lodide Emetine Equivalent Hydrochloridorf 1.0 per cent of Emetine Enalapril Maleate Encephalitis Virus, Tick- borne, Cent Eur Enoxacin Enoxaparin Sodium Enoximone Enoximone Ephedrine (1) Internal (1) 30mg (MD) (other than nasal sprays or nasal drops) 60mg (MDD) (2) 2.0 per (2) Nasal	Embutramid	e			
Emetine Bismuth lodide Emetine Equivalent Hydrochlorideof 1.0 per cent of Emetine Enalapril Maleate Encephalitis Virus, Tick- borne, Cent Eur Enoxacin Enoxacin Enoxacin Enoxaparin Sodium Enoximone Ephedrine (1) Internal (1) 30mg (MD) (other than nasal sprays or nasal drops) 60mg (MDD) (2) 2.0 per (2) Nasal		L			
Bismuth lodide Emetine Equivalent Hydrochlorideof 1.0 per cent of Emetine Enalapril Maleate Encephalitis Virus, Tick- borne, Cent Eur Enoxacin Enoxaparin Sodium Enoximone Ephedrine (1) Internal (1) 30mg (MD) (other than nasal sprays or nasal drops) 60mg (MDD) (2) 2.0 per (2) Nasal	Emetine	1.0 per cent			
Hydrochlorideof 1.0 per cent of EmetineEnalapril MaleateEnalapril MaleateEncephalitis Virus, Tick- borne, Cent EurEnoxacinEnoxaparin SodiumEnoximoneEnoximoneEphedrine(1) Internal (other than nasal sprays or nasal drops)60mg (MDD) (2) 2.0 per(2) 2.0 per(2) 2.0 per	Bismuth				
Maleate Encephalitis Virus, Tick- borne, Cent Eur Enoxacin Enoxaparin Sodium Enoximone Ephedrine (1) Internal (1) 30mg (MD) (other than nasal sprays or nasal drops) 60mg (MDD) (2) 2.0 per (2) Nasal		leof 1.0 per cent of			
Virus, Tick- borne, Cent Eur Enoxacin Enoxaparin Sodium Enoximone Ephedrine (1) Internal (1) 30mg (MD) (other than nasal sprays or nasal drops) 60mg (MDD) (2) 2.0 per (2) Nasal					
Enoxaparin Sodium Enoximone Ephedrine (1) Internal (1) 30mg (MD) (other than nasal sprays or nasal drops) 60mg (MDD) (2) 2.0 per (2) Nasal	Virus, Tick- borne, Cent				
Sodium Enoximone Ephedrine (1) Internal (1) 30mg (MD) (other than nasal sprays or nasal drops) 60mg (MDD) (2) 2.0 per (2) Nasal	Enoxacin				
Ephedrine (1) Internal (1) 30mg (MD) (other than nasal sprays or nasal drops) 60mg (MDD) (2) 2.0 per (2) Nasal					
(other than nasal sprays or nasal drops) 60mg (MDD) (2) 2.0 per (2) Nasal	Enoximone				
(2) 2.0 per (2) Nasal	Ephedrine		(other than nasal sprays or nasal	(1) 30mg (MD)	
				60mg (MDD)	
(3) External		(2) 2.0 per cent	sprays or nasal drops		

		from the restring only medicine	ictions on the sale and supply 25) of
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administrati use or pharmaceut form	Column 4 Treatment limitations ion,	Column 5 Maximum quantity
Ephedrine Hydrochlorid	le	(1) Internal (other than	(1) Equivalent of 30mg of Ephedrine (MD)	
		nasal sprays or nasal drops)	Equivalent of 60mg of Ephedrine (MDD)	
	(2) Equivalent of 2.0 per cent of Ephedrine	(2) Nasal sprays or nasal drops		
		(3) External		
Ephedrine Sulphate		(1) Internal (other than nasal sprays or nasal drops)	(1) Equivalent of 30mg of Ephedrine (MD)	
			Equivalent of 60mg of Ephedrine (MDD)	
	(2) Equivalent of 2.0 per cent of Ephedrine	(2) Nasal sprays or nasal drops		
		(3) External		
Epicillin				
Epirubicin				
Epirubicin Hydrochlorid	le			
Epithiazide				
Epoetin Alfa				
Epoetin Beta				
Epoprosteno Sodium	1			
Ergometrine Maleate				

		from the restruction only medicine	ictions on the sale and supp	ply of
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administrati use or pharmaceut form		Column 5 Maximum quantity
Ergometrine Tartrate				
Ergot, Prepared				
Ergotamine Tartrate				
Erythromycin				
Erythromycin Estolate				
Erythromycin Ethylcarbonat				
Erythromycin Ethyl Succinate				
Erythromycin Lactobionate				
Erythromycin Phosphate				
Erythromycin Stearate				
Erythromycin Thiocyanate				
Esmolol Hydrochlorid	e			
Estramustine Phosphate				
[^{F131} Estramust Sodium Phosphate]	ine			
Etafedrine Hydrochlorid	e			
Ethacrynic Acid				
Ethambutol Hydrochlorid	e			

		from the restric only medicine	ctions on the sale and supp s	ply of
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administratio use or pharmaceutio form	Column 4 Treatment limitations on,	Column 5 Maximum quantity
Ethamivan				
Ethamsylate				
Ethiazide				
Ethinyl Androstenedi	ol			
Ethinyloestra	diol			
Ethionamide				
Ethisterone				
Ethoglucid				
Ethoheptazin Citrate	e			
Ethopropazin Hydrochlorid				
Ethosuximide	e			
Ethotoin				
Ethyl Biscoumaceta	ate			
Ethynodiol Diacetate				
Etodolac				
Etomidate				
Etomidate Hydrochlorid	e			
Etoposide				
Etretinate				
[^{F107} Exemesta	ine]			
Famciclovir				
Famotidine		For the	10mg (MD)	
		short-term symptomatic	20mg (MDD)	
		relief of heartburn, dyspepsia, indigestion,	For maximum period of 14 days	

		from the restri only medicine	ctions on the sale and supply	y of
Column 1	Column 2	Column 3	Column 4	Column 5
Substance	Maximum	Route of	Treatment limitations	Maximum
Substance	strength	administrati		quantity
	sirengin	use or	011,	quantity
		pharmaceuti	ical	
		form	cur	
		acid		
		indigestion		
		and		
		hyperacidity,		
		and		
		prevention		
		of these		
		symptoms		
		when		
		associated		
		with food		
		and drink,		
		including nocturnal		
		symptoms		
		symptoms		
Fazadinium Bromide				
Felbinac	3.17 per	External	For maximum period of 7	Container
	cent	[^{F133} For the	days	or package
		relief of		containing
		rheumatic		not more
		pain, pain of		than
		non-serious		[^{F132} 50g] of
				medicinal
		arthritic		product
		conditions		product
				product
		conditions and soft tissue		product
		conditions and soft tissue injuries such		product
		conditions and soft tissue injuries such as sprains,		product
		conditions and soft tissue injuries such as sprains, strains and		product
		conditions and soft tissue injuries such as sprains,		product
		conditions and soft tissue injuries such as sprains, strains and contusions] For use in		product
		conditions and soft tissue injuries such as sprains, strains and contusions] For use in adults and		product
		conditions and soft tissue injuries such as sprains, strains and contusions] For use in adults and children not		product
		conditions and soft tissue injuries such as sprains, strains and contusions] For use in adults and children not less than 12		product
		conditions and soft tissue injuries such as sprains, strains and contusions] For use in adults and children not		product
Felodipine		conditions and soft tissue injuries such as sprains, strains and contusions] For use in adults and children not less than 12		product
Felodipine Felypressin		conditions and soft tissue injuries such as sprains, strains and contusions] For use in adults and children not less than 12		product
Felypressin		conditions and soft tissue injuries such as sprains, strains and contusions] For use in adults and children not less than 12		product
-		conditions and soft tissue injuries such as sprains, strains and contusions] For use in adults and children not less than 12		product

72

		from the restri	ictions on the sale and suppers	ply of	
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administrati use or pharmaceut form	Column 4 Treatment limitations ion,	Column 5 Maximum quantity	
Fenfluramin Hydrochlori					
Fenofibrate					
Fenoprofen					
Fenoprofen Calcium					
Fenoterol Hydrobromi	de				
Fenticonazo Nitrate	le	[^{F125} External use (but in the case of vaginal use, only for the treatment of vaginal candidiasis)]			
Feprazone					
Ferrous Arsenate					
[^{F107} Ferumox	sil]				
[^{F110} Fexofena Hydrochlorie					
Filgrastim					
Finasteride					
Flavoxate Hydrochlori	de				
Flecainide Acetate					
Flosequinan					
Fluanisone					
Flubendazol	e				
Fluclorolone Acetonide	•				
Flucloxacilli Magnesium	n				
			72		

73

	-	<i>Exemptions from the restrictions on the sale and supply of prescription only medicines</i>					
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administrati use or pharmaceut form		Column 5 Maximum quantity			
Flucloxacilli Sodium	n						
Fluconazole		For oral administration for the treatment of vaginal candidiasis [^{F134} or associated candidal balanitis] in persons aged not less than 16 but less than 60 years		Container or package containing not more than 150mg of Fluconazole			
Flucytosine							
Fludrocortise Acetate	one						
Flufenamic Acid							
Flumazenil							
Flumethason	e						
Flumethason Pivalate	e						
Flunisolide	0.025 per cent	(a) For the prevention and treatment of seasonal allergic rhinitis, including hay fever [^{F135} For use	(a) 50mcg per nostril (MD) 100mcg per nostril (MDD)	(a) Container or package containing not more than 6,000mcg of Flunisolide			
		in persons aged 18	maximum period of 3 months]				

	Exemptions from the restrictions on the sale and supply of prescription only medicines					
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administrat use or pharmaceut form		Column 5 Maximum quantity		
		years and over]				
		In the form of a non- pressurised nasal spray				
		F137	F137	F137		
			F137			
		F137				
		F137				
Fluocinolone Acetonide						
Fluocinonide						
Fluocortin Butyl						
Fluocortolon	e					
Fluocortolone Hexanoate	2					
Fluocortolone Pivalate	3					
Fluorescein Dilaurate						
Fluoromethol	lone					
Fluorouracil						
Fluorouracil Trometamol						
Fluoxetine Hydrochlorid	e					
Flupenthixol Decanoate						

	Exemptions from the restrictions on the sale and supply of prescription only medicines					
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administrat use or pharmaceut form	Column 4 Treatment limitations ion,	Column 5 Maximum quantity		
Flupenthixol Hydrochlorid	e					
Fluperolone Acetate						
Fluphenazine Decanoate	;					
Fluphenazine Enanthate	;					
Fluphenazine Hydrochlorid						
Flupredniden Acetate	e					
Fluprednisolo	one					
Fluprostenol Sodium						
Flurandrenol	one					
Flurbiprofen	[^{F138} 8.75 mg]	[^{F139} Throat lozenges]	[^{F140} 43.75 mg (MDD)]	[^{F141} Container or package containing not more than 140 mg of Flurbiprofen]		
Flurbiprofen Sodium						
Fluspirilene						
Flutamide						
Fluticasone Propionate						
[^{F110} Flutrimaz	zole]					
Fluvastatin Sodium						
Fluvoxamine Maleate						
Folic Acic			500mcg (MDD)			

	<i>Exemptions from the restrictions on the sale and supply of prescription only medicines</i>				
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administratic use or pharmaceutic form	Column 4 Treatment limitations on,	Column 5 Maximum quantity	
Formestane					
Formocortal					
Foscarnet Sodium					
Fosfestrol Sodium					
Fosfomycin Trometamol					
Fosinopril Sodium					
Framycetin Sulphate					
Frusemide					
Furazolidone					
Fusafungine					
Fusidic Acid					
Gabapentin					
Gadoteridol					
Gallamine Triethiodide					
Ganciclovir					
Ganciclovir Sodium					
Gelsemine	0.1 per cent				
Gelsemium			25mg (MD)		
			75mg (MDD)		
Gemeprost					
Gemfibrozil					
Gentamicin					
Gentamicin Sulphate					
Gestodene					

		from the restri only medicine	ctions on the sale and support	ply of
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administrativ use or pharmaceuti form		Column 5 Maximum quantity
Gestrinone				
Gestronol				
Gestronol Hexanoate				
Glibenclamic	de			
Glibornuride	:			
Gliclazide				
Glipizide				
Gliquidone				
Glisoxepide				
Glucagon				
Glycopyrron	ium		1mg (MD)	
Bromide			2mg (MDD)	
Glymidine				
Gonadorelin				
Goserelin Acetate				
Gramicidin	0.2 per cent	External		
Granisetron Hydrochlorid	le			
Griseofulvin				
Growth Hormone				
Guanethidine Monosulpha				
Guanfacine Hydrochlorid	le			
Guanoclor Sulphate				
Guanoxan Sulphate				
Halcinonide				

		from the restruction only medicine	ictions on the sale and supp	ply of
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administrati use or pharmaceut form	Column 4 Treatment limitations ion,	Column 5 Maximum quantity
Halofantrine Hydrochlori				
Haloperidol				
Haloperidol Decanoate				
Heparin		External		
Heparin Calcium		External		
Heparin Sodium				
Hexachlorop	ohane	External		
	(a) 2.0 per cent	(a) Soaps		
	(b) 0.1 per cent	(b) Aerosols		
	(c) 0.75 per cent	(c) preparations other than soaps and aerosols		
Hexamine Phenylcinch	oninate			
Hexobarbito	ne			
Hexobarbito Sodium	ne			
Hexoestrol				
Hexoestrol Dipropionate	e			
L-Histidine Hydrochlori	de	Dietary supplementa	tion	
Homatropine	e	(1) Internal	(1) 0.15mg (MD)	
			0.45mg (MDD)	
		(2) External (except ophthalmic)		

		from the restrictions on the sale and supp	ply of
Column 1 Substance	prescription Column 2 Maximum strength	only medicines Column 3 Column 4 Route of Treatment limitations administration, use or pharmaceutical	Column 5 Maximum quantity
Homatropine		<i>form</i> 0.2mg (MD)	
Hydrobromic		0.6mg (MDD)	
Homatropine	:	2mg (MD)	
Methylbromi	de	6mg (MDD)	
Hydralazine Hydrochloric	le		
Hydrargaphe	n	Local application to skin	
Hydrobromic Acid	2		
Hydrochloro	thiazide		
Hydrocortiso	ne [^{F142} (1)0.5 per cent]	[^{F142} (1) External (a) For use in combination with Nystatin of maximum strength 3.0 per cent for intertrigo (b) For use in adults and children not less than 10 years]	(fon(a))ner or package containing not more than 15g of medicinal product]
	[^{F143} (2)].0 per cent	[^{F143} (2)] External (a) For use either alone 80	(Fon(a)))er or package containing not more than 15g

	<i>Exemptions from the restrictions on the sale and supply of prescription only medicines</i>						
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administrat use or pharmaceut	Column 4 Treatment limitations ion,	Column 5 Maximum quantity			
		form					
		form or in conjun with Crotan in irritant dermat contact allergid dermat insect bite reactio mild to modera eczema and either in combin with Clotrim [^{F144} or Micona Nitrate for athlete foot and candid intertrii or in combin with lignoca for anal and periana itch	niton fitis, t c titis, ns, ate a, nation nazole azole l 's al go nation aine	of medicinal product (cream or ointment) or 30ml (spray)			

	Exemptions	from the restric	ctions on the sale and sup	ply of
		only medicines		
Column 1	Column 2	Column 3	Column 4	Column 5
Substance	Maximum	Route of	Treatment limitations	Maximum
Substance	strength	administratio		quantity
	sirengin	use or	<i>, , , , , , , , , ,</i>	quantity
			o	
		pharmaceutio	cai	
		form		
		(b) For		
		use in		
		adults		
		and		
		children	l	
		not		
		less		
		than		
		10		
		years		
		(c) Cream		
		ointmen	ıt	
		or		
		spray		
Hydrocortic	onEquivalent	External		
Acetate	to 1.0	External		
Acetale	ner cent	For use		Container
		in irritant		or package
	Hydrocortisc	dermatitis,		containing
		contact		not more
		allergic		than 15g of
		dermatitis,		medicinal
		insect bite		product
		reactions,		
		mild to		In the
		moderate		case of
		eczema,		suppositories,
		and in		container
		combination		or package
		with one or		containing
		more of the		no more
		following:		than 12
		Benzyl		
		Benzoate,		
		Bismuth		
		Oxide,		
		Bismuth		
		Subgallate,		
		Peru		
		Balsam,		
		Pramoxine	_	
		Hydrochlorid	e,	
		Zinc		
		Oxide, for		
		haemorrhoids		
			82	

	Exemptions from the restrictions on the sale and supply of prescription only medicines					
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administratio use or pharmaceutio form		Column 5 Maximum quantity		
		[^{F145} or in combination with Miconazole Nitrate, for athlete's foot and candidal intertrigo]				
		For use in adults and children not less than 10 years				
		Cream, ointment or suppositories				
Hydrocortiso Butyrate Hydrocortiso						
Caprylate Hydrocortiso Hydrogen Succinate	ne					
Hydrocortiso Sodium Phosphate	ne					
Hydrocortiso Sodium Succinate	nEquivalent to 2.5mg Hydrocortiso	External For aphthous ulceration of the mouth for adults and children not less than 12 years		Container or package containing not more than equivalent to 50mg of Hydrocortisone		
		In the form of pellets				

		from the restrient from the restrient from the restrict from the r	ctions on the sale and sup	ply of
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administratio use or pharmaceuti form	Column 4 Treatment limitations on,	Column 5 Maximum quantity
[^{F109} Hydrocy Acid]	vanic			
Hydroflume	thiazide			
Hydroxychlo Sulphate	oroquine	Prophylaxis of malaria		
Hydroxypro	gesterone			
Hydroxyprog Enanthate	gesterone			
Hydroxyprog Hexanoate	gesterone			
Hydroxyurea	a			
Hydroxyzine Embonate	2			
Hydroxyzine		(a) For the management of pruritis associated with acute or chronic urticaria or atopic dermatitis or contact dermatitis, in adults and in children not less than 12 years	(a) 25mg (MD) 75mg (MDD)	(a) Container or package containing not more than 750mg of Hydroxyzine Hydrochloride
		(b) For the management of pruritis associated with acute or chronic urticaria or atopic dermatitis or contact dermatitis,	(b) 25 mg (MD) 50mg (MDD)	 (b) Container or package containing not more than 750mg of Hydroxyzine Hydrochloride
			84	

		from the restri	ictions on the sale and sup	ply of
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administrati use or pharmaceut form		Column 5 Maximum quantity
		in children not less than 6 years but less than 12 years		
Hyoscine	(1) 0.15 per cent	(1) Internal		
		(2) External (except ophthalmic)		
Hyoscine		(1) Internal		
Butylbromid	e	(a) by inhaler		
		(b) otherwise than by inhaler	(b) 20mg (MD) 80mg (MDD)	(b) Container or package containing not more than 240mg of Hyoscine Butylbromide
		(2) External		
Hyoscine		(1) Internal		
Hydrobromi	Hydrobromide			
		(b) otherwise	(b) 300mcg (MD)	
			900mcg (MDD)	
		(2) External (except ophthalmic)		
Hyoscine		(1) Internal		
Methobromi	de	(a) by inhaler		
		(b) otherwise	(b) 2.5mg (MD) 7.5mg (MDD)	

		from the restri only medicine	ictions on the sale and supply 25	v of
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administrati use or pharmaceut form than by inhaler		Column 5 Maximum quantity
		(2) External		
Hyoscine		(1) Internal		
Methonitrate		(a) by inhaler		
		(b) otherwise than by inhaler	(b) 2.5mg (MD) 7.5mg (MDD)	
		(2) External		
Hyoscyamine		(1) Internal		
		(b) otherwise than by inhaler	(b) 300mcg (MD) 1mg (MDD)	
		(2) External		
Hyoscyamine		(1) Internal		
Hydrobromid	Hydrobromide			
			(b) Equivalent of 300mcg of Hyoscyamine (MD)Equivalent of 1mg of Hyoscyamine (MDD)	
		(2) External		
Hyoscyamine		(1) Internal		
Sulphate		(a) by inhaler		
		(b) otherwise than by inhaler(2) External	(b) Equivalent of 300mcg of Hyoscyamine (MD) Equivalent of 1mg of Hyoscyamine (MDD)	

		from the restri only medicine	ctions on the sale and supply s	y of
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administration use or pharmaceution form		Column 5 Maximum quantity
Ibuprofen		Rheumatic and muscular pain, pain of non-serious arthritic conditions, backache, neuralgia, migraine, headache, dental pain, dysmenorrho feverishness, symptoms of colds and influenza	ea,	
		(1) Internal	(1)(a) In the case of a prolonged release preparation 600mg (MD)	
			1,200mg (MDD)	
			(b) in any other case 400mg (MD)	
			1,200mg (MDD)	
	(2) 5.0 per cent	(2) External		
	[^{F146} (3) 10.0 per cent]	[^{F146} (3) External]	[^{F146} (3) 125 mg (MD) 500 mg (MDD)]	[^{F146} (3) Container or package containing not more than [^{F147} 50g] of medicinal product]
[^{F109} Ibuprofen Lysine	1	Rheumatic and muscular pain, pain of non-serious arthritic	(a) in the case of a prolonged release preparation 600 mg (MD) 1,200 mg (MDD)	

	prescription	from the restrict only medicine	ictions on the sale and supp es	ly of	
Substance	Column 2 Maximum strength	Column 3 Route of administrati use or pharmaceut		Column 5 Maximum quantity	
		form conditions, backache, neuralgia, migraine, headache, dental pain, dysmenorrho feverishness, symptoms of colds and influenza			
		Internal	(b) in any other case 400 mg (MD) 1,200 mg (MDD)]		
Idarubicin Hydrochloride					
Idoxuridine					
Ifosfamide					
Ignatius Bean					
[^{F106} Imidapril Hydrochloride]				
Imipenem Hydrochloride					
Imipramine					
Imipramine Hydrochloride					
Imipramine Ion Exchange Resin Bound Salt or Complex					
[^{F121} Indapamid	e]				
Indapamide Hemihydrate					
2					

		from the restrict only medicine	ctions on the sale and sup	ply of	
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administratio use or pharmaceuti form	Column 4 Treatment limitations on,	Column 5 Maximum quantity	
Indomethacir Sodium	1				
Indoprofen					
Indoramin Hydrochlorid	le				
Inosine Pranobex					
[^{F148} Insulin]					
Iodamide					
Iodamide Meglumine					
Iodamide Sodium					
Iohexol					
Iomeprol					
Iopamidol					
Iopentol					
Iothalamic Acid					
Ioversol					
Ioxaglic Acid					
Ipratropium Bromide					
Iprindole Hydrochlorid	le				
Iproniazid Phosphate					
[^{F110} Irbesartai	n]				
Isoaminile					
Isoaminile Citrate					
Isocarboxazi	d				

		from the restri only medicine	ctions on the sale and suppl	y of
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administration use or pharmaceution form		Column 5 Maximum quantity
Isoconazole Nitrate		External but in the case of vaginal use only external use for the treatment of vaginal candidiasis		
Isoetharine				
Isoetharine Hydrochloride	e			
Isoetharine Mesylate				
Isoniazid				
Isoprenaline Hydrochloride	9			
Isoprenaline Sulphate				
Isopropamide Iodide			Equivalent of 2.5mg of Isopropamide ion (MD)	
			Equivalent of 5.0mg of Isopropamide ion (MDD)	
Isotretinoin				
Isradipine				
Itraconazole				
Jaborandi		External		
Kanamycin Acid Sulphate				
Kanamycin Sulphate				
Ketamine Hydrochloride	e			

		from the restri only medicine	ctions on the sale and suppl s	y of
Substance	Column 2 Maximum strength	Column 3 Route of administratio use or pharmaceuti form		Column 5 Maximum quantity
Ketoconazole 2	2.0 per cent	U U	xtEtn(a)] Maximum frequency of application of once every 3 days	[^{F149} (a)] Container or package containing not more than 120ml of medicinal product and containing not more than 2,400mg of Ketoconazole
		[^{F151} (b) For the treatment of the following mycotic infections of the skin: tinea pedis, tinea cruris and candidal intertrigo]		
Ketoprofen 2	2.5 per cent	External For rheumatic and muscular pain in adults and children not less than 12	For maximum period of 7 days	Container or package containing not more than 30g of medicinal product
Ketorolac Trometamol				
Ketotifen Fumarate				
Labetalol				

		from the restric only medicines	ctions on the sale and supp	oly of
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administratic use or pharmaceutic form	Column 4 Treatment limitations on,	Column 5 Maximum quantity
Lachesine Chloride				
Lacidipine				
Lamotrigine				
Lanatoside C				
Lanatoside Complex A, B and C				
[^{F121} Lansopraz	ole]			
Latamoxef Disodium				
[^{F121} Lercanidip Hydrochloride				
Levallorphan Tartrate				
Levobunolol Hydrochloride	:			
		(1) Nasal sprays For the symptomatic treatment of seasonal allergic rhinitis		(1) Container or package containing not more than 10 ml of medicinal product
		(2) Aqueous eye drops		(2) Container
		For the symptomatic treatment of seasonal allergic conjunctivitis		or package containing not more than 4 ml of medicinal product]
[^{F152} Levocarnit	tine]	[^{F152} For dietary supplementati	on]	

		from the restri only medicine	ctions on the sale and supp s	ly of
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administration use or pharmaceution form	Column 4 Treatment limitations on,	Column 5 Maximum quantity
Levodopa				
[^{F110} Levofloxac	in]			
Levonorgestre	^{F153} 0.75mg]	[^{F153} for use as an emergency contraceptive in women aged 16 years and over]	,	
Lidoflazine				
Lignocaine		Non- ophthalmic use		
Lignocaine Hydrochloride		Non- ophthalmic use		
Lincomycin				
Lincomycin Hydrochloride				
Liothyronine Sodium				
Lisinopril				
Lithium Carbonate			Equivalent of 5mg of Lithium (MD)	
			Equivalent of 15mg of Lithium (MDD)	
Lithium Citrate				
Lithium Succinate				
Lithium Sulphate			Equivalent of 5mg of Lithium (MD)	
			Equivalent of 15mg of Lithium (MDD)	
Lobeline		(1) Internal	(1) 3mg (MD) 93	

		from the restri only medicine	ctions on the sale and suppl	y of
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administrativ use or pharmaceuti	Column 4 Treatment limitations on,	Column 5 Maximum quantity
		form		
			9mg (MDD)	
		(2) External		
Lobeline Hydrochloric	le	(1) Internal	(1) Equivalent of 3mg of Lobeline (MD)	
			Equivalent of 9mg of Lobeline (MDD)	
		(2) External		
Lobeline Sulphate		(1) Internal	(1) Equivalent of 3mg of Lobeline (MD)	
			Equivalent of 9mg of Lobeline (MDD)	
		(2) External		
Lodoxamide Trometamol	[^{F154} equivaler of 0.1 per cent Lodoxamide	treatment of ocular	5,	
Lofepramine				
Lofepramine Hydrochloric				
Lofexidine Hydrochloric	le			
Lomefloxaci Hydrochloric				
Lomustine				
Loperamide Hydrochloric	le	Treatment of acute diarrhoea		
Loratidine			10mg (MDD)	F156

	1	from the restr	ictions on the sale and suppersive the sale and supper	ply of
Column 1	Column 2	Column 3	Column 4	Column 5
Substance	Maximum strength	Route of administrat use or pharmaceut		Maximum quantity
		form		

. . .

[^{F122}Lornoxicam]

[^{F122} Losartan Potassium]
Loxapine Succinate
Lung Surfactant Porcine
Luteinising Hormone
Lymecycline
Lynoestrenol
Lypressin
Lysuride Maleate
Mafenide
Mafenide Acetate
Mafenide Hydrochloride
Mafenide 5.0 per cent Eye drops Propionate
Magnesium Fluoride
Magnesium Metrizoate
Mandragora Autumnalis
Mannomustine Hydrochloride
Maprotiline Hydrochloride
Mebanazine

		from the restri	ctions on the sale and supp s	ly of
Column 1 Substance	Column 2 Aaximum trength	Column 3 Route of administratio use or pharmaceuti form	Column 4 Treatment limitations on,	Column 5 Maximum quantity
Mebendazole		For oral use in the treatment of enterobiasis in adults and in children not less than 2 years	100mg (MD)	Container or package containing not more than 800mg of Mebendazole
Mebeverine Hydrochloride		[^{F157} (a)For the symptomatic relief of irritable bowel syndrome	[^{F157} (a) 135 mg (MD) 405 mg (MDD)]	
		(b) For uses other than the symptomatic relief of irritable bowel syndrome]	[^{F157} (b) 100 mg (MD) 300 mg (MDD)]	
Mebeverine Pamoate				
Mebhydrolin				
Mebhydrolin Napadisylate				
Mecamylamine Hydrochloride				
Mecillinam				
Meclofenoxate Hydrochloride				
Medigoxin				
Medrogestone				
Medroxyproges Acetate	terone			

	Exemptions from the restrictions on the sale and supply of prescription only medicines				
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administrati use or pharmaceut form	Column 4 Treatment limitations ion,	Column 5 Maximum quantity	
Mefenamic Acid					
Mefloquine Hydrochlorid	e				
Mefruside					
Megestrol					
Megestrol Acetate					
Meglumine Gadopentetate	e				
Meglumine Iodoxamate					
Meglumine Ioglycamate					
Meglumine Iothalamate					
Meglumine Iotroxate					
Meglumine Ioxaglate					
[^{F121} Meloxicat	m]				
Melphalan					
Melphalan Hydrochlorid	e				
Menotrophin					
Mepenzolate			25mg (MD)		
Bromide			75mg (MDD)		
Mephenesin					
Mephenesin Carbamate					
Mepivacaine Hydrochlorid	e	Any use except ophthalmic use			

		from the restruction only medicine	ictions on the sale and suppers	ply of	
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administrati use or pharmaceut form	Column 4 Treatment limitations ion,	Column 5 Maximum quantity	
Meptazinol Hydrochloric	le				
Mequitazine					
[^{F110} Mercapta Bitartrate]	amine				
Mercaptopur	ine				
Mersalyl					
Mersalyl Acid					
Mesalazine					
Mesna					
Mestranol					
Metaraminol Tartrate					
Metergoline					
Metformin Hydrochlorid	le				
Methacycline	e				
Methacycline Calcium	e				
Methacycline Hydrochlorie					
Methallenoes	stril				
Methicillin Sodium					
Methixene					
Methixene Hydrochlorid	le				
Methocarbar	nol				
Methocidin		Throat lozenges and throat pastilles			

		from the restri	ctions on the sale and support	ply of
Column 1 Column 2 Substance Maximum strength		Column 3 Route of administratio use or pharmaceuti form	Column 4 Treatment limitations on,	Column 5 Maximum quantity
Methohexito: Sodium	ne			
Methoin				
Methoserpidi	ine			
Methotrexate	;			
Methotrexate Sodium	•			
Methotrimep	razine			
Methotrimep Hydrochloric				
Methotrimep Maleate	razine			
Methoxamin Hydrochloric		Nasal sprays or nasal drops not containing liquid paraffin as a vehicle		
Methsuximid	le			
Methyclothia	zide			
Methyldopa				
Methyldopat Hydrochloric				
Methylephed			30mg (MD)	
Hydrochloric	le		60mg (MDD)	
Methylpredn	isolone			
Methylpredn Acetate	isolone			
Methylpredn Sodium Succinate	isolone			
Methylthiour	acil			
Methysergide Maleate	e			

		from the restr only medicine	ictions on the sale and supres	ply of
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administrati use or pharmaceut form		Column 5 Maximum quantity
Metipranolo	1			
Metirosine				
Metoclopran Hydrochlorie				
Metolazone				
Metoprolol Fumarate				
Metoprolol Succinate				
Metoprolol Tartrate				
Metronidazo	le			
Metronidazo Benzoate	le			
Metyrapone				
Mexiletine Hydrochlori	de			
Mezlocillin Sodium				
Mianserin Hydrochlori	de			
Miconazole		External but in the case of vaginal use only external use for the treatment of vaginal candidiasis		
Miconazole Nitrate		External but in the case of vaginal use only external use for the treatment		

	prescription	from the restriction only medicine	ctions on the sale and sup s	ply of
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administratio use or pharmaceuti form		Column 5 Maximum quantity
		of vaginal candidiasis		
Mifepristone				
Miglitol				
Milrinone				
Milrinone Lactate				
Minocycline				
Minocycline Hydrochlorid	le			
Minoxidil	[^{F158} (1) 2.0 per cent]	[^{F158} (1) External		
	[^{F158} (2) 5.0 per cent	(2) External use for the treatment of alopecia androgenetica in men aged 18 to 65 (but not in women);]	a,	
[^{F106} Mirtazap	ine]			
Misoprostol				
Mitobronitol				
Mitomycin				
Mitozantrone Hydrochloric				
Mivacurium Chloride				
[^{F131} Mizolast	ine]			
Moclobemid	e			
[^{F110} Modafini	1]			
[^{F107} Moexipri Hydrochlorid	l le]			

		from the restr	ictions on the sale and suppersive	ply of
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administrati use or pharmaceut form		Column 5 Maximum quantity
Molgramosti	m			
Molindone Hydrochlorid	le			
Mometasone Furoate				
Moracizine Hydrochlorid	le			
Morazone Hydrochlorid	le			
[^{F106} Moxonid	ine]			
Mupirocin				
Mupirocin Calcium				
Mustine Hydrochlorid	le			
Nabilone				
Nabumetone				
Nadolol				
Nafarelin Acetate				
Naftidrofuryl Oxalate				
Naftifine Hydrochlorid	le			
Nalbuphine Hydrochlorid	le			
Nalidixic Acid				
Nalorphine Hydrobromic	le			
Naloxone Hydrochlorid	le			
Naltrexone Hydrochlorid	le			

Column 1 Substance Naphazoline (Hydrochloride	Column 2 Maximum strength (1) 0.05 per cent (2) 0.015 per cent	only medicines Column 3 Route of administratic use or pharmaceutic form (1) Nasal sprays or nasal drops not containing liquid paraffin as a vehicle (2) Eye drops	Column 4 Treatment limitatio on,	ons	Column 5 Maximum quantity
Hydrochloridæ	(2) 0.015 per cent 0.05 per	sprays or nasal drops not containing liquid paraffin as a vehicle (2) Eye drops			
(per cent 0.05 per	drops			
	-	Nosel annour			
Naphazoline (Nitrate c		Nasal sprays or nasal drops not containing liquid paraffin as a vehicle			
Naproxen					
Naproxen Sodium					
[^{F110} Naratriptar Hydrochloride					
Natamycin					
[^{F122} Nebivolol Hydrochloride					
a 11	[^{F159} 2.0 per cent]	[^{F159} For the prevention, relief and treatment of seasonal and perennial allergic conjunctivitis]		[^{F159} Container or package containing not more than 3 ml of medicinal product]
Nefazodone Hydrochloride	2				
Nefopam Hydrochloride	•				
Neomycin					

	<i>Exemptions from the restrictions on the sale and supply of prescription only medicines</i>				
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administrati use or pharmaceut form		Column 5 Maximum quantity	
Neomycin Oleate					
Neomycin Palmitate					
Neomycin Sulphate					
Neomycin Undecanoate					
Neostigmine Bromide					
Neostigmine Methylsulphat	e				
Netilmicin Sulphate					
Nicardipine Hydrochloride	,				
Nicergoline					
[^{F131} Niceritrol]					
Nicotinic Acid		Any use, except for the treatment of hyperlipidae			
Nicoumalone					
Nifedipine					
Nifenazone					
Nikethamide					
[^{F109} Nilutamid	e]				
Nimodipine					
Niridazole					
[^{F122} Nisoldipin	e]				
Nitrendipine					
Nitrofurantoin					

		from the restruction from the restruction from the formation of the second seco	ictions on the sale and suppers	ply of
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administrati use or pharmaceut form	Column 4 Treatment limitations ion,	Column 5 Maximum quantity
Nitrofurazone	2			
Nizatidine		For the prevention [^{F160} and treatment] of the symptoms of food- related heartburn [^{F160} and meal- induced indigestion] For use in	75mg (MD) [^{F161} 150mg (MDD)] [^{F162} For a maximum period of 14 days]	
		adults and children not less than 16 years		
Nomifensine Maleate				
Noradrenalin	e			
Noradrenalin Acid Tartrate	e			
Norethisteror	e			
Norethisteror Acetate	le			
Norethisteror Enanthate	ie			
Norethynodre	el			
Norfloxacin				
Norgestimate				
Norgestrel				
Nortriptyline Hydrochlorid	e			
Noscapine				

		from the restric only medicines	tions on the sale and sup	ply of
Column 1 Substance	Column 2 Maximum strength	Column 3	Column 4 Treatment limitations n,	Column 5 Maximum quantity
Noscapine Hydrochlorid	e			
Novobiocin Calcium				
Novobiocin Sodium				
Nux Vomica Seed				
Nystatin	[^{F163} 3.0 per cent]	[^{F163} External For use in combination with Hydrocortison of maximum strength 0.5 per cent for intertrigo For use in adults and children not less than 10 years]	e	[^{F163} Container or package containing not more than 15g of medicinal product]
Octacosactrin	1			
Octreotide				
Oestradiol Oestradiol Benzoate				
Oestradiol Cypionate				
Oestradiol Dipropionate				
Oestradiol Diundecanoa	te			
Oestradiol Enanthate				

		from the restruction only medicine	ictions on the sale and suppers	ply of	
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administrati use or pharmaceut form	Column 4 Treatment limitations ion,	Column 5 Maximum quantity	
Oestradiol Phenylpropic	onate				
Oestradiol Undecanoate					
Oestradiol Valerate					
Oestriol					
Oestriol Succinate					
Oestrogenic Substances Conjugated					
Oestrone					
Ofloxacin					
Olsalazine Sodium					
Omeprazole					
[^{F106} Omepraz Magnesium]	cole				
Ondansetron Hydrochlorid					
Orciprenaline Sulphate	9				
Orphenadrine Citrate	9				
Orphenadrine Hydrochloric					
Ouabain					
Ovarian Gland Dried					
Oxamniquine	e				
Oxantel Embonate					
Oxaprozin					

	Exemptions from the restrictions on the sale and supply of prescription only medicines			
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administrati use or pharmaceut form		Column 5 Maximum quantity
Oxatomide				
Oxedrine Tartrate				
Oxethazaine			10mg (MD)	Container
			30mg (MDD)	or package containing not more than 400mg of Oxethazaine
Oxitropium Bromide				
Oxolinic Acid				
Oxpentifyllin	ne			
Oxprenolol Hydrochlorid	le			
Oxybuprocai Hydrochloric		Non- ophthalmic use		
Oxybutynin Hydrochlorid	le			
Oxypertine				
Oxypertine Hydrochloric	le			
Oxyphenbuta	azone			
Oxyphencycl Hydrochlorid				
Oxyphenoniu Bromide	ım		5mg (MD) 15mg (MDD)	
Oxytetracycl	ine			
Oxytetracycl Calcium	ine			
Oxytetracycl Dihydrate	ine			

		from the restri only medicine	ctions on the sale and supply s	y of
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administrati use or pharmaceuti form	Column 4 Treatment limitations on,	Column 5 Maximum quantity
Oxytetracycl Hydrochlorid				
Oxytocin, natural				
Oxytocin, synthetic				
Pancreatin	(1) 21,000 European Pharmacopo units of lipase per capsule	(1) capsules eia		
	(2) 25,000 European Pharmacopo units of lipase per gram	(2) powder eia		
Pancuronium Bromide	L			
[^{F121} Pantopra Sodium]	zole			
Papaverine		(1) By inhaler		
		(2)	(2) 50mg (MD)	
		Otherwise than by inhaler	150mg (MDD)	
Papaverine Hydrochlorid	le	(1) By inhaler		
		(2) Otherwise	(2) Equivalent of 50mg of Papaverine (MD)	
		than by inhaler	Equivalent of 150mg of Papaverine (MDD)	
[^{F111} Paracetar	mol (1) [^{F164} 2.	50mg]) Non- effervescent tablets and capsules		(1) The quantity sold or supplied in

		from the restrictions on the sale and sup only medicines	oply of
Column 1 Substance	Column 2 Maximum strength	Column 3 Column 4 Route of Treatment limitations administration, use or pharmaceutical form	Column 5 Maximum quantity
	(2) 500 mg	[^{F165} wholly or mainly] for use in children aged less than 12 years (2) Non- effervescent tablets and capsules [^{F166} wholly or mainly] for use in adults and children not less than 12 years	one container or package shall not exceed 32 The quantity of non- effervescent tablets, capsules or a combination of both sold or supplied to a person at any one time shall not exceed 100
		(3) All preparations other than non- effervescent tablets and capsules	(2) The quantity sold or supplied in one container or package shall not exceed 32 The quantity of non- effervescent tablets, capsules or a

	<i>Exemptions from the restrictions on the sale and supply of prescription only medicines</i>						
Column I Column Substance Maxim strengt	n 2 Column 3 um Route of	Column 4 Treatment limitations ion,	Column 5 Maximum quantity				
			combination of both sold or supplied to a person at any one time shall not exceed 100]				
Paraldehyde			100]				
Paramethadione							
Paramethasone Acetate							
Parathyroid Gland							
Pargyline Hydrochloride							
Paroxetine Hydrochloride							
Pecilocin							
Penamecillin							
Penbutolol Sulphate							
[^{F121} Penciclovir]							
Penicillamine							
Penicillamine Hydrochloride							
Pentamidine Isethionate							
Penthienate		5mg (MD)					

		from the restrie only medicine.	ctions on the sale and sup s	pply of
Substance	Column 2 Maximum strength	Column 3 Route of administratio use or pharmaceuti form		Column 5 Maximum quantity
Pentolinium Tartrate				
Perfluamine				
Pergolide Mesylate				
Perhexiline Maleate				
Pericyazine				
Perindopril				
Perindopril Erbumine				
Perphenazine				
Phenacetin 0	.1 per cent			
Phenazone		External		
Phenazone Salicylate				
Phenbutrazate Hydrochloride				
Phenelzine Sulphate				
Phenethicillin Potassium				
Phenformin Hydrochloride				
Phenglutarimid Hydrochloride	le			
Phenindione				
[^{F167} Phenolphth	alein.]			
Phenoxybenzar Hydrochloride	nine			
Phenoxymethy	lpenicillin			
Phenoxymethy Calcium	lpenicillin			

		from the restring only medicine	ictions on the sale and supp	ply of
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administrati use or pharmaceuti form	Column 4 Treatment limitations ion,	Column 5 Maximum quantity
Phenoxymet Potassium	hylpenicillin			
Phenprocour	non			
Phensuximic	le			
Phentolamin Hydrochlorie				
Phentolamin Mesylate	e			
Phenylbutaz	one			
Phenylbutaz Sodium	one			
Phenylpropa		Internal		
Hydrochlori	de	(1) all preparations except prolonged release capsules, nasal sprays and nasal drops	(1) 25mg (MD) 100mg (MDD)	
		(2)	(2) 50mg (MD)	
		prolonged release capsules	100mg (MDD)	
	(3) 2.0 per cent	(3) nasal sprays and nasal drops		
Phenytoin				
Phenytoin Sodium				
Phthalylsulp	hathiazole			
Physostigmi	ne			
Physostigmi Aminoxide Salicylate	ne			

	prescription	n only medicine	ctions on the sale and suppos	oly of
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administrati use or pharmaceuti form		Column 5 Maximum quantity
Physostigmi Salicylate	ne			
Physostigmi Sulphate	ne			
[^{F109} Phytome	enadione	Any use except the prevention or treatment of haemorrhagic disorders]	c	
Picrotoxin				
Pilocarpine				
Pilocarpine Hydrochlori	de			
Pilocarpine Nitrate				
Pimozide				
Pindolol				
Pipenzolate			5mg (MD)	
Bromide			15mg (MDD)	
Piperacillin Sodium				
Piperazine Oestrone Sulphate				
Piperidolate	1		50mg (MD)	
Hydrochlori	de		150mg (MDD)	
Pipothiazine Palmitate				
Piracetam				
Pirbuterol Acetate				
Pirbuterol Hydrochlori	de			

		from the restri	ctions on the sale and suppl	ly of
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administrati use or pharmaceuti form		Column 5 Maximum quantity
[^{F168} Pirenzep Dihydrochlo Monohydrate	ride			
Pirenzepine Hydrochlorid	de			
Piretanide				
Piroxicam	0.5 per cent	External For the relief of rheumatic pain, pain of non-serious arthritic conditions and muscular aches, pains and swellings such as strains, sprains and sports injuries For use in adults and children not less than 12 years	For maximum period of 7 days	Container or package containing not more than 30g of medicinal product
[^{F131} Piroxican Beta- cyclodextrin				
Pituitary Gland (Whole Dried)		By inhaler		
Pituitary Powdered (Posterior Lobe)		By inhaler		

	prescription	from the restri n only medicine	ctions on the sale and suppos	ply of	
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administrati use or pharmaceuti form		Column 5 Maximum quantity	
Pivampicillin	n				
Pivampicillin Hydrochlorid					
Pivmecillina	m				
Pivmecillina Hydrochlorid					
Pizotifen					
Pizotifen Malate					
Plicamycin					
Podophylloto	oxin				
Podophyllun	n				
Podophyllun Indian	n				
Podophyllun	n 20.0 per	External			
Resin	cent	Ointment or impregnated plaster			
Poldine			2mg (MD)		
Methylsulph	ate		6mg (MDD)		
Polidexide					
Polyestradio Phosphate	1				
Polymyxin B Sulphate					
Polythiazide					
Poppy Capsule					
Potassium Arsenite	0.0127 per cent				
Potassium Bromide					
Potassium Canrenoate					
			116		

	Exemptions from the restrictions on the sale and supply of prescription only medicines					
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administrati use or pharmaceut form	Column 4 Treatment limitations ion,	Column 5 Maximum quantity		
Potassium Clavulanate						
Potassium Perchlorate						
Practolol						
Pralidoxime Chloride						
Pralidoxime Iodide						
Pralidoxime Mesylate						
[^{F110} Pramipex Hydrochloric						
Pravastatin Sodium						
Prazosin Hydrochloric	le					
Prednisolone						
Prednisolone Acetate						
Prednisolone Butylacetate						
Prednisolone Hexanoate						
Prednisolone Metasulphob						
Prednisolone Metasulphob Sodium						
Prednisolone Pivalate						
Prednisolone Sodium Phosphate						

		from the restriction only medicine.	restrictions on the sale and supply of icines			
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administratio use or pharmaceuti form	Column 4 Treatment limitations on,	Column 5 Maximum quantity		
Prednisolone Steaglate						
Prednisone						
Prednisone Acetate						
Prenalterol Hydrochlorid	e					
Prenylamine Lactate						
Prilocaine Hydrochlorid	e	Non- ophthalmic use				
Primidone						
Probenecid						
Probucol						
Procainamide Hydrochlorid						
Procaine Hydrochlorid	e	Non- ophthalmic use				
Procaine Penicillin						
Procarbazine Hydrochlorid	e					
Prochlorperaz	zine					
Prochlorperaz Edisylate	zine					
Prochlorperaz Maleate	z ifi^{gs}3mg]	[^{F125} Buccal tablets for the treatment of nausea and vomiting in cases of previously diagnosed migraine	[^{F125} 12mg (MDD)]	[^{F125} Container or package containing not more than 8 tablets]		

118

	Exemptions from the restrictions on the sale and supply of prescription only medicines					
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administratuuse or pharmaceut form		Column 5 Maximum quantity		
		only. For use in				
		persons aged 18 years and over.]				
Prochlorpera Mesylate	zine					
Procyclidine Hydrochlorid						
Progesterone	;					
Prolactin						
Proligestone						
Prolintane Hydrochlorid	de					
Promazine Embonate						
Promazine Hydrochlorid	le					
Propafenone						
Propafenone Hydrochlorid						
Propanidid						
Propanthelin	e		15mg (MD)			
Bromide			45mg (MDD)			
[^{F122} Propiver Hydrochlorid	ine le]					
Propofol						
Propranolol Hydrochlorid	le					
Propylthiour						
Proquazone						
Protamine Sulphate						
Sulphate						

		from the restring only medicine	ctions on the sale and supply	v of
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administrati use or pharmaceut form		Column 5 Maximum quantity
Prothionamic	le			
Protirelin				
Protriptyline Hydrochloric	le			
Proxymetaca Hydrochloric		Non- ophthalmic use		
Pseudoephedrine Hydrochloride		Internal	(a) In the case of a prolonged release preparation	
			120mg (MD)	
			240mg (MDD)	
			(b) in any other case 60mg (MD)	
			240mg (MDD)	
Pseudoephed	rine		60mg (MD)	
Sulphate			180mg (MDD)	
Pyrantel Embonate		(a) For the treatment of enterobiosis, in adults and children not less than 12 years	(a) 750mg MDD (as a single dose)	(a) Container or package containing not more than 750mg of Pyrantel Embonate
		(b) For the treatment of enterobiosis, in children less than 12 years but not less than 6 years	(b) 500mg MDD (as a single dose)	(b) Container or package containing not more than 750mg of Pyrantel Embonate
		(c) For the treatment of enterobiosis in children less than 6	(c) 250mg MDD (as a single dose)	(c) Container or package containing not more

		from the restri only medicine	ctions on the sale and supp s	ly of
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administration use or pharmaceution form	,	Column 5 Maximum quantity
		years but not less than 2 years		than 750mg of Pyrantel Embonate
Pyrantel Tartrate				
Pyrazinamide				
Pyridostigmin Bromide	e			
Pyrimethamin	e			
[^{F122} Quetiapin Fumarate]	e			
[^{F107} Quinagoli Hydrochloride				
Quinapril				
[^{F168} Quinapril Hydrochloride	2]			
Quinestradol				
Quinestrol				
Quinethazone				
Quinidine				
Quinidine Bisulphate				
Quinidine Polygalacturo	nate			
Quinidine Sulphate				
Quinine			100mg (MD)	
			300mg (MDD)	
Quinine Bisulphate			Equivalent of 100mg of Quinine (MD)	
			Equivalent of 300mg of Quinine (MDD)	
Quinine Cinchophen			Equivalent of 100mg of Quinine (MD)	
			121	

	from the restrictions on the sale and supp n only medicines	ply of
Column 1 Column 2 Substance Maximum strength	Column 3 Column 4 Route of Treatment limitations administration, use or pharmaceutical form	Column 5 Maximum quantity
	Equivalent of 300mg of Quinine (MDD)	
Quinine Dihydrochloride	Equivalent of 100mg of Quinine (MD)	
	Equivalent of 300mg of Quinine (MDD)	
Quinine Ethyl	Equivalent of 100mg of Quinine (MD)	
Carbonate	Equivalent of 300mg of Quinine (MDD)	
Quinine Glycerophosphate	Equivalent of 100mg of Quinine (MD)	
	Equivalent of 300mg of Quinine (MDD)	
Quinine Hydrobromide	Equivalent of 100mg of Quinine (MD)	
	Equivalent of 300mg of Quinine (MDD)	
Quinine Hydrochloride	Equivalent of 100mg of Quinine (MD)	
5	Equivalent of 300mg of Quinine (MDD)	
Quinine Iodobismuthate	Equivalent of 100mg of Quinine (MD)	
	Equivalent of 300mg of Quinine (MDD)	
Quinine Phosphate	Equivalent of 100mg of Quinine (MD)	
	Equivalent of 300mg of Quinine (MDD)	
Quinine Salicylate	Equivalent of 100mg of Quinine (MD)	
-	Equivalent of 300mg of Quinine (MDD)	
Quinine Sulphate	Equivalent of 100mg of Quinine (MD) 122	

		from the restri only medicine	ctions on the sale and supply	v of
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administration use or pharmaceutit form	Column 4 Treatment limitations on,	Column 5 Maximum quantity
			Equivalent of 300mg of Quinine (MDD)	
Quinine Tannate			Equivalent of 100mg of Quinine (MD)	
			Equivalent of 300mg of Quinine (MDD)	
Quinine in combination with Urea Hydrochloride	9			
Ramipril				
[^{F106} Ranitidine Bismuth Citrate]	;			
Ranitidine Hydrochloride	2	For the short term	Equivalent to 75mg of Ranitidine (MD)	
		symptomatic relief of heartburn,	Equivalent to 300mg of Ranitidine (MDD)	
		heartourn, dyspepsia, indigestion, acid indigestion and hyperacidity [^{F169} or the prevention of these symptoms when associated with consuming food and drink]	For a maximum period of 14 days	
Rauwolfia Serpentina				
Rauwolfia Vomitoria				

		from the restr	ictions on the sale and suppersisted of the sale and sale and suppersisted of the sale and sale and suppersisted of the sale and sale	ply of	
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administrati use or pharmaceut form	Column 4 Treatment limitations ion,	Column 5 Maximum quantity	
Razoxane					
[^{F110} Reboxeti Mesilate]	ne				
Remoxipride Hydrochlorid					
Reproterol Hydrochlorid	de				
Rescinnamin	ie				
Reserpine					
Rifabutin					
Rifampicin					
Rifampicin Sodium					
Rifamycin					
[^{F106} Rimexol	one]				
Rimiterol Hydrobromi	de				
Risperidone					
Ritodrine Hydrochlorid	le				
Rolitetracycl Nitrate	ine				
[^{F126} Ropiniro Hydrochlorio					
Sabadilla					
Salbutamol					
Salbutamol Sulphate					
Salcatonin					
Salcatonin Acetate					
Salmefamol					

Exemptions from the restrictions on the sale and supply of prescription only medicines				ply of
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administrati use or pharmaceut form	Column 4 Treatment limitations ion,	Column 5 Maximum quantity
Salmeterol Xinafoate				
Salsalate				
Saralasin Acetate				
Selegiline Hydrochlorid	e			
Semisodium Valproate				
[^{F110} Sertindol	e]			
[^{F106} Sertraline Hydrochlorid				
Serum Gonadotroph	in			
[^{F106} Sevoflura	ine]			
Silver Sulphadiazin	e			
Simvastatin				
Sissomicin				
Sissomicin Sulphate				
Snake Venoms				
Sodium Acetrizoate				
Sodium Aminosalicyl	ate			
Sodium Antimonylglu	uconate			
Sodium Arsanilate				
Sodium Arsenate				

		from the restrictions on the sale and sup only medicines	ply of
Column 1 Substance	Column 2 Maximum strength	Column 3 Column 4 Route of Treatment limitations administration, use or pharmaceutical form	Column 5 Maximum quantity
Sodium Arsenite	0.013 per cent		
Sodium Bromide			
Sodium Clodronate			
Sodium Cromoglyca	te	(a) For nasal admistration	
	(b) 2.0 per cent	(b) For the treatment of acute seasonal allergic conjunctivitis [^{F170} or perennial allergic conjunctivitis]	(b) Container or package containing not more than 10ml of medicinal product
		In the form of aqueous eye drops	
	(c) 4.0 per cent	 (c) For the treatment of acute seasonal allergic conjunctivitis In the form of an eye 	(c) Container or package containing not more than 5g of medicinal product
Sodium		ointment	
Ethacrynate			
Sodium Fluoride	(1) 0.33 per cent	(1) Dentifrices	
		(2) Other preparations for use in the prevention	
		126	

		from the restri only medicine	ctions on the sale and suppos	ply of	
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administrati use or pharmaceute form of dental		Column 5 Maximum quantity	
		caries In the form			
		of			
		(a) tablets or drops	(a) 2.2 mg (MDD)		
	(b) 0.2 per cent	(b) mouth rinses other than those for daily use			
	(c) 0.05 per cent	(c) mouth rinses for daily use			
Sodium Fusidate					
Sodium Metrizoate					
Sodium Monofluoro	1.14 per phæmpthate	Dentrifrice			
Sodium Oxidronate					
Sodium Stiboglucon	ate				
Sodium Valproate					
Somatorelin Acetate					
Sotalol Hydrochlori	de				
[^{F107} Sparflox	(acin]				
Spectinomy	cin				
Spectinomy Hydrochlori					
Spiramycin					
Spiramycin Adipate					
			105		

		from the restric only medicines	ctions on the sale and sup	vly of
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administratio use or pharmaceutio form	Column 4 Treatment limitations on,	Column 5 Maximum quantity
Spironolacto	ne			
Stannous Fluoride	([^{F171} 1]) 0.62 per cent	([^{F171} 1]) Dentifrice		
	[^{F171} (2) 0.4 per]	[^{F171} (2) Dental gels for use in the prevention and treatment of dental caries and decalcification of the teeth]	n	
Stilboestrol				
Stilboestrol Dipropionate	2			
Streptodorna	se	External		
Streptokinas	e	External		
Streptomycin	1			
Streptomycir Sulphate	1			
Strychnine				
Strychnine Arsenate				
Strychnine Hydrochlorid	le			
[^{F109} Strychnin Nitrate]	ne			
Styramate				
Succinylsulp	hathiazole			
Sucralfate				
Sulbactam Sodium				

Exemptions from the restrictions on the sale and supply of prescription only medicines				ply of
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administratio use or pharmaceuti form	Column 4 Treatment limitations on,	Column 5 Maximum quantity
Sulbenicillin				
Sulbenicillin Sodium				
Sulconazole Nitrate		External (except vaginal)		
[^{F109} Sulfaben:	zamide]			
Sulfacytine				
Sulfadoxine				
Sulfamerazin	e			
Sulfamerazin Sodium	e			
Sulfametopy	razine			
Sulfamonom	ethoxine			
Sulindac				
Sulphacetam	ide			
Sulphacetam Sodium	ide			
Sulphadiazin	e			
Sulphadiazin Sodium	e			
Sulphadimeth	noxine			
Sulphadimidi	ine			
Sulphadimidi Sodium	ine			
Sulphafurazo	le			
Sulphafurazo Diethanolam				
Sulphaguanic	line			
Sulphaloxic Acid				
Sulphamethiz	zole			
Sulphamethiz	zole			

		from the restri only medicine	ictions on the sale and supp	ply of	
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administrati use or pharmaceut form	Column 4 Treatment limitations ion,	Column 5 Maximum quantity	
Sulphametho	oxazole				
Sulphametho	oxydiazine				
Sulphametho	oxypyridazine				
Sulphametho Sodium	oxypyridazine				
Sulphamoxo	le				
Sulphanilam	ide				
Sulphaphena	zole				
Sulphapyridi	ine				
Sulphapyridi Sodium	ine				
Sulphasalazi	ne				
Sulphathiazo	ole				
Sulphathiazo Sodium	ole				
Sulphaurea					
Sulphinpyraz	zone				
Sulpiride					
Sultamicillin	l				
Sultamicillin Tosylate	l				
Sulthiame					
Sumatriptan Succinate					
Suprofen					
Suxamethon Bromide	ium				
Suxamethon Chloride	ium				
Suxethonium Bromide	1				

	prescription	<i>Exemptions from the restrictions on the sale and supply of prescription only medicines</i>					
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administratio use or pharmaceutio form		Column 5 Maximum quantity			
[^{F122} Tacalcito Monohydrate							
Tacrine Hydrochlorid	le						
Talampicillir	ı						
Talampicillir Hydrochlorid							
Talampicillir Napsylate	1						
Tamoxifen							
Tamoxifen Citrate							
[^{F121} Tamsulo Hydrochlorid							
[^{F106} Tazarote	ne]						
Tazobactam Sodium							
Teicoplanin							
[^{F110} Temocap Hydrochlorid							
Temocillin Sodium							
Tenoxicam							
Terazosin Hydrochlorid	le						
Terbinafine	[^{F172} 1.0 per cent]	[^{F173} External use for the treatment of tinea pedis, tinea cruris and tinea corporis. In the form of a gel]		[^{F174} Container or package containing not more than 30 grams of medicinal product]			

prescript	ns from the restrictions on the sale and sup on only medicines	pply of
Column 1 Column 2 Substance Maximum strength		Column 5 Maximum quantity
[^{F175} Terbinafin <mark></mark>] ^{F175} 1.0 pe Hydrochloridedent]	r ([^{F176} 1]) [^{F177} Preparations, other than spray solutions, for][^{F175} external use for the treatment of tinea pedis and tinea cruris]	([^{F176} 1]) [^{F175} Container or package containing not more than 15 g of medicinal product.]
	[^{F178} (2) Spray solutions for external use for the treatment of tinea corporis, tinea cruris and tinea pedis]	[^{F178} (2) Container containing not more than 30ml of medicinal product]
Terbutaline		
Terbutaline Sulphate		
Terfenadine	F179	F179
Terlipressin		
Terodiline Hydrochloride		
[^{F110} Testosterone]		
Tetrabenazine		
Tetracosactrin		
Tetracosactrin Acetate		
Tetracycline		

132

		from the restric only medicines	ctions on the sale and sup	ply of
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administratic use or pharmaceutic form	Column 4 Treatment limitations on,	Column 5 Maximum quantity
Tetracycline Hydrochloric	le			
Tetracycline Phosphate Complex				
Tetroxoprim				
Thallium Acetate				
Thallous Chloride				
Thiabendazo	le			
Thiambutosi	ne			
Thiethylpera: Malate	zine			
Thiethylpera: Maleate	zine			
Thiocarlide				
Thioguanine				
Thiopentone Sodium				
Thiopropazat Hydrochloric				
Thioproperaz Mesylate	vine			
Thioridazine				
Thioridazine Hydrochlorid	le			
Thiosinamine	e			
Thiotepa				
Thiothixene				
Thiouracil				
Thymoxamir Hydrochlorid				
Thyroid				

Exemptions from the restrictions on the sale and supply of prescription only medicines					
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administrati use or pharmaceuti form		Column 5 Maximum quantity	
Thyrotrophir	1				
Thyroxine Sodium					
Tiamulin Fumarate					
Tiaprofenic Acid					
Tibolone					
Ticarcillin Sodium					
[^{F121} Ticlopidi Hydrochlorid					
Tigloidine Hydrobromi	de				
[^{F121} Tiludron Disodium]	ate				
Timolol Maleate					
Tinidazole					
Tinzaparin					
Tioconazole	(1) 2.0 per cent	(1) External (except vaginal)			
		(2) Vaginal for treatment of vaginal candidiasis			
[^{F107} Tizanidin Hydrochlorid					
Tobramycin					
Tobramycin Sulphate					
Tocainide Hydrochlorid	de				

	<i>Exemptions from the restrictions on the sale and supply of prescription only medicines</i>					
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administrati use or pharmaceut form	Column 4 Treatment limitations on,	Column 5 Maximum quantity		
Tofenacin Hydrochloride	;					
Tolazamide						
Tolazoline Hydrochloride	;	External				
Tolbutamide						
Tolbutamide Sodium						
Tolfenamic Acid						
Tolmetin Sodium						
[^{F106} Topiramat	e]					
[^{F131} Torasemid	e]					
[^{F121} Toremifen	e]					
Tramadol Hydrochloride	;					
Trandolapril						
Tranexamic Acid						
Tranylcyprom Sulphate	ine					
Trazodone Hydrochloride	;					
Treosulfan						
Tretinoin						
Triamcinolone	;					
Triamcinolone Acetonide	[^{F180} (1)] 0.1 per cent	[^{F180} (1)] For the treatment of common mouth ulcers		[^{F180} (1)] Container or package containing not more than 5g of		

		from the restring only medicine	ctions on the sale and suppl	y of
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administrati use or pharmaceut form	Column 4 Treatment limitations on,	Column 5 Maximum quantity
		John		medicinal product
		[^{F181} (2) In the form of a non- pressurised nasal spray, for the treatment of symptoms of seasonal allergic rhinitis in persons aged 18 years and over]	[^{F181} (2) 110mcg per nostril (MD) 110mcg per nostril (MDD) For a maximum period of 3 months]	[^{F181} Container or package containing not more than 3.575mg of Triamcinolone Acetonide]
Triamcinolone Diacetate	e			
Triamcinolone Hexacetonide	2			
Triamterene				
Tribavirin				
Triclofos Sodium				
Trientine Dihydrochlori	de			
Trifluoperazin	e			
Trifluoperazin Hydrochloride				
Trifluperidol				
Trifluperidol Hydrochloride)			
Trilostane				
Trimeprazine				
Trimeprazine Tartrate				

	Exemptions from the restrictions on the sale and supply of prescription only medicines					
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administratio use or pharmaceuti form	Column 4 Treatment limitations on,	Column 5 Maximum quantity		
Trimetaphan Camsylate						
Trimetazidine	;					
Trimetazidine Hydrochlorid						
Trimethoprim	l					
Trimipramine Maleate	;					
Trimipramine Mesylate	;					
Tropicamide						
Tropisetron Hydrochlorid	e					
Troxidone						
L- Tryptophan		(1) Oral				
пурюрнан		Dietary supplementat	ion			
		(2) External				
Tubocurarine Chloride						
Tulobuterol						
Tulobuterol Hydrochlorid	e					
Tyrothricin		Throat lozenges or throat pastilles				
Uramustine						
Urea Stibamine						
Urethane						
Uridine 5'- triphosphate						
Urofollitroph	in					

	<i>Exemptions from the restrictions on the sale and supply of prescription only medicines</i>					
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administrati use or pharmaceut form	Column 4 Treatment limitations ion,	Column 5 Maximum quantity		
Urokinase						
Ursodeoxycl Acid	noic					
Vaccine: Bacillus Salmonella Typhi						
Vaccine: Poliomyeliti (Oral)	S					
[^{F107} Valacicle Hydrochlorie						
Valproic Acid						
[^{F110} Valsartar	1]					
Vancomycin Hydrochlori						
Vasopressin						
Vasopressin Tannate						
Vecuronium Bromide						
[^{F107} Venlafax Hydrochlori	tine de]					
Verapamil Hydrochlori	de					
Veratrine						
Veratrum, Green						
Veratrum, White						
Vidarabine						
Vigabatrin						
Viloxazine Hydrochlori	de					
			120			

		from the restruction only medicine	ictions on the sale and suppl	ly of
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administrati use or pharmaceut form	Column 4 Treatment limitations ion,	Column 5 Maximum quantity
Vinblastine Sulphate				
Vincristine Sulphate				
Vindesine Sulphate				
Viomycin Pantothenate				
Viomycin Sulphate				
Vitamin A		(1) Internal	(1) 7,500iu (2,250mcg Retinol equivalent) (MDD)	
		(2) External		
Vitamin A Acetate		(1) Internal	(1) Equivalent to 7,500iuVitamin A (2,250mcgRetinol equivalent)(MDD)	
		(2) External		
Vitamin A Palmitate		(1) Internal	(1) Equivalent to 7,500iuVitamin A (2,250mcgRetinol equivalent)(MDD)	
		(2) External		
Warfarin				
Warfarin Sodium				
Xamoterol Fumarate				
Xipamide				
Yohimbine Hydrochlorid	e			
[^{F107} Zalcitabin	ne]			
Zidovudine				

Exemptions from the restrictions on the sale and supply of prescription only medicines					
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administratiuse or pharmaceut form	Column 4 Treatment limitations ion,	Column 5 Maximum quantity	
Zimeldine Hydrochlorid	le				
Zolpidem Tartrate					
Zomepirac Sodium					
Zopiclone					
Zuclopenthix Acetate	xol				
Zuclopenthix Decanoate	col				
Zuclopenthix Hydrochlorid					

F106	Words in Sch. 1 inserted (9.8.2000) by The Prescription Only Medicines (Human Use) Amendmer
1100	Order 2000 (S.I. 2000/1917), arts. 1(1), 3(c)
F107	Words in Sch. 1 inserted (19.1.2000) by The Prescription Only Medicines (Human Use) Amendmer
	(No. 2) Order 1999 (S.I. 1999/3463), arts. 1(1), 2(c)
F108	Words in Sch. 1 inserted (24.8.2001) by The Prescription Only Medicines (Human Use) Amendment
	Order 2001 (S.I. 2001/2777), arts. 1(1), 3(a)
F109	Words in Sch. 1 inserted (16.9.1998) by The Prescription Only Medicines (Human Use) Amendment
	(No. 3) Order 1998 (S.I. 1998/2081), art. 1(1), Sch.
F110	Sch. 1 entries inserted (24.8.2001) by The Prescription Only Medicines (Human Use) Amendment Ord
	2001 (S.I. 2001/2777), arts. 1(1), 3(g)
F111	Words in Sch. 1 inserted (16.9.1998) by The Prescription Only Medicines (Human Use) Amendme
	Order 1997 (S.I. 1997/2044), art. 1(1), Sch. 1
F112	Words in Sch. 1 inserted (22.4.1999) by The Prescription Only Medicines (Human Use) Amendme
	Order 1999 (S.I. 1999/1044), arts. 1(1), 2(a)
F113	Words in Sch. 1 substituted (16.9.1998) by The Prescription Only Medicines (Human Use) Amendme
	(No. 3) Order 1998 (S.I. 1998/2081), arts. 1(1), 3(a)
F114	Sch. 1: entries renumbered (22.4.1999) by The Prescription Only Medicines (Human Use) Amendme
	Order 1999 (S.I. 1999/1044), arts. 1(1), 2(a)
F115	Words in Sch. 1 omitted (16.9.1998) by virtue of The Prescription Only Medicines (Human Us
	Amendment (No. 3) Order 1998 (S.I. 1998/2081), arts. 1(1), 3(b)
F116	Words in Sch. 1 inserted (16.11.2000) by The Prescription Only Medicines (Human Use) Amendme
	(No. 2) Order 2000 (S.I. 2000/2899), arts. 1(1), 4(a)
F117	Words in Sch. 1 substituted (16.11.2000) by The Prescription Only Medicines (Human Use) Amendme
	(No. 2) Order 2000 (S.I. 2000/2899), arts. 1(1), 4(a)

- F118 Word in Sch. 1 substituted (22.4.1999) by The Prescription Only Medicines (Human Use) Amendment Order 1999 (S.I. 1999/1044), arts. 1(1), 2(b)
- **F119** Words in Sch. 1 inserted (16.9.1998) by The Prescription Only Medicines (Human Use) Amendment (No. 3) Order 1998 (S.I. 1998/2081), arts. 1(1), **3(c)(ii)**
- F120 Words in Sch. 1 substituted (16.9.1998) by virtue of The Prescription Only Medicines (Human Use) Amendment (No. 3) Order 1998 (S.I. 1998/2081), arts. 1(1), 3(c)(i)
- F121 Words in Sch. 1 inserted (16.11.2000) by The Prescription Only Medicines (Human Use) Amendment (No. 2) Order 2000 (S.I. 2000/2899), arts. 1(1), 4(h)
- F122 Words in Sch. 1 inserted (22.4.1999) by The Prescription Only Medicines (Human Use) Amendment Order 1999 (S.I. 1999/1044), arts. 1(1), 2(e)
- F123 Word in Sch. 1 substituted (16.9.1997) by The Prescription Only Medicines (Human Use) Amendment Order 1997 (S.I. 1997/2044), arts. 1(1), 2(a)
- F124 Words in Sch. 1 revoked (31.12.2001) by The Prescription Only Medicines (Human Use) Amendment (No. 2) Order 2001 (S.I. 2001/3942), arts. 1(1), 2(a)
- F125 Sch. 1 entries inserted (24.8.2001) by The Prescription Only Medicines (Human Use) Amendment Order 2001 (S.I. 2001/2777), arts. 1(1), 3(f)
- F126 Sch. 1 entries inserted (31.12.2001) by The Prescription Only Medicines (Human Use) Amendment (No. 2) Order 2001 (S.I. 2001/3942), arts. 1(1), 2(e)
- F127 Sch. 1 entries inserted (16.11.2000) by The Prescription Only Medicines (Human Use) Amendment (No. 2) Order 2000 (S.I. 2000/2899), arts. 1(1), 4(b)
- F128 Words in Sch. 1 inserted (1.6.1998) by The Prescription Only Medicines (Human Use) Amendment (No. 2) Order 1998 (S.I. 1998/1178), arts. 1(1), 2(a)
- **F129** Words in Sch. 1 substituted (16.9.1998) by The Prescription Only Medicines (Human Use) Amendment (No. 3) Order 1998 (S.I. 1998/2081), arts. 1(1), **3(d)**
- **F130** Words in Sch. 1 substituted (16.11.2000) by The Prescription Only Medicines (Human Use) Amendment (No. 2) Order 2000 (S.I. 2000/2899), arts. 1(1), 4(c)
- F131 Words in Sch. 1 inserted (13.2.1998) by The Prescription Only Medicines (Human Use) Amendment Order 1998 (S.I. 1998/108), arts. 1, 3(e)(i)
- F132 Word in Sch. 1 substituted (19.1.2000) by The Prescription Only Medicines (Human Use) Amendment (No. 2) Order 1999 (S.I. 1999/3463), arts. 1(1), 2(a)
- **F133** Words in Sch. 1 substituted (16.9.1998) by The Prescription Only Medicines (Human Use) Amendment (No. 3) Order 1998 (S.I. 1998/2081), arts. 1(1), **3(e)**
- **F134** Words in Sch. 1 inserted (24.8.2001) by The Prescription Only Medicines (Human Use) Amendment Order 2001 (S.I. 2001/2777), arts. 1(1), **3(b)**
- F135 Words in Sch. 1 substituted (16.9.1998) by The Prescription Only Medicines (Human Use) Amendment (No. 3) Order 1998 (S.I. 1998/2081), arts. 1(1), 3(f)(i)
- **F136** Words in Sch. 1 inserted (16.9.1998) by The Prescription Only Medicines (Human Use) Amendment (No. 3) Order 1998 (S.I. 1998/2081), arts. 1(1), **3(f)(ii)**
- F137 Words in Sch. 1 omitted (16.9.1998) by virtue of The Prescription Only Medicines (Human Use) Amendment (No. 3) Order 1998 (S.I. 1998/2081), arts. 1(1), 3(f)(iii)
- **F138** Words in Sch. 1 inserted (31.12.2001) by The Prescription Only Medicines (Human Use) Amendment (No. 2) Order 2001 (S.I. 2001/3942), arts. 1(1), **2(b)(i)**
- **F139** Words in Sch. 1 inserted (31.12.2001) by The Prescription Only Medicines (Human Use) Amendment (No. 2) Order 2001 (S.I. 2001/3942), arts. 1(1), **2(b)(ii)**
- F140 Words in Sch. 1 inserted (31.12.2001) by The Prescription Only Medicines (Human Use) Amendment (No. 2) Order 2001 (S.I. 2001/3942), arts. 1(1), 2(b)(iii)
- F141 Words in Sch. 1 inserted (31.12.2001) by The Prescription Only Medicines (Human Use) Amendment (No. 2) Order 2001 (S.I. 2001/3942), arts. 1(1), 2(b)(iv)
- F142 Words in Sch. 1 inserted (22.4.1999) by The Prescription Only Medicines (Human Use) Amendment Order 1999 (S.I. 1999/1044), arts. 1(1), 2(c)
- **F143** Sch. 1: entries renumbered (22.4.1999) by The Prescription Only Medicines (Human Use) Amendment Order 1999 (S.I. 1999/1044), arts. 1(1), **2(c)**

- F144 Words in Sch. 1 inserted (13.2.1998) by The Prescription Only Medicines (Human Use) Amendment Order 1998 (S.I. 1998/108), arts. 1, 3(a)
- F145 Words in Sch. 1 inserted (24.8.2001) by The Prescription Only Medicines (Human Use) Amendment Order 2001 (S.I. 2001/2777), arts. 1(1), 3(c)
- F146 Words in Sch. 1 inserted (9.8.2000) by The Prescription Only Medicines (Human Use) Amendment Order 2000 (S.I. 2000/1917), arts. 1(1), **3(a)**
- F147 Words in Sch. 1 substituted (16.11.2000) by The Prescription Only Medicines (Human Use) Amendment (No. 2) Order 2000 (S.I. 2000/2899), arts. 1(1), 4(d)
- F148 Word in Sch. 1 inserted (13.8.1998) by The Prescription Only Medicines (Human Use) Amendment Order 1998 (S.I. 1998/108), arts. 1, 3(e)(ii)
- **F149** Word in Sch. 1 inserted (16.9.1998) by The Prescription Only Medicines (Human Use) Amendment (No. 3) Order 1998 (S.I. 1998/2081), arts. 1(1), **3(g)(ii)**
- **F150** Words in Sch. 1 inserted (16.9.1998) by The Prescription Only Medicines (Human Use) Amendment (No. 3) Order 1998 (S.I. 1998/2081), arts. 1(1), **3(g)(i)**
- F151 Words in Sch. 1 inserted (16.9.1998) by The Prescription Only Medicines (Human Use) Amendment (No. 3) Order 1998 (S.I. 1998/2081), arts. 1(1), 3(g)(iii)
- F152 Words in Sch. 1 inserted (19.1.2000) by The Prescription Only Medicines (Human Use) Amendment (No. 2) Order 1999 (S.I. 1999/3463), arts. 1(1), 2(b)
- F153 Sch. 1 entries inserted (1.1.2001) by The Prescription Only Medicines (Human Use) Amendment (No. 3) Order 2000 (S.I. 2000/3231), arts. 1(1), 2
- F154 Words in Sch. 1 inserted (16.11.2000) by The Prescription Only Medicines (Human Use) Amendment (No. 2) Order 2000 (S.I. 2000/2899), arts. 1(1), 4(e)(i)
- F155 Words in Sch. 1 inserted (16.11.2000) by The Prescription Only Medicines (Human Use) Amendment (No. 2) Order 2000 (S.I. 2000/2899), arts. 1(1), 4(e)(ii)
- F156 Words in Sch. 1 revoked (31.12.2001) by The Prescription Only Medicines (Human Use) Amendment (No. 2) Order 2001 (S.I. 2001/3942), arts. 1(1), 2(c)
- F157 Words in Sch. 1 substituted (13.2.1998) by The Prescription Only Medicines (Human Use) Amendment Order 1998 (S.I. 1998/108), arts. 1, **3(b)**
- F158 Words in Sch. 1 substituted (1.6.1998) by The Prescription Only Medicines (Human Use) Amendment (No. 2) Order 1998 (S.I. 1998/1178), arts. 1(1), 2(b)
- **F159** Words in Sch. 1 inserted (16.9.1998) by The Prescription Only Medicines (Human Use) Amendment (No. 3) Order 1998 (S.I. 1998/2081), arts. 1(1), **3(h)**
- **F160** Words in Sch. 1 inserted (1.6.1998) by The Prescription Only Medicines (Human Use) Amendment (No. 2) Order 1998 (S.I. 1998/1178), arts. 1(1), **2(c)(i)**
- **F161** Words in Sch. 1 inserted (1.6.1998) by The Prescription Only Medicines (Human Use) Amendment (No. 2) Order 1998 (S.I. 1998/1178), arts. 1(1), **2(c)(ii)**
- F162 Words in Sch. 1 substituted (1.6.1998) by The Prescription Only Medicines (Human Use) Amendment (No. 2) Order 1998 (S.I. 1998/1178), arts. 1(1), 2(c)(iii)
- F163 Words in Sch. 1 inserted (22.4.1999) by The Prescription Only Medicines (Human Use) Amendment Order 1999 (S.I. 1999/1044), arts. 1(1), 2(d)
- **F164** Words in Sch. 1 substituted (16.11.2000) by The Prescription Only Medicines (Human Use) Amendment (No. 2) Order 2000 (S.I. 2000/2899), arts. 1(1), **4(f)(i)**
- **F165** Words in Sch. 1 inserted (16.11.2000) by The Prescription Only Medicines (Human Use) Amendment (No. 2) Order 2000 (S.I. 2000/2899), arts. 1(1), 4(f)(ii)
- **F166** Words in Sch. 1 inserted (16.11.2000) by The Prescription Only Medicines (Human Use) Amendment (No. 2) Order 2000 (S.I. 2000/2899), arts. 1(1), 4(f)(iii)
- **F167** Words in Sch. 1 inserted (16.9.1998) by The Prescription Only Medicines (Human Use) Amendment (No. 2) Order 1998 (S.I. 1998/1178), arts. 1(1), **2(d)(ii)**
- **F168** Words in Sch. 1 inserted (1.6.1998) by The Prescription Only Medicines (Human Use) Amendment (No. 2) Order 1998 (S.I. 1998/1178), arts. 1(1), **2(d)(i)**
- F169 Words in Sch. 1 added (13.2.1998) by The Prescription Only Medicines (Human Use) Amendment Order 1998 (S.I. 1998/108), arts. 1, 3(c)

- F170 Words in Sch. 1 inserted (13.2.1998) by The Prescription Only Medicines (Human Use) Amendment Order 1998 (S.I. 1998/108), arts. 1, 3(d)
- **F171** Sch. 1: entries renumbered (24.8.2001) by The Prescription Only Medicines (Human Use) Amendment Order 2001 (S.I. 2001/2777), arts. 1(1), **3(d)**
- F172 Words in Sch. 1 inserted (31.12.2001) by The Prescription Only Medicines (Human Use) Amendment (No. 2) Order 2001 (S.I. 2001/3942), arts. 1(1), 2(d)(i)
- **F173** Words in Sch. 1 inserted (31.12.2001) by The Prescription Only Medicines (Human Use) Amendment (No. 2) Order 2001 (S.I. 2001/3942), arts. 1(1), **2(d)(ii)**
- F174 Words in Sch. 1 inserted (31.12.2001) by The Prescription Only Medicines (Human Use) Amendment (No. 2) Order 2001 (S.I. 2001/3942), arts. 1(1), 2(d)(iii)
- F175 Words in Sch. 1 inserted (9.8.2000) by The Prescription Only Medicines (Human Use) Amendment Order 2000 (S.I. 2000/1917), arts. 1(1), **3(b)**
- **F176** Sch. 1: entries renumbered (24.8.2001) by The Prescription Only Medicines (Human Use) Amendment Order 2001 (S.I. 2001/2777), arts. 1(1), **3(e)**
- F177 Words in Sch. 1 inserted (24.8.2001) by The Prescription Only Medicines (Human Use) Amendment Order 2001 (S.I. 2001/2777), arts. 1(1), **3(e)**
- **F178** Sch. 1 entries inserted (24.8.2001) by The Prescription Only Medicines (Human Use) Amendment Order 2001 (S.I. 2001/2777), arts. 1(1), **3(e)**
- F179 Words in Sch. 1 omitted (16.9.1997) by virtue of The Prescription Only Medicines (Human Use) Amendment Order 1997 (S.I. 1997/2044), arts. 1(1), 2(b)
- **F180** Sch. 1 entries re-numbered (16.11.2000) by The Prescription Only Medicines (Human Use) Amendment (No. 2) Order 2000 (S.I. 2000/2899), arts. 1(1), 4(g)
- **F181** Sch. 1 entries inserted (16.11.2000) by The Prescription Only Medicines (Human Use) Amendment (No. 2) Order 2000 (S.I. 2000/2899), arts. 1(1), 4(g)

	Circumstances excluding medicinal products from the class of prescription only medicines				
Column 1	Column 2	Column 3	Column 4		
Substance	Maximum strength	Pharmaceutical Form	Maximum Dose		
Codeine and its salts	Equivalent of 1.5 per cent of codeine monohydrate		Equivalent of 20 mg of codeine monohydrate		
Dihydrocodeine and its salts	Equivalent of 1.5 per cent of dihydrocodeine		Equivalent of 10 mg of dihydrocodeine		
Ethylmorphine andits salts	Equivalent of 0.2 per cent of ethylmorphine		Equivalent of 7.5 mg of ethylmorphine		
Morphine and its salts	(1) Equivalent of 0.02 per cent anhydrous morphine	(1) Liquid	(1) Equivalent of3 mg of anhydrousmorphine		
	(2) Equivalent of 0.04 per cent of anhydrous morphine; equivalent of 300	(2) Solid	(2) Equivalent of 3 mg of anhydrous morphine		

SCHEDULE 2

Articles 6(1) and 10

	<i>Circumstances excluding medicinal products from the class of prescription only medicines</i>				
Column 1	Column 2	Column 3	Column 4		
Substance	Maximum strength	Pharmaceutical Form	Maximum Dose		
	mcg of anhydrous morphine				
Medicinal Opium	(1) Equivalent of 0.02 per cent of anhydrous morphine	(1) Liquid	(1) Equivalent of 3 mg of anhydrous morphine		
	(2) Equivalent of 0.04 per cent of anhydrous morphine	(2) Solid	(2) Equivalent of 3 mg of anhydrous morphine		
Pholcodine and its salts	Equivalent of 1.5 per cent of pholcodine monohydrate		Equivalent of 20 mg of pholcodine monohydrate		

SCHEDULE 3

Article 2(b)

DESCRIPTIONS AND CLASSES OF PRESCRIPTION ONLY MEDICINES IN RELATION TO WHICH APPROPRIATE NURSE PRACTITIONERS ARE APPROPRIATE PRACTITIONERS

[^{F182}Co-danthramer Capsules NPF]

[^{F182}Co-danthramer Capsules, Strong NPF]

Co-danthramer-Oral Suspension NPF

Co-danthramer-Oral Suspension Strong NPF

Co-danthrusate Capsules

[^{F182}Co-danthrusate Oral Suspension NPF]

Mebendazole Tablets NPF

Mebendazole Oral Suspension NPF

Miconazole Oral Gel NPF

Nystatin Oral Suspension

Nystatin Pastilles NPF

Streptokinase and Streptodornase Topical Powder NPF

[^{F183}Water for Injections]

Textual Amendments

F182 Words in Sch. 3 inserted (13.2.1998) by The Prescription Only Medicines (Human Use) Amendment Order 1998 (S.I. 1998/108), arts. 1, 4

F183 Words in Sch. 3 inserted (4.4.2003) by The Prescription Only Medicines (Human Use) Amendment Order 2003 (S.I. 2003/696), arts. 1(1), 14

[^{F184}SCHEDULE 3A

Article 3A

SUBSTANCES WHICH MAY BE PRESCRIBED, ADMINISTERED OR DIRECTED FOR ADMINISTRATION BY EXTENDED FORMULARY NURSE PRESCRIBERS AND CONDITIONS FOR SUCH PRESCRIPTION OR ADMINISTRATION

Textual Amendments

F184 Sch. 3A inserted (1.4.2002) by The Prescription Only Medicines (Human Use) Amendment Order 2002 (S.I. 2002/549), arts. 1(1), 9

Column 1 Substance	Column 2 Requirements as to use, route of		
rF185	administration, or pharmaceutical form		
[^{F185} Acetylcysteine	Parenteral]		
Aciclovir	External use		
Acrivastine	Oral		
Adapalene	External use		
[^{F185} Adrenaline	Parenteral]		
Alclometasone dipropionate	External use		
Alimemazine tartrate (trimeprazine tartrate)	Oral		
[^{F185} Alteplase	Parenteral]		
[^{F185} Amiodarone	Parenteral]		
[^{F186} Amitriptyline hydrochloride	Oral [^{F187} administration in palliative care]]		
Amorolfine hydrochloride	External use		
Amoxycillin trihydrate	Oral		
Aspirin	Oral		
Azelaic acid	External use		
Azelastine hydrochloride	Ophthalmic use or nasal		
[^{F186} Azithromycin dihydrate	Oral]		
Baclofen	Oral administration in palliative care		
Beclometasone dipropionate	External use or nasal [^{F188} inhalation]		
[^{F185} Bemiparin sodium	Parenteral]		
[^{F185} Benzatropine mesilate	Parenteral]		
[^{F189} Benzylpenicillin sodium	Parenteral]		
Betamethasone dipropionate	External use		
Betamethasone sodium phosphate	Aural or nasal		
Betamethasone valerate	External use		

Column 1 Substance	Column 2 Requirements as to use, route of administration, or pharmaceutical form	
Budesonide	Nasal [^{F190} inhalation]	
[^{F185} Calcipotriol	External]	
[^{F185} Calcitriol	External]	
[^{F186} Carbamazepine	Oral or rectal [^{F191} administration in palliative care]]	
Carbaryl	External use	
Carbenoxolone sodium	Mouthwash	
[^{F185} Cefotaxime sodium	Parenteral]	
[^{F185} Ceftriaxone Sodium	Parenteral]	
[^{F185} Certoparin sodium	Parenteral]	
Cetirizine hydrochloride	Oral	
[^{F185} Chlorphenamine maleate	Parenteral]	
Chloramphenicol	Ophthalmic use	
Cimetidine	Oral	
[^{F185} Cimetidine	Parenteral]	
Cinchocaine hydrochloride	External use	
[^{F186} Clavulanic acid [^{F192} (as potassium clavulanate)]	Oral]	
Clindamycin phosphate	External use	
Clobetasone butyrate	External use	
Clotrimazole	External use	
[^{F193} Codeine Phosphate	Oral]	
[^{F186} Conjugated oestrogens (equine)	External use]	
[^{F193} Co-Phenotrope	Oral]	
F194	F194	
[^{F185} Cyclizine hydrochloride	Oral]	
[^{F185} Cyclizine lactate	Parenteral]	
[^{F185} Dalteparin sodicum	Parenteral]	
Dantrolene sodium	Oral administration in palliative care	
Dantron	Oral	
Desogestrel	Oral	

146

Column 1 Substance	Column 2 Requirements as to use, route of administration, or pharmaceutical form		
Desoximetasone (Desoxymethasone)	External use		
Dexamethasone	Aural		
Dexamethasone isonicotinate	Nasal		
[^{F185} Dexamethasone sodium phosphate	Oral]		
[^{F185} Dextran 70	Parenteral]		
[^{F193} Diazepam	Oral, parenteral or rectal administration F195		
]		
Diclofenac diethylammonium	External use		
[^{F186} Diclofenac potassium	Oral]		
[^{F186} Diclofenac sodium	Oral F196		
	rectal [^{F197} or ophthalmic]]		
[^{F193} Dihydrocodeine Tartrate	Oral]		
[^{F185} Dolesetron mesilate	Oral and parenteral]		
Domperidone	Oral or rectal administration F198		
Domperidone maleate	Oral administration F199		
7200			
Doxycycline [^{F200} hyclate]	Oral		
[^{F201} Doxycycline monohydrate	Oral]		
Econazole nitrate	External use		
[^{F201} Emedastine	Ophthalmic use]		
[^{F185} Enoxaparin	Parenteral]		
Erythromycin	External use [^{F202} or oral]		
[^{F186} Erythromycin ethyl succinate	Oral]		
[^{F186} Erythromycin stearate	Oral]		
[^{F186} Estradiol	External use]		
[^{F186} Estriol	External use]		
Ethinylestradiol	Oral		
[^{F186} Etonogestrel	Implant]		
Etynodiol diacetate (ethynodiol diacetate)	Oral		

147

Column 1 Substance	Column 2 Requirements as to use, route of
Trucciding	administration, or pharmaceutical form
Famotidine Felbinac	Oral
Fenticonazole nitrate	External use
	External use Oral
Fexofenadine hydrochloride	Oral
[^{F201} Flucloxacillin magnesium Flucloxacillin sodium	-
	Oral [^{F203} or parenteral]
Fluconazole	Oral
Fludroxycortide (Flurandrenolone)	External use
[^{F186} Flumazenil	Parenteral]
Flumetasone pivalate	Aural
Flunisolide	Nasal
Fluocinolone acetonide	External use
Fluocinonide	External use
Fluocortolone hexanoate	External use
Fluocortolone pivalate	External use
Flurbiprofen	Lozenges
Fluticasone propionate	External use or nasal
[^{F185} Furosemide	Oral and parenteral]
Fusidic acid	[^{F204} External Use]
[^{F186} Gabapentin	Oral [^{F205} administration in palliative care]]
[^{F185} Gelatin 3.5 – 4%	Parenteral]
Gentamicin sulphate	Aural
Gestodene	Oral
[^{F186} Glucagon hydrochloride	Parenteral]
[^{F186} Glucose	Parenteral]
[^{F185} Glucose 5%	Parenteral]
$[\![^{F185}Glucose 5\%$ with Potassium (K $^+$ 40 mmol/ L) ready made infusion bag	Parenteral]
[^{F185} Granisetron hydrochloride	Parenteral]
[^{F185} Heparin sodium	Parenteral for the purpose of cannulae flushing]
[^{F185} Hexastarch	Parenteral]
[^{F185} Human soluble insulin	Parenteral]

Column 1 Substance	Column 2 Requirements as to use, route of administration, or pharmaceutical form	
Hydrocortisone	External use	
Hydrocortisone acetate	External use [^{F206} or aural]	
Hydrocortisone butyrate	External use	
Hydrocortisone sodium succinate	Lozenges [^{F207} or parenteral]	
[^{F185} Hydroxyethl starch	Parenteral]	
[^{F208} Hyoscine	Transdermal administration in palliative care	
Hyoscine butylbromide	Parenteral F209	
	administration in palliative care	
Hyoscine hydrobromide	[^{F210} Oral or parenteral administration in palliative care]	
Ibuprofen	External use or oral	
Ibuprofen lysine	Oral	
[^{F186} Imipramine hydrochloride	Oral [^{F211} administration in palliative care]]	
Ipratropium bromide	Nasal [^{F212} inhalation]	
Isotretinoin	External use	
Ketoconazole	External use	
Ketoprofen	External use	
Levocabastine hydrochloride	Ophthalmic use or nasal	
[^{F185} Levomepromazine	Oral and parenteral]	
F213	F213	
F213	F213	
Levonorgestrel	Oral	
[^{F186} Lignocaine hydrochloride	External use or parenteral	
Lithium succinate	External use	
Lodoxamide trometamol	Ophthalmic use	
Loperamide hydrochloride	Oral	
Loratadine	Oral	
(^{F193} Lorazepam	Oral or parenteral administration F214	
]	

149

Column 1 Substance	Column 2 Requirements as to use, route of administration, or pharmaceutical form		
Mebendazole	Oral		
Medroxyprogesterone acetate	Parenteral		
Mestranol	Oral		
Metoclopramide hydrochloride	Oral or parenteral administration F215		
Metronidazole	[^{F216} External use, oral or rectal]		
Metronidazole benzoate	Oral		
Miconazole	Dental lacquer		
Miconazole nitrate	External use		
[^{F193} Midazolam	Parenteral administration F217		
]		
Minocycline	Oral		
[^{F201} Mizolastine	Oral]		
[^{F201} Minocycline hydrochloride	Oral]		
Mometasone furoate	External use or nasal		
[^{F185} Naloxone	Parenteral]		
Nedocromil sodium	Ophthalmic use		
Nefopam hydrochloride	Oral		
Neomycin sulphate	Aural		
Neomycin undecenoate	Aural		
Nitrofurantoin	Oral		
Nizatidine	Oral		
Norethisterone 9	Oral		
Norethisterone acetate	Oral		
Norethisterone enanthate	Parenteral		
Norgestimate	Oral		
Norgestrel	Oral		
[^{F186} Nortriptyline hydrochloride	Oral [^{F218} administration in palliative care]]		
Nystatin	External use		
[^{F185} Omeprazole	Oral]		
[^{F185} Omeprazole sodium	Parenteral]		

Column 1 Substance	Column 2 Requirements as to use, route of administration, or pharmaceutical form
[^{F185} Ondansetron Hydrochloride	Oral and parenteral]
[^{F185} Oxbuprocaine hydrochloride	Ophalmic]
Oxytetracycline dihydrate	Oral
Paracetamol	Oral
Penciclovir	External use
[^{F185} Pentastarch	Parenteral]
Piroxicam	External use
[^{F186} Prednisolone	Oral]
Prednisolone hexanoate	External use
Prednisolone sodium phosphate	Aural [^{F219} or oral]
[^{F185} Prilocaine	External and parenteral]
[^{F185} Prochlorperazine maleate	Oral, rectal and buccal]
[^{F185} Prochlorperazine mesilate	Oral and rectal]
[^{F185} Proxymetacaine hydrochloride	Ophthalmic]
Ranitidine hydrochloride	Oral [^{F220} or parenteral]
[^{F185} Reteplase	Parenteral]
[^{F186} Salbutamol sulphate	Inhalation]
Silver sulphadiazine	External use
^{F185} Sodium chloride 0.9%	Parental, for reconstitution of injections and for the purpose of cannulae flushing]
[^{F185} Sodium chloride 0.9% & Glucose 5% ready made infusion bag	Parenteral]
[^{F185} Sodium chloride 0.45% & Glucose 5% ready made infusion bag]	
[^{F185} Sodium chloride 0.9% with Potassium (K ⁺ 40 mmol/L) ready made infusion bag	Parenteral]
[^{F185} Sodium chloride 0.45% and Glucose 5% with Potassium 20mmol per 500 ml ready made infusion bag	Parenteral]
Sodium cromoglycate	Ophthalmic use
[^{F186} Sodium fusidate	External use]
Streptodornase	External use
Streptokinase	External use

Column 1 Substance	Column 2 Requirements as to use, route of administration, or pharmaceutical form
[^{F185} Streptokinase	Parenteral]
Sulconazole nitrate	External use
[^{F185} Tacalcitol	External]
[^{F185} Tenecteplase	Parenteral]
[^{F185} Tetanus immunoglobulin	Parenteral]
Terbinafine hydrochloride	External use
[^{F186} Terbutaline sulphate	Inhalation]
[^{F185} Tetracaine	External]
Tetracycline hydrochloride	External use or oral
[^{F185} Tinzaparin sodium	Parenteral]
Tretinoin	External use
Triamcinolone acetonide	External use, aural, nasal or oral paste
Trimethoprim	Oral
[^{F185} Tropicamide	Ophthalmic]
[^{F185} Tropisetron hydrochloride	Parenteral]
Tuberculin PPD	Parenteral
[^{F185} Unfractionated Heparin	Parenteral]
Vaccine, Adsorbed Diphtheria	Parenteral
Vaccine, Adsorbed Diphtheria And Tetanus	Parenteral
Vaccine, Adsorbed Diphtheria And Tetanus For Adults And Adolescents	Parenteral
Vaccine, Adsorbed Diphtheria For Adults And Adolescents	Parenteral
Vaccine, Adsorbed Diphtheria, Tetanus And Pertussis	Parenteral
Vaccine, Adsorbed Diphtheria, Tetanus And Pertussis (Acellular Component)	Parenteral
Vaccine, BCG	Parenteral
Vaccine, BCG Percutaneous	Parenteral
[^{F185} Vaccine – Combined Tetanus, diphtheria, [^{F221} acellular pertussis], inactivated poliomyelitis and haemophilus influenza type B	Parenteral]
Vaccine, Haemophilus Influenzae Type B (Hib)	Parenteral

Column 1	Column 2
Substance	Requirements as to use, route of administration, or pharmaceutical form
Vaccine, Haemophilus Influenzae Type B (Hib) with Diphtheria, Tetanus And Pertussis	Parenteral
Vaccine, Haemophilus Influenzae Type B, Diphtheria, Tetanus And Acellular Pertussis	Parenteral
Vaccine, Hepatitis A	Parenteral
Vaccine, Hepatitis A With Typhoid	Parenteral
Vaccine, Hepatitis A, Inactivated, With Recombinant (DNA) Hepatitis B	Parenteral
Vaccine, Hepatitis B	Parenteral
[^{F185} Vaccine – Inactivated Poliomyelitis	Parenteral]
Vaccine, Influenza	Parenteral
Vaccine, Live Measles, Mumps And Rubella (MMR)	Parenteral
Vaccine, Meningococcal Group C Conjugate	Parenteral
Vaccine, Meningococcal Polysaccharide A and C	Parenteral
[^{F185} Vaccine – Meningococcal Polysaccharide A, C, W135 and Y	Parenteral]
Vaccine, Pneumococcal	Parenteral
F222	F222
Vaccine, Poliomyelitis, Live (Oral)	Oral
Vaccine, Rubella, Live	Parenteral
Vaccine, Tetanus, Adsorbed	Parenteral
Vaccine, Typhoid, Live Attenuated (Oral)	Oral
Vaccine, Typhoid, Polysaccharide	Parenteral
[^{F201} Water for Injections	Parenteral]]

Textual Amendments

- **F185** Words in Sch. 3A inserted (7.4.2005) by The Medicines for Human Use (Prescribing) Order 2005 (S.I. 2005/765), arts. 1(1), 7(a)
- F186 Sch. 3A entries inserted (31.1.2004) by The Prescription Only Medicines (Human Use) Amendment Order 2004 (S.I. 2004/2), arts. 1(1), 3(g)
- **F187** Words in Sch. 3A inserted (19.11.2004) by The Prescription Only Medicines (Human Use) Amendment (No. 3) Order 2004 (S.I. 2004/2693), arts. 1(1), **5(a)**
- **F188** Words in Sch. 3A added (7.4.2005) by The Medicines for Human Use (Prescribing) Order 2005 (S.I. 2005/765), arts. 1(1), **7(b)**

- **F189** Words in Sch. 3A inserted (30.6.2005) by The Medicines for Human Use (Prescribing) (Miscellaneous Amendments) Order 2005 (S.I. 2005/1507), arts. 1(1), **6(a)**
- **F190** Words in Sch. 3A added (7.4.2005) by The Medicines for Human Use (Prescribing) Order 2005 (S.I. 2005/765), arts. 1(1), 7(c)
- **F191** Words in Sch. 3A inserted (19.11.2004) by The Prescription Only Medicines (Human Use) Amendment (No. 3) Order 2004 (S.I. 2004/2693), arts. 1(1), **5(b)**
- **F192** Words in Sch. 3A added (18.5.2004) by The Prescription Only Medicines (Human Use) Amendment (No. 2) Order 2004 (S.I. 2004/1189), arts. 1(1), **3(a)**
- **F193** Words in Sch. 3A inserted (10.12.2003) by The Prescription Only Medicines (Human Use) Amendment (No. 2) Order 2003 (S.I. 2003/2915), arts. 1(1), **3**
- **F194** Words in Sch. 3A omitted (7.4.2005) by virtue of The Medicines for Human Use (Prescribing) Order 2005 (S.I. 2005/765), arts. 1(1), 7(d)
- F195 Words in Sch. 3A omitted (7.4.2005) by virtue of The Medicines for Human Use (Prescribing) Order 2005 (S.I. 2005/765), arts. 1(1), 7(e)
- **F196** Word in Sch. 3A omitted (7.4.2005) by virtue of The Medicines for Human Use (Prescribing) Order 2005 (S.I. 2005/765), arts. 1(1), 7(f)
- **F197** Word in Sch. 3A added (7.4.2005) by The Medicines for Human Use (Prescribing) Order 2005 (S.I. 2005/765), arts. 1(1), 7(f)
- **F198** Words in Sch. 3A omitted (7.4.2005) by virtue of The Medicines for Human Use (Prescribing) Order 2005 (S.I. 2005/765), arts. 1(1), 7(g)
- **F199** Words in Sch. 3A omitted (7.4.2005) by virtue of The Medicines for Human Use (Prescribing) Order 2005 (S.I. 2005/765), arts. 1(1), 7(h)
- F200 Words in Sch. 3A inserted (4.4.2003) by The Prescription Only Medicines (Human Use) Amendment Order 2003 (S.I. 2003/696), arts. 1(1), 15(a)
- F201 Words in Sch. 3A inserted (4.4.2003) by The Prescription Only Medicines (Human Use) Amendment Order 2003 (S.I. 2003/696), arts. 1(1), 15(c)
- F202 Words in Sch. 3A inserted (31.1.2004) by The Prescription Only Medicines (Human Use) Amendment Order 2004 (S.I. 2004/2), arts. 1(1), 3(a)
- **F203** Words in Sch. 3A added (7.4.2005) by The Medicines for Human Use (Prescribing) Order 2005 (S.I. 2005/765), arts. 1(1), **7(i)**
- **F204** Words in Sch. 3A substituted (31.1.2004) by The Prescription Only Medicines (Human Use) Amendment Order 2004 (S.I. 2004/2), arts. 1(1), **3(b)**
- F205 Words in Sch. 3A inserted (19.11.2004) by The Prescription Only Medicines (Human Use) Amendment (No. 3) Order 2004 (S.I. 2004/2693), arts. 1(1), 5(c)
- **F206** Words in Sch. 3A added (18.5.2004) by The Prescription Only Medicines (Human Use) Amendment (No. 2) Order 2004 (S.I. 2004/1189), arts. 1(1), **3(b)**
- **F207** Words in Sch. 3A added (7.4.2005) by The Medicines for Human Use (Prescribing) Order 2005 (S.I. 2005/765), arts. 1(1), **7(j)**
- **F208** Words in Sch. 3A inserted (18.5.2004) by The Prescription Only Medicines (Human Use) Amendment (No. 2) Order 2004 (S.I. 2004/1189), arts. 1(1), **3(d)**
- **F209** Words in Sch. 3A omitted (18.5.2004) by virtue of The Prescription Only Medicines (Human Use) Amendment (No. 2) Order 2004 (S.I. 2004/1189), arts. 1(1), **3(c)**
- F210 Words in Sch. 3A substituted (31.1.2004) by The Prescription Only Medicines (Human Use) Amendment Order 2004 (S.I. 2004/2), arts. 1(1), 3(d)
- F211 Words in Sch. 3A inserted (19.11.2004) by The Prescription Only Medicines (Human Use) Amendment (No. 3) Order 2004 (S.I. 2004/2693), arts. 1(1), 5(d)
- **F212** Words in Sch. 3A added (7.4.2005) by The Medicines for Human Use (Prescribing) Order 2005 (S.I. 2005/765), arts. 1(1), 7(k)
- F213 Words in Sch. 3A omitted (30.6.2005) by virtue of The Medicines for Human Use (Prescribing) (Miscellaneous Amendments) Order 2005 (S.I. 2005/1507), arts. 1(1), 6(b)
- F214 Words in Sch. 3A omitted (7.4.2005) by virtue of The Medicines for Human Use (Prescribing) Order 2005 (S.I. 2005/765), arts. 1(1), 7(1)

- F215 Words in Sch. 3A omitted (7.4.2005) by virtue of The Medicines for Human Use (Prescribing) Order 2005 (S.I. 2005/765), arts. 1(1), 7(m)
- F216 Words in Sch. 3A substituted (31.1.2004) by The Prescription Only Medicines (Human Use) Amendment Order 2004 (S.I. 2004/2), arts. 1(1), 3(e)
- F217 Words in Sch. 3A omitted (7.4.2005) by virtue of The Medicines for Human Use (Prescribing) Order 2005 (S.I. 2005/765), arts. 1(1), 7(n)
- **F218** Words in Sch. 3A inserted (19.11.2004) by The Prescription Only Medicines (Human Use) Amendment (No. 3) Order 2004 (S.I. 2004/2693), arts. 1(1), **5(e)**
- F219 Words in Sch. 3A substituted (31.1.2004) by The Prescription Only Medicines (Human Use) Amendment Order 2004 (S.I. 2004/2), arts. 1(1), **3(f)**
- F220 Words in Sch. 3A inserted (7.4.2005) by The Medicines for Human Use (Prescribing) Order 2005 (S.I. 2005/765), arts. 1(1), 7(o)
- F221 Words in Sch. 3A substituted (30.6.2005) by The Medicines for Human Use (Prescribing) (Miscellaneous Amendments) Order 2005 (S.I. 2005/1507), arts. 1(1), 6(c)
- F222 Words in Sch. 3A omitted (4.4.2003) by virtue of The Prescription Only Medicines (Human Use) Amendment Order 2003 (S.I. 2003/696), arts. 1(1), 15(b)

[^{F223}SCHEDULE 3B

Regulation 3B(3)(a)(iii)

PARTICULARS FOR CLINICAL MANAGEMENT PLANS

Textual Amendments

F223 Sch. 3B inserted (4.4.2003) by The Prescription Only Medicines (Human Use) Amendment Order 2003 (S.I. 2003/696), arts. 1(1), 16

A clinical management plan shall contain the following particulars-

- (a) the name of the patient to whom the plan relates;
- (b) the illnesses or conditions which may be treated by the supplementary prescriber;
- (c) the date on which the plan is to take effect and when it is to be reviewed by the doctor or dentist who is a party to the plan;
- (d) reference to the class or description of medicinal product which may be prescribed or administered under the plan;
- (e) any restrictions or limitations as to the strength or dose of any product which may be prescribed or administered under the plan, and any period of administration or use of any medicinal product which may be prescribed or administered under the plan;
- (f) relevant warnings about the known sensitivities of the patient to, or known difficulties of the patient with, particular medicinal products;
- (g) the arrangements for notification of—
 - (i) suspected or known adverse reactions to any medicinal product which may be prescribed or administered under the plan, and
 - (ii) suspected or known adverse reactions to any other medicinal product taken at the same time as any medicinal product prescribed or administered under the plan; and
- (h) the circumstances in which the supplementary prescriber should refer to, or seek the advice of, the doctor or dentist who is a party to the plan.]

SCHEDULE 4

Article 8(4)(c)

SUBSTANCES NOT TO BE CONTAINED IN A PRESCRIPTION ONLY MEDICINE SOLD OR SUPPLIED UNDER THE EXEMPTION CONFERRED BY ARTICLE 8(3)

Ammonium Bromide Calcium Bromide Calcium Bromidolactobionate Embutramide Fencamfamin Hydrochloride Fluanisone Hexobarbitone Hexobarbitone Sodium Hydrobromic Acid Meclofenoxate Hydrochloride Methohexitone Sodium Pemoline Piracetam Potassium Bromide Prolintane Hydrochloride Sodium Bromide Strychnine Hydrochloride Tacrine Hydrochloride Thiopentone Sodium

SCHEDULE 5

Article 11(1)(a)

EXEMPTION FOR CERTAIN PERSONS FROM SECTION 58(2) OF THE ACT

PART I

EXEMPTION FROM RESTRICTIONS ON SALE OR SUPPLY

Column 1 Persons exempted	Column 2 Prescription only medicines to which the exemption applies		Column 3 Conditions	
1. Persons selling or supplying prescription only medicines to universities, other institutions concerned with higher education or institutions concerned with research.	1. All prescription only medicines	1.	 The sale or supply shall be- (a) subject to the presentation of an order signed by the principal of the institution 	

Column 1 Persons exempted			
			concerned with education or research or the appropriate head of department in charge of a specified course of research stating- (i) the name of the institution for which the prescription only medicine is required, (ii) the purpose for which the prescription only medicine is required, (iii) the purpose for which the prescription only medicine is required, and (iii) the total quantity required, and (b) for the purposes of the education or research with which the institution is concerned.
2.	 Persons selling or supplying prescription only medicines to any the following– (1) a public analyst appointed under section 27 of the Food Safety Act 1990(15) or artia 36 of the Food (Northern Irelan Order 1989(16), (2) an authorized officer within the meaning of section 5(6) of the 	d)	2. The sale or supply shall be subject to the presentation of an order signed by or on behalf of any person listed in column 1 of this paragraph stating the status of the person signing it and the amount of prescription only medicine required, and shall be only in connection with the exercise by those persons of their statutory functions.

^{(15) 1990} c. 16. (16) S.I. 1989/846 (N.I. 6).

Column 1 Persons exempted		Column 2 Prescription only medicines to which the exemption		Column 3 Conditions		
	Food Safety Act 1990,	appl	ies			
(3)	a sampling officer within the meaning of article 38(1) of the Food (Northern Ireland) Order 1989,					
(4)	a person duly authorized by an enforcement authority under sections 111 and 112,					
(5)	a sampling officer within the meaning of Schedule 3 to the Act.					
prescription to any per engaged in scheme for and check of the drug supplied u Health Se the Nation (Scotland) the Health Services (Order 197 subordina	a selling or supplying on only medicines roon employed or n connection with a or testing the quality ting the amount gs and appliances under the National rvice Act 1977(17), nal Health Service) Act 1978(18) and n and Personal Social Northern Ireland) V2(19), or under any te legislation made se Acts or that Order.		l prescription only cines.	3. Th be (a)	subject to the presentation of an order signed by or on behalf of the person so employed or engaged stating the status of the person signing it and the amount of prescription only medicine required, and	
4. Registered midwives.		4. Prescription only medicines containing any of the following substances– Chloral hydrate Ergometrine maleate		4. The sale or supply shall be only in the course of their professional practice and in the case of Ergometrine maleate only when contained in a medicinal product which is not for parenteral administration.		

^{(17) 1977} c. 49. (18) 1978 c. 29. (19) S.I. 1972/1265 (N.I. 14).

Column 1	Column		Column 3
Persons exempted	-	tion only medicines the exemption	Conditions
		Pentazocine hydrochloride [^{F224} Phytomenadione Triclofos sodium.	9]
5. Persons lawfully conducting a retail pharmacy business within the meaning of section 69.	mec not	scription only licines which are for parenteral ninistration and	5. The sale or supply shall be subject to the presentation of an order signed by a [^{F229} registered optometrist].

Column 1 Persons exempted	Column 2 Prescription only medicines to which the exemption applies	Column 3 Conditions	
	^{F227} Tropicamide.		
6. [^{F230} Registered optometrists]	6. Prescription only medicineslisted in column 2 of paragraph5.	 6. The sale or supply shall be only– (a) in the course of their professional practice and (b) in an emergency. 	
[^{F231} 6A Persons lawfully	Homotropine hydrobromide	The sale or supply shall be subject to the presentation	
conducting a retail pharmacy business within the meaning of	Ketotifen	of an order signed by an	
section 69.	Levocabastine	additional supply optometrist.	
	Lodoxamide		
	Nedocromil sodium		
	Olopatadine		
	Pilocarpine hydrochloride		
	Polymyxin B/bacitracin		
	Polymyxin B/trimethoprim		
	Sodium cromoglycate.		
6B Additional supply optometrists.	Prescription only medicines specified in column 2 of paragraph 6A.	 The sale or supply shall be only— (a) in the course of their professional practice, and (b) in an emergency.] 	
7. Persons selling or supplying prescription only medicines to the British Standards Institution.	7. All prescription only medicines.	 7. The sale or supply shall be– (a) subject to the presentation of an order signed on behalf of the British Standards Institution stating the status of the person signing it and the amount of the prescription only medicine required, and 	

Column 1 Persons exempted	Column 2 Prescription only medicines to which the exemption applies	Column 3 Conditions
		(b) only for the purpose of testing containers of medicinal products or determining the standards for such containers.
8. Holders of marketing authorizations, product licences or manufacturer's licences.	8. Prescription only medicines referred to in the authorizations or licences.	 8. The sale or supply shall be only– (a) to a pharmacist, (b) so as to enable that pharmacist to prepare an entry relating to the prescription only medicine in question in a tablet or capsule identification guide or similar publication, and (c) of no greater quantity than is reasonably necessary for that purpose.
9. Pharmacists selling or supplying to persons to whom cyanide salts may be sold by virtue of section 3 (regulation of poisons) or section 4 (exclusion of sales by wholesale and certain other sales) of the Poisons Act 1972(20) or by virtue of article 5 (prohibitions and regulations with respect to sale of poisons) or article 6 (exemption with respect to certain sales) of the Poisons (Northern Ireland) Order 1976(21).	9. Amyl nitrite.	9. The sale or supply shall only be so far as is necessary to enable an antidote to be available to persons at risk of cyanide poisoning.

[^{r252}10. ^{r253}... registered 10. The following 10. chiropodists who hold a prescription only medicines— be only certificate of competence in profess

10. The sale or supply shall be only in the course of their professional practice and (a)

⁽**20**) 1972 c. 66.

⁽²¹⁾ S.I. 1976/1214 (N.I. 23).

Column 1	Column 2	Column 3
Persons exempted	Prescription only medicines to which the exemption applies	Conditions
the use of the medicines specified in Column 2 issued by or with the approval of the Chiropodists Board [^{F234} or the Health Professions Council].	 (a) Co-dydramol 10/500 tablets; (b) Amorolfine hydrochloride cream where the maximum strength of the Amorolfine in the cream does not exceed 0.25 per cent 	10/500 tablets the quantity sold or supplied to a person at any one time shall not exceed the amount sufficient for 3 days' treatment to a maximum of 24 tablets.]
	by weight in weight; (c) Amorolfine hydrochloride lacquer where the maximum strength of the Amorolfine in the lacquer does not exceed 5 per cent by weight in volume; and	
	 (d) Topical hydrocortisone where the maximum strength of the hydrocortisone in the medicinal product does not exceed 1 per cent by weight in weight. 	2

Textual Amendments

- F224 Word in Sch. 5 Pt. 1 para. 4 inserted (16.9.1998) by The Prescription Only Medicines (Human Use) Amendment (No. 3) Order 1998 (S.I. 1998/2081), arts. 1(1), 4(a)
- F225 Words in Sch. 5 Pt. 1 para. 5 omitted (7.4.2005) by virtue of The Medicines for Human Use (Prescribing) Order 2005 (S.I. 2005/765), arts. 1(1), 8(a)
- **F226** Words in Sch. 5 Pt. 1 para. 5 inserted (7.4.2005) by The Medicines for Human Use (Prescribing) Order 2005 (S.I. 2005/765), arts. 1(1), **8(b)**
- F227 Words in Sch. 5 Pt. 1 omitted (7.4.2005) by virtue of The Medicines for Human Use (Prescribing) Order 2005 (S.I. 2005/765), arts. 1(1), 8(c)
- F228 Words in Sch. 5 Pt. 1 para. 5 omitted (30.6.2005) by virtue of The Medicines for Human Use (Prescribing) (Miscellaneous Amendments) Order 2005 (S.I. 2005/1507), arts. 1(1), 7(1)(a)
- F229 Words in Order substituted (30.6.2005 as notified in the London Gazette dated 3.6.2005) by The Opticians Act 1989 (Amendment) Order 2005 (S.I. 2005/848), Sch. 1 para. 27(b)
- F230 Words in Order substituted (30.6.2005 as notified in the London Gazette dated 3.6.2005) by The Opticians Act 1989 (Amendment) Order 2005 (S.I. 2005/848), Sch. 1 para. 27(b)
- **F231** Sch. 5 Pt. 1 paras. 6A, 6B inserted (30.6.2005) by The Medicines for Human Use (Prescribing) (Miscellaneous Amendments) Order 2005 (S.I. 2005/1507), arts. 1(1), 7(1)(b)

- F232 Sch. 5 Pt. 1 para. 10 inserted (13.2.1998) by The Prescription Only Medicines (Human Use) Amendment Order 1998 (S.I. 1998/108), art. 1, Sch.
- **F233** Word in Sch. 5 Pt. 1 para. 10 omitted (9.7.2003) by virtue of The Health Professions Order 2001 (Consequential Amendments) Order 2003 (S.I. 2003/1590), art. 1, Sch. para. 21(3)(a)(i)
- F234 Words in Sch. 5 Pt. 1 para. 10 inserted (9.7.2003) by The Health Professions Order 2001 (Consequential Amendments) Order 2003 (S.I. 2003/1590), art. 1, Sch. para. 21(3)(a)(ii)

Article 11(1)(b)

PART II

EXEMPTIONS FROM THE RESTRICTION ON SUPPLY

Column 1	Column 2	Column 3
Persons exempted	Prescription only medicines to which the exemption applies	Conditions
1. Royal National Lifeboat Institution and certified first aiders of the Institution.	1. All prescription only medicines.	1. The supply shall be only so far as is necessary for the the treatment of sick or injured persons in the exercise of the functions of the Institution.
2. The owner or the master of a ship which does not carry a doctor on board as part of her complement.	2. All prescription only medicines.	2. The supply shall be only so far as is necessary for the treatment of persons on the ship.
3. Persons authorized by licences granted under regulation 5 of the Misuse of Drugs Regulations to supply a controlled drug.	3. Such prescription only medicines, being controlled drugs, as are specified in the licence.	3. The supply shall be subject to such conditions and in such circumstances and to such an extent as may be specified in the licence.
[^{F235} 3A. Persons employed or engaged in the provision of lawful drug treatment services.	3A. Ampoules of sterile water for injection containing not more than 2 ml of sterile water.	3A. The supply shall be only in the course of provision of lawful drug treatment services.]
4. Persons requiring prescription only medicines for the purpose of enabling them, in the course of any business carried on by them, to comply with any requirements made by or in pursuance of any enactment with respect to the medical treatment of their employees.	4. Such prescription only medicines as may be specified in the relevant enactment.	 4. The supply shall be- (a) for the purpose of enabling them to comply with any requirements made by or in pursuance of any such enactment, and (b) subject to such conditions and in such circumstances as may be specified

Column 1 Persons exempted	Column 2 Prescription only medicines to which the exemption applies	Column 3 Conditions
		in the relevant enactment.
5. Persons operating an occupational health scheme.	5. Prescription only medicines sold or supplied to a person operating an occupational health scheme in response to an order in writing signed by a doctor or a registered nurse.	 5. — (1) The supply shall be in the course of an occupational health scheme. (2) The individual supplying the prescription only medicine, if not a doctor, shall be a registered nurse acting in accordance with the written instructions of a doctor as to the circumstances in which prescription only medicines of the description in question are to be used in the course of the occupational health scheme.
6. The operator or commander of an aircraft.	6. Prescription only medicines which are not for parenteral administration and which have been sold or supplied to the operator or commander of the aircraft in response to an order in writing signed by a doctor.	6. The supply shall be only so far as is necessary for the immediate treatment of sick or injured persons on the aircraft and shall be in accordance with the written instructions of a doctor as to the circumstances in which prescription only medicines of the description in question are to be used on the aircraft.
7. Persons employed as qualified first-aid personnel on offshore installations.	7. All prescription only medicines.	7. The supply shall be only so far as is necessary for the treatment of persons on the installation.

Textual Amendments

F235 Sch. 5 Pt. 2 para. 3A inserted (30.6.2005) by The Medicines for Human Use (Prescribing) (Miscellaneous Amendments) Order 2005 (S.I. 2005/1507), arts. 1(1), 7(2)

Article 11(2)

PART III

EXEMPTIONS FROM RESTRICTION ON ADMINISTRATION Column 1

Column 1 Persons exempted	Column 2 Prescription only medicines to which the exemption applies	Column 3 Conditions
1. F236 registered chiropodists who hold a certificate of competence in the use of analgesics issued by or with the approval of the Chiropodists Board [^{F237} or the Health Professions Council].	 Prescription only medicines for parenteral administration that contain, as the sole active ingredient, not more than one of the following substances- [^{F238}Bupivacaine hydrochloride Bupivacaine hydrochloride with adrenaline where the maximum strength of the adrenaline does not exceed 1 mg in 200 ml of bupivacaine hydrochloride Lignocaine hydrochloride Lignocaine hydrochloride with adrenaline where the maximum strength of the adrenaline does not exceed 1 mg in 200 ml of lignocaine hydrochloride with adrenaline does not exceed 1 mg in 200 ml of lignocaine hydrochloride [^{F239}Mepivacaine hydrochloride] Prilocaine hydrochloride] 	1. The administration shall be only in the course of their professional practice.
2. Registered midwives.	2. Prescription only medicines for parenteral administration containing any of the following substances but no other substance specified in column 1 of Schedule 1 to this Order– [^{F240} Diamorphine]	2. The administration shall be only in the course of their professional practice and in the case of Promazine hydrochloride, Lignocaine and Lignocaine hydrochloride shall be only while attending on a woman in childbirth.

Column 1 Persons exempted	Column 2 Prescription only medicines to which the exemption applies	Column 3 Conditions	
	Ergometrine maleate Lignocaine Lignocaine hydrochloride [^{F240} Morphine] Naloxone hydrochloride Oxytocins, natural and synthetic Pentazocine lactate Pethidine hydrochloride Phytomenadione Promazine hydrochloride.		
3. Persons who are authorized as members of a group by a group authority granted under regulations 8(3) or 9(3) of the Misuse of Drugs Regulations to supply a controlled drug by way of administration only.	3. Prescription only medicines that are specified in the group authority.	3. The administration shall be subject to such conditions and in such circumstances and to such extent as may be specified in the group authority.	
4. The owner or master of a ship which does not carry a doctor on board as part of her complement.	4. All prescription only medicines that are for parenteral administration.	4. The administration shall be only so far as is necessary for the treatment of persons on the ship.	
5. Persons operating an occupational health scheme.	5. Prescription only medicines for parenteral administration sold or supplied to the person operating an occupational health scheme in response to an order in writing signed by a doctor or a registered nurse.	 5. — (1) The administration shall be in the course of an occupational health scheme. (2) The individual administering the prescription only medicine, if neither a doctor nor acting in accordance with the directions of a doctor, shall be a registered nurse acting in accordance with the written instructions of a doctor as to the circumstances in 	

Column 1 Persons exempted	Column 2 Prescription only medicines to which the exemption applies	Column 3 Conditions
		which prescription only medicines of the description in question are to be used in the course of the occupational health scheme.
6. The operator or commander of an aircraft.	6. Prescription only medicines for parenteral administration which have been sold or supplied to the operator or commander of the aircraft in response to an order in writing signed by a doctor.	6. The administration shall be only so far as is necessary for the immediate treatment of sick or injured persons on the aircraft and shall be in accordance with the written instructions of a doctor as to the circumstances in which prescription only medicines of the description in question are to be used on the aircraft.
7. Persons who are, and at 11th February 1982 were, persons customarily administering medicinal products to human beings by parenteral administration in the course of a business in the field of osteopathy, naturopathy, acupuncture or other similar field except chiropody.	7. Medicinal products that are prescription only medicines by reason only that they fall within the class specified in article 3(c) (products for parenteral administration).	7. The person administering the prescription only medicine shall have been requested by or on behalf of the person to whom it is administered and in that person's presence to use his own judgement as to the treatment required.
8. Persons employed as qualified first-aid personnel on offshore installations.	8. All prescription only medicines that are for parenteral administration.	8. The administration shall be only so far as is necessary for the treatment of persons on the installation.
9. Persons who hold a certificate of proficiency in ambulance paramedic skills issued by, or with the approval of, the Secretary of State [^{F241} or persons who are [^{F242} registered] paramedics].	 9. The following prescription only medicines for parenteral administration– (a) Diazepam 5 mg per ml emulsion for injection; (b) Succinylated Modified Fluid Gelatin 4 per cent intravenous infusion; (bb) [^{F243}medicines containing the 	9. The administration shall be only for the immediate, necessary treatment of sick or injured persons and in the case of a prescription only medicine containing Heparin Sodium shall be only for the purpose of cannula flushing.

Column 1 Persons exempted	Column 2 Prescription only medicines to which the exemption applies		Column 3 Conditions	
	иррись	substances		
		Ergometrine		
		Maleate 500mcg		
		per ml with		
		Oxytocin 5 iu per		
		ml, but no other		
	(4)	active ingredient]		
	(d)	prescription only medicines		
		containing one		
		or more of		
		the following		
		substances, but no		
		active ingredient-		
		Adrenaline		
		Acid Tartrate		
		[^{F244} Amiodaro	ne]	
		Anhydrous		
		Glucose		
		[^{F245} Benzylper		
		[^{F246} Bretylium		
		Tosylate]		
		Compound		
		Sodium		
		Lactate		
		Intravenous Infusion		
		(Hartmann's		
		Solution)		
		Ergometrine		
		Maleate		
		[^{F245} Frusemide	el	
		Glucose		
		Heparin		
		Sodium		
		Lignocaine		
		Hydrochloride		
		[^{F245} Metoclopi		
		[^{F245} Morphine		
		Sulphate]		
		Nalbuphine		
		Hydrochloride	2	
		Naloxone		
		Hydrochloride		
		Polygeline		
		[^{F247} Reteplase		

Column 1	Column 2	Column 3
Persons exempted	Prescription only medicines to which the exemption applies	Conditions
	Sodium	
	Bicarbonate	
	Sodium	
	Chloride	
	[^{F245} Streptokin	ase
	[^{F247} Tenectep]	ase.]

Textual Amendments F236 Word in Sch. 5 Pt. 3 para. 1 omitted (9.7.2003) by virtue of The Health Professions Order 2001 (Consequential Amendments) Order 2003 (S.I. 2003/1590), art. 1, Sch. para. 21(3)(b)(i)(aa) F237 Words in Sch. 5 Pt. 3 para. 1 inserted (9.7.2003) by The Health Professions Order 2001 (Consequential Amendments) Order 2003 (S.I. 2003/1590), art. 1, Sch. para. 21(3)(b)(i)(bb) F238 Words in Sch. 5 Pt. 3 substituted (13.2.1998) by The Prescription Only Medicines (Human Use) Amendment Order 1998 (S.I. 1998/108), arts. 1, 5(2) F239 Words in Sch. 5 Pt. 3 para. 1 inserted (16.9.1998) by The Prescription Only Medicines (Human Use) Amendment (No. 3) Order 1998 (S.I. 1998/2081), arts. 1(1), 4(b) F240 Words in Sch. 5 Pt. 3 para. 2 inserted (31.1.2004) by The Prescription Only Medicines (Human Use) Amendment Order 2004 (S.I. 2004/2), arts. 1(1), 4 F241 Words in Sch. 5 Pt. 3 para. 9 added (16.11.2000) by The Prescription Only Medicines (Human Use) Amendment (No. 2) Order 2000 (S.I. 2000/2899), arts. 1(1), 5(a) F242 Word in Sch. 5 Pt. 3 para. 9 substituted for words (9.7.2003) by The Health Professions Order 2001 (Consequential Amendments) Order 2003 (S.I. 2003/1590), art. 1, Sch. para. 21(3)(b)(ii) F243 Words in Sch. 5 Pt. 3 para. 9 inserted (16.11.2000) by The Prescription Only Medicines (Human Use) Amendment (No. 2) Order 2000 (S.I. 2000/2899), arts. 1(1), 5(b) F244 Word in Sch. 5 Pt. 3 para. 9 inserted (19.11.2004) by The Prescription Only Medicines (Human Use) Amendment (No. 3) Order 2004 (S.I. 2004/2693), arts. 1(1), 6 F245 Words in Sch. 5 Pt. 3 para. 9 inserted (16.11.2000) by The Prescription Only Medicines (Human Use) Amendment (No. 2) Order 2000 (S.I. 2000/2899), arts. 1(1), 5(c) F246 Words in Sch. 5 Pt. 3 para. 9 inserted (1.6.1998) by The Prescription Only Medicines (Human Use) Amendment (No. 2) Order 1998 (S.I. 1998/1178), arts. 1(1), 3 F247 Words in Sch. 5 Pt. 3 para. 9 inserted (18.5.2004) by The Prescription Only Medicines (Human Use) Amendment (No. 2) Order 2004 (S.I. 2004/1189), arts. 1(1), 4

SCHEDULE 6

Article 16(1)

ORDERS REVOKED

Column 1	Column 2
Orders	References
The Medicines (Products other than Veterinary Drugs) (Prescription Only) Order 1983	S.I. 1983/1212

Column 1 Orders	Column 2 References
The Medicines (Products other than Veterinary Drugs) (Prescription Only) Amendment Order 1984	S.I. 1984/756
The Medicines (Products other than Veterinary Drugs) (Prescription Only) Amendment Order 1986	S.I. 1986/586
The Medicines (Products other than Veterinary Drugs) (Prescription Only) Amendment Order 1987	S.I. 1987/674
The Medicines (Products other than Veterinary Drugs) (Prescription Only) Amendment (No. 2) Order 1987	S.I. 1987/1250
The Medicines (Products other than Veterinary Drugs) (Prescription Only) Amendment Order 1988	S.I. 1988/2017
The Medicines (Products other than Veterinary Drugs) (Prescription Only) Amendment Order 1991	S.I. 1991/962
The Medicines (Products other than Veterinary Drugs) (Prescription Only) Amendment Order 1992	S.I. 1992/1534
The Medicines (Products other than Veterinary Drugs) (Prescription Only) Amendment (No. 2) Order 1992	S.I. 1992/2937
The Medicines (Products other than Veterinary Drugs) (Prescription Only) Amendment Order 1993	S.I. 1993/1890
The Medicines (Products other than Veterinary Drugs) (Prescription Only) Amendment (No. 2) Order 1993	S.I. 1993/3256
The Medicines (Products other than Veterinary Drugs) (Prescription Only) Amendment Order 1994	S.I. 1994/558
The Medicines (Products other than Veterinary Drugs) (Prescription Only) Amendment (No. 2) Order 1994	S.I. 1994/3016
The Medicines (Products other than Veterinary Drugs) (Prescription Only) Amendment (No. 3) Order 1994	S.I. 1994/3050
The Medicines (Products other than Veterinary Drugs) (Prescription Only) Amendment Order 1995	S.I. 1995/1384

Column 1 Orders	Column 2 References
The Medicines (Products other than Veterinary Drugs) (Prescription Only) Amendment (No. 2) Order 1995	S.I. 1995/3174
The Medicines (Products other than Veterinary Drugs) (Prescription Only) Amendment Order 1996	S.I. 1996/1514
The Medicines (Products other than Veterinary Drugs) (Prescription Only) Amendment (No. 2) Order 1996	S.I. 1996/3193

[^{F248}SCHEDULE 7

Articles 12A to 12C

Textual Amendments

F248 Sch. 7 inserted (9.8.2000) by The Prescription Only Medicines (Human Use) Amendment Order 2000 (S.I. 2000/1917), arts. 1(1), 2(e)

PART I

PARTICULARS TO BE INCLUDED IN A PATIENT GROUP DIRECTION

- (a) the period during which the Direction shall have effect;
- (b) the description or class of prescription only medicine to which the Direction relates;
- (c) whether there are any restrictions on the quantity of medicine which may be supplied on any one occasion, and, if so, what restrictions;
- (d) the clinical situations which prescription only medicines of that description or class may be used to treat;
- (e) the clinical criteria under which a person shall be eligible for treatment;
- (f) whether any class of person is excluded from treatment under the Direction and, if so, what class of person;
- (g) whether there are circumstances in which further advice should be sought from a doctor or dentist and, if so, what circumstances;
- (h) the pharmaceutical form or forms in which prescription only medicines of that description or class are to be administered;
- (i) the strength, or maximum strength, at which prescription only medicines of that description or class are to be administered;
- (j) the applicable dosage or maximum dosage;
- (k) the route of administration;
- (l) the frequency of administration;
- (m) any minimum or maximum period of administration applicable to prescription only medicines of that description or class;

- (n) whether there are any relevant warnings to note, and, if so, what warnings;
- (o) whether there is any follow up action to be taken in any circumstances, and, if so, what action and in what circumstances;
- (p) arrangements for referral for medical advice;
- (q) details of the records to be kept of the supply, or the administration, of medicines under the Direction.

PART II

PERSONS ON WHOSE BEHALF A PATIENT GROUP DIRECTION MUST BE SIGNED

Column 1	Column 2
Class of person by whom a prescription only medicine is supplied or administered	Person on whose behalf the Direction must be signed
Common Services Agency	The Agency
[^{F249} Strategic Health Authority]	[^{F249} The Strategic Health Authority]
Health Authority	The Health Authority
Special Health Authority	The Special Health Authority
NHS trust [^{F250} or NHS foundation trust]	The trust
Primary Care Trust	The Trust
A person who supplies or administers a prescription only medicine pursuant to an arrangement made with the Common Services Agency, a Health Authority, a Special Health Authority, an NHS trust, [^{F251} , an NHS foundation trust] or a Primary Care Trust	The Common Services Agency, where the arrangement has been made with the Agency; or the Health Authority, Special Health Authority, NHS trust [^{F252} or NHS foundation trust] or Primary Care Trust with which the arrangement has been made

Textual Amendments

- **F249** Words in Sch. 7 Pt. 2 inserted (1.10.2002) by The National Health Service Reform and Health Care Professions Act 2002 (Supplementary, Consequential etc. Provisions) Regulations 2002 (S.I. 2002/2469), reg. 1, Sch. 1 para. 73(4)
- **F250** Words in Sch. 7 Pt. 2 inserted (1.4.2004) by The Health and Social Care (Community Health and Standards) Act 2003 (Supplementary and Consequential Provision) (NHS Foundation Trusts) Order 2004 (S.I. 2004/696), arts. 1(1)(b), 3(2), **Sch. 2**
- **F251** Words in Sch. 7 Pt. 2 inserted (1.4.2004) by The Health and Social Care (Community Health and Standards) Act 2003 (Supplementary and Consequential Provision) (NHS Foundation Trusts) Order 2004 (S.I. 2004/696), arts. 1(1)(b), 3(4), **Sch. 4**
- **F252** Words in Sch. 7 Pt. 2 inserted (1.4.2004) by The Health and Social Care (Community Health and Standards) Act 2003 (Supplementary and Consequential Provision) (NHS Foundation Trusts) Order 2004 (S.I. 2004/696), arts. 1(1)(b), 3(3), **Sch. 3**

[^{F253}PART IIA

PERSONS BY WHOM OR ON WHOSE BEHALF A PATIENT GROUP DIRECTION USED IN THE PROVISION OF HEALTH CARE BY OR ON BEHALF OF THE POLICE, THE PRISON SERVICES OR THE ARMED FORCES MUST BE SIGNED

2003 (S.I. 2003/696), arts. 1(1), 17		
Column 1	Column 2	
Force or service by whom or on whose behalf the health care is provided	Person by whom or on whose behalf the Direction must be signed	
A police force in England or Wales	The chief officer of police for that police force (within the meaning of the Police Act 1996)	
A police force in Scotland	The chief constable of that police force (within the meaning of the Police (Scotland) Act 1997	
The Police Service of Northern Ireland	The Chief Constable of the Police Service of Northern Ireland	
The prison service in England and Wales	The governor of the prison in relation to which the health care in question is being provided	
The prison service in Scotland	The Scottish Prison Service Management Board	
The prison service in Northern Ireland	The Northern Ireland Prison Service Management Board	
Her Majesty's Forces	(i) the Surgeon General,	
	(ii) a Medical Director General, or	
	(iii) a chief executive of an executive agency of the Ministry of Defence	

PART III

CLASSES OF INDIVIDUAL [^{F254}BY WHOM PRESCRIPTION ONLY MEDICINES MAY BE SUPPLIED OR ADMINISTERED]

Textual Amendments

F254 Words in Sch. 7 Pt. 3 heading substituted (16.11.2000) by The Prescription Only Medicines (Human Use) Amendment (No. 2) Order 2000 (S.I. 2000/2899), arts. 1(1), **3(2)**

[^{F255}Registered paramedics or individuals who hold a certificate of proficiency in ambulance paramedic skills issued by, or with the approval of, the Secretary of State.]

Pharmacists.

F256

Registered midwives.

Registered nurses.

[F257Registered optometrists]

[^{F258}Registered] chiropodists.

[^{F259}Registered orthoptists.

Registered physiotherapists.

Registered radiographers.]

[F260"Registered dietitians.";]

[^{F260}"Registered occupational therapists.";]

[^{F260}"Registered orthotists and prosthetists."; and]

[F260...Registered speech and language therapists."]]

Textual Amendments

- F255 Words in Sch. 7 Pt. 3 substituted (9.7.2003) by The Health Professions Order 2001 (Consequential Amendments) Order 2003 (S.I. 2003/1590), art. 1, Sch. para. 21(4)(a)
- F256 Words in Sch. 7 Pt. 3 omitted (1.8.2004) by virtue of The Health Act 1999 (Consequential Amendments) (Nursing and Midwifery) Order 2004 (S.I. 2004/1771), art. 1(1), Sch. para. 39(b)
- F257 Words in Order substituted (30.6.2005 as notified in the London Gazette dated 3.6.2005) by The Opticians Act 1989 (Amendment) Order 2005 (S.I. 2005/848), Sch. 1 para. 27(b)
- F258 Word in Sch. 7 Pt. 3 substituted (9.7.2003) by The Health Professions Order 2001 (Consequential Amendments) Order 2003 (S.I. 2003/1590), art. 1, Sch. para. 21(4)(b)
- F259 Words in Sch. 7 Pt. 3 substituted (9.7.2003) by The Health Professions Order 2001 (Consequential Amendments) Order 2003 (S.I. 2003/1590), art. 1, Sch. para. 21(4)(c)
- F260 Words in Sch. 7 Pt. 3 added (18.5.2004) by The Prescription Only Medicines (Human Use) Amendment (No. 2) Order 2004 (S.I. 2004/1189), arts. 1(1), 5

EXPLANATORY NOTE

(This note is not part of the Order)

This Order consolidates with amendments the Medicines (Products Other Than Veterinary Drugs) (Prescription Only) Order 1983 as amended. That Order and the Orders amending it ("the 1983 Order as amended") are revoked by article 16 and Schedule 6.

This Order specifies the descriptions and classes of prescription only medicines (i.e. medicinal products which, subject to exemptions, may be sold or supplied by retail only in accordance with a prescription given by an appropriate practitioner and which may be administered only by or in accordance with the directions of such a practitioner). Many medicinal products are included in a class of such medicines by reason of the substances contained in them (*see*Schedule 1) but others

are included because of other criteria, such as their method of administration (seearticle 3). In many cases the provisions of the Act apply subject to exemptions (seearticles 4 and 5 to 13 and Schedule 1).

The principal amendments relate to those medicines in respect of which marketing authorizations have been granted by the European Community. They include as prescription only medicines those medicines in respect of which such an authorization has been granted which classifies a medicine as being subject to medical prescription (article 3(f)). They exclude from the class of prescription only medicines those medicines in respect of which such an authorization provides for supply which is not subject to medical prescription (article 6(3)).

The differences between this Order and the 1983 Order as amended are in the main technical changes concerning the location of provisions such as the division of material in Schedule 1 to the 1983 Order as amended between the new Schedules 1 and 2. But within the new Schedule 1 there are changes which relate to-

- (a) the deletion from Column 1 of substances which are no longer used in those medicinal products which are on the market;
- (b) the use of current names for the substances which are specified in that Column where their names have changed;
- (c) the incorporation in that Schedule of provisions from article 4 of, and Part IV of Schedule 1 to, the 1983 Order as amended so that they may be found more easily;
- (d) a change in the legal base for the entries in Columns 2 to 4 so that those entries now form the criteria for exemptions from the sale or supply requirements of section 58(2) of the Medicines Act 1968 instead of the criteria for excluding medicinal products from the class of prescription only medicines (*see also*article 5);
- (e) the introduction of a fifth Column which specifies the maximum pack sizes to which exemptions apply.

As this order will impose no additional costs to business a compliance cost assessment has not been prepared.

Status:

Point in time view as at 30/06/2005.

Changes to legislation:

There are currently no known outstanding effects for the The Prescription Only Medicines (Human Use) Order 1997.